#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Examining resting-state functional connectivity in first-episode schizophrenia with 7T fMRI and MEG
#Text=Schizophrenia is often characterized by dysconnections in the brain, which can be estimated via functional connectivity analyses.
1-1	0-9	Examining	_	
1-2	10-23	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[1]	
1-3	24-34	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[1]	
1-4	35-47	connectivity	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[1]	
1-5	48-50	in	_	
1-6	51-64	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis	
1-7	65-78	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-8	79-83	with	_	
1-9	84-86	7T	_	
1-10	87-91	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
1-11	92-95	and	_	
1-12	96-99	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography	
1-13	100-113	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-14	114-116	is	_	
1-15	117-122	often	_	
1-16	123-136	characterized	_	
1-17	137-139	by	_	
1-18	140-154	dysconnections	_	
1-19	155-157	in	_	
1-20	158-161	the	_	
1-21	162-167	brain	_	
1-22	167-168	,	_	
1-23	169-174	which	_	
1-24	175-178	can	_	
1-25	179-181	be	_	
1-26	182-191	estimated	_	
1-27	192-195	via	_	
1-28	196-206	functional	_	
1-29	207-219	connectivity	_	
1-30	220-228	analyses	_	
1-31	228-229	.	_	

#Text=Commonly measured using resting-state functional magnetic resonance imaging (fMRI) in order to characterize the intrinsic or baseline function of the brain, fMRI functional connectivity has significantly contributed to the understanding of schizophrenia.
2-1	230-238	Commonly	_	
2-2	239-247	measured	_	
2-3	248-253	using	_	
2-4	254-267	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
2-5	268-278	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
2-6	279-287	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
2-7	288-297	resonance	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
2-8	298-305	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
2-9	306-307	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
2-10	307-311	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
2-11	311-312	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
2-12	313-315	in	_	
2-13	316-321	order	_	
2-14	322-324	to	_	
2-15	325-337	characterize	_	
2-16	338-341	the	_	
2-17	342-351	intrinsic	_	
2-18	352-354	or	_	
2-19	355-363	baseline	_	
2-20	364-372	function	_	
2-21	373-375	of	_	
2-22	376-379	the	_	
2-23	380-385	brain	_	
2-24	385-386	,	_	
2-25	387-391	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
2-26	392-402	functional	_	
2-27	403-415	connectivity	_	
2-28	416-419	has	_	
2-29	420-433	significantly	_	
2-30	434-445	contributed	_	
2-31	446-448	to	_	
2-32	449-452	the	_	
2-33	453-466	understanding	_	
2-34	467-469	of	_	
2-35	470-483	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
2-36	483-484	.	_	

#Text=However, these measures may not capture the full extent of functional connectivity abnormalities in schizophrenia as fMRI is temporally limited by the hemodynamic response.
3-1	485-492	However	_	
3-2	492-493	,	_	
3-3	494-499	these	_	
3-4	500-508	measures	_	
3-5	509-512	may	_	
3-6	513-516	not	_	
3-7	517-524	capture	_	
3-8	525-528	the	_	
3-9	529-533	full	_	
3-10	534-540	extent	_	
3-11	541-543	of	_	
3-12	544-554	functional	_	
3-13	555-567	connectivity	_	
3-14	568-581	abnormalities	_	
3-15	582-584	in	_	
3-16	585-598	schizophrenia	_	
3-17	599-601	as	_	
3-18	602-606	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
3-19	607-609	is	_	
3-20	610-620	temporally	_	
3-21	621-628	limited	_	
3-22	629-631	by	_	
3-23	632-635	the	_	
3-24	636-647	hemodynamic	_	
3-25	648-656	response	_	
3-26	656-657	.	_	

#Text=In order to extend fMRI functional connectivity findings, the complementary modality of magnetoencephalography (MEG) can be utilized to capture electrophysiological functional connectivity abnormalities in schizophrenia that are not obtainable with fMRI.
4-1	658-660	In	_	
4-2	661-666	order	_	
4-3	667-669	to	_	
4-4	670-676	extend	_	
4-5	677-681	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
4-6	682-692	functional	_	
4-7	693-705	connectivity	_	
4-8	706-714	findings	_	
4-9	714-715	,	_	
4-10	716-719	the	_	
4-11	720-733	complementary	_	
4-12	734-742	modality	_	
4-13	743-745	of	_	
4-14	746-768	magnetoencephalography	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography[3]	
4-15	769-770	(	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography[3]	
4-16	770-773	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography[3]	
4-17	773-774	)	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography[3]	
4-18	775-778	can	_	
4-19	779-781	be	_	
4-20	782-790	utilized	_	
4-21	791-793	to	_	
4-22	794-801	capture	_	
4-23	802-822	electrophysiological	_	
4-24	823-833	functional	_	
4-25	834-846	connectivity	_	
4-26	847-860	abnormalities	_	
4-27	861-863	in	_	
4-28	864-877	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
4-29	878-882	that	_	
4-30	883-886	are	_	
4-31	887-890	not	_	
4-32	891-901	obtainable	_	
4-33	902-906	with	_	
4-34	907-911	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
4-35	911-912	.	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	

#Text=Therefore, we implemented a multimodal functional connectivity analysis using resting-state 7 Tesla fMRI and MEG data in a sample of first-episode patients with schizophrenia (n = 19) and healthy controls (n = 24). fMRI and MEG data were decomposed into components reflecting resting state networks using a group spatial independent component analysis.
5-1	913-922	Therefore	_	
5-2	922-923	,	_	
5-3	924-926	we	_	
5-4	927-938	implemented	_	
5-5	939-940	a	_	
5-6	941-951	multimodal	_	
5-7	952-962	functional	_	
5-8	963-975	connectivity	_	
5-9	976-984	analysis	_	
5-10	985-990	using	_	
5-11	991-1004	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
5-12	1005-1006	7	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
5-13	1007-1012	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
5-14	1013-1017	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]	
5-15	1018-1021	and	_	
5-16	1022-1025	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography	
5-17	1026-1030	data	_	
5-18	1031-1033	in	_	
5-19	1034-1035	a	_	
5-20	1036-1042	sample	_	
5-21	1043-1045	of	_	
5-22	1046-1059	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[7]	
5-23	1060-1068	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[7]	
5-24	1069-1073	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[7]	
5-25	1074-1087	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[7]	
5-26	1088-1089	(	_	
5-27	1089-1090	n	_	
5-28	1090-1091	 	_	
5-29	1091-1092	=	_	
5-30	1092-1093	 	_	
5-31	1093-1095	19	_	
5-32	1095-1096	)	_	
5-33	1097-1100	and	_	
5-34	1101-1108	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
5-35	1109-1117	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
5-36	1118-1119	(	_	
5-37	1119-1120	n	_	
5-38	1120-1121	 	_	
5-39	1121-1122	=	_	
5-40	1122-1123	 	_	
5-41	1123-1125	24	_	
5-42	1125-1126	)	_	
5-43	1126-1127	.	_	
5-44	1128-1132	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
5-45	1133-1136	and	_	
5-46	1137-1140	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography	
5-47	1141-1145	data	_	
5-48	1146-1150	were	_	
5-49	1151-1161	decomposed	_	
5-50	1162-1166	into	_	
5-51	1167-1177	components	_	
5-52	1178-1188	reflecting	_	
5-53	1189-1196	resting	_	
5-54	1197-1202	state	_	
5-55	1203-1211	networks	_	
5-56	1212-1217	using	_	
5-57	1218-1219	a	_	
5-58	1220-1225	group	_	
5-59	1226-1233	spatial	_	
5-60	1234-1245	independent	_	
5-61	1246-1255	component	_	
5-62	1256-1264	analysis	_	
5-63	1264-1265	.	_	

#Text=Functional connectivity between resting-state networks was computed and group differences were observed.
6-1	1266-1276	Functional	_	
6-2	1277-1289	connectivity	_	
6-3	1290-1297	between	_	
6-4	1298-1311	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[9]	
6-5	1312-1320	networks	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[9]	
6-6	1321-1324	was	_	
6-7	1325-1333	computed	_	
6-8	1334-1337	and	_	
6-9	1338-1343	group	_	
6-10	1344-1355	differences	_	
6-11	1356-1360	were	_	
6-12	1361-1369	observed	_	
6-13	1369-1370	.	_	

#Text=In fMRI, patients demonstrated hyperconnectivity between subcortical and auditory networks, as well as hypoconnectivity between interhemispheric homotopic sensorimotor network components.
7-1	1371-1373	In	_	
7-2	1374-1378	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
7-3	1378-1379	,	_	
7-4	1380-1388	patients	_	
7-5	1389-1401	demonstrated	_	
7-6	1402-1419	hyperconnectivity	_	
7-7	1420-1427	between	_	
7-8	1428-1439	subcortical	_	
7-9	1440-1443	and	_	
7-10	1444-1452	auditory	_	
7-11	1453-1461	networks	_	
7-12	1461-1462	,	_	
7-13	1463-1465	as	_	
7-14	1466-1470	well	_	
7-15	1471-1473	as	_	
7-16	1474-1490	hypoconnectivity	_	
7-17	1491-1498	between	_	
7-18	1499-1515	interhemispheric	_	
7-19	1516-1525	homotopic	_	
7-20	1526-1538	sensorimotor	_	
7-21	1539-1546	network	_	
7-22	1547-1557	components	_	
7-23	1557-1558	.	_	

#Text=In MEG, patients demonstrated hypoconnectivity between sensorimotor and task positive networks in the delta frequency band.
8-1	1559-1561	In	_	
8-2	1562-1565	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography	
8-3	1565-1566	,	_	
8-4	1567-1575	patients	_	
8-5	1576-1588	demonstrated	_	
8-6	1589-1605	hypoconnectivity	_	
8-7	1606-1613	between	_	
8-8	1614-1626	sensorimotor	_	
8-9	1627-1630	and	_	
8-10	1631-1635	task	_	
8-11	1636-1644	positive	_	
8-12	1645-1653	networks	_	
8-13	1654-1656	in	_	
8-14	1657-1660	the	_	
8-15	1661-1666	delta	_	
8-16	1667-1676	frequency	_	
8-17	1677-1681	band	_	
8-18	1681-1682	.	_	

#Text=Results not only support the dysconnectivity hypothesis of schizophrenia, but also suggest the importance of jointly examining multimodal neuroimaging data as critical disorder-related information may not be detectable in a single modality alone.
9-1	1683-1690	Results	_	
9-2	1691-1694	not	_	
9-3	1695-1699	only	_	
9-4	1700-1707	support	_	
9-5	1708-1711	the	_	
9-6	1712-1727	dysconnectivity	_	
9-7	1728-1738	hypothesis	_	
9-8	1739-1741	of	_	
9-9	1742-1755	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
9-10	1755-1756	,	_	
9-11	1757-1760	but	_	
9-12	1761-1765	also	_	
9-13	1766-1773	suggest	_	
9-14	1774-1777	the	_	
9-15	1778-1788	importance	_	
9-16	1789-1791	of	_	
9-17	1792-1799	jointly	_	
9-18	1800-1809	examining	_	
9-19	1810-1820	multimodal	_	
9-20	1821-1833	neuroimaging	_	
9-21	1834-1838	data	_	
9-22	1839-1841	as	_	
9-23	1842-1850	critical	_	
9-24	1851-1867	disorder-related	_	
9-25	1868-1879	information	_	
9-26	1880-1883	may	_	
9-27	1884-1887	not	_	
9-28	1888-1890	be	_	
9-29	1891-1901	detectable	_	
9-30	1902-1904	in	_	
9-31	1905-1906	a	_	
9-32	1907-1913	single	_	
9-33	1914-1922	modality	_	
9-34	1923-1928	alone	_	
9-35	1928-1929	.	_	

#Text=Highlights
#Text=Altered subcortical-auditory fMRI functional connectivity at rest in first-episode.
#Text=fMRI sensorimotor interhemispheric homotopic connectivity altered in first-episode.
10-1	1930-1940	Highlights	_	
10-2	1941-1948	Altered	_	
10-3	1949-1969	subcortical-auditory	_	
10-4	1970-1974	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
10-5	1975-1985	functional	_	
10-6	1986-1998	connectivity	_	
10-7	1999-2001	at	_	
10-8	2002-2006	rest	_	
10-9	2007-2009	in	_	
10-10	2010-2023	first-episode	_	
10-11	2023-2024	.	_	
10-12	2025-2029	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
10-13	2030-2042	sensorimotor	_	
10-14	2043-2059	interhemispheric	_	
10-15	2060-2069	homotopic	_	
10-16	2070-2082	connectivity	_	
10-17	2083-2090	altered	_	
10-18	2091-2093	in	_	
10-19	2094-2107	first-episode	_	
10-20	2107-2108	.	_	

#Text=Sensorimotor-task positive connectivity alterations in delta frequency band.
11-1	2109-2126	Sensorimotor-task	_	
11-2	2127-2135	positive	_	
11-3	2136-2148	connectivity	_	
11-4	2149-2160	alterations	_	
11-5	2161-2163	in	_	
11-6	2164-2169	delta	_	
11-7	2170-2179	frequency	_	
11-8	2180-2184	band	_	
11-9	2184-2185	.	_	

#Text=Introduction
#Text=Schizophrenia is frequently described as a heterogeneous disorder of brain connectivity as it is characterized by altered functional and structural cortical network integration.
12-1	2186-2198	Introduction	_	
12-2	2199-2212	Schizophrenia	_	
12-3	2213-2215	is	_	
12-4	2216-2226	frequently	_	
12-5	2227-2236	described	_	
12-6	2237-2239	as	_	
12-7	2240-2241	a	_	
12-8	2242-2255	heterogeneous	_	
12-9	2256-2264	disorder	_	
12-10	2265-2267	of	_	
12-11	2268-2273	brain	_	
12-12	2274-2286	connectivity	_	
12-13	2287-2289	as	_	
12-14	2290-2292	it	_	
12-15	2293-2295	is	_	
12-16	2296-2309	characterized	_	
12-17	2310-2312	by	_	
12-18	2313-2320	altered	_	
12-19	2321-2331	functional	_	
12-20	2332-2335	and	_	
12-21	2336-2346	structural	_	
12-22	2347-2355	cortical	_	
12-23	2356-2363	network	_	
12-24	2364-2375	integration	_	
12-25	2375-2376	.	_	

#Text=These aberrant interactions between brain regions may be induced by abnormal physiological and neuronal processes.
13-1	2377-2382	These	_	
13-2	2383-2391	aberrant	_	
13-3	2392-2404	interactions	_	
13-4	2405-2412	between	_	
13-5	2413-2418	brain	_	
13-6	2419-2426	regions	_	
13-7	2427-2430	may	_	
13-8	2431-2433	be	_	
13-9	2434-2441	induced	_	
13-10	2442-2444	by	_	
13-11	2445-2453	abnormal	_	
13-12	2454-2467	physiological	_	
13-13	2468-2471	and	_	
13-14	2472-2480	neuronal	_	
13-15	2481-2490	processes	_	
13-16	2490-2491	.	_	

#Text=Resting-state functional connectivity measures are often implemented to examine these altered connections between functional networks.
14-1	2492-2505	Resting-state	_	
14-2	2506-2516	functional	_	
14-3	2517-2529	connectivity	_	
14-4	2530-2538	measures	_	
14-5	2539-2542	are	_	
14-6	2543-2548	often	_	
14-7	2549-2560	implemented	_	
14-8	2561-2563	to	_	
14-9	2564-2571	examine	_	
14-10	2572-2577	these	_	
14-11	2578-2585	altered	_	
14-12	2586-2597	connections	_	
14-13	2598-2605	between	_	
14-14	2606-2616	functional	_	
14-15	2617-2625	networks	_	
14-16	2625-2626	.	_	

#Text=In the absence of a task being performed, resting-state functional connectivity measures the temporal coherence between spatially separate regions of the brain.
15-1	2627-2629	In	_	
15-2	2630-2633	the	_	
15-3	2634-2641	absence	_	
15-4	2642-2644	of	_	
15-5	2645-2646	a	_	
15-6	2647-2651	task	_	
15-7	2652-2657	being	_	
15-8	2658-2667	performed	_	
15-9	2667-2668	,	_	
15-10	2669-2682	resting-state	_	
15-11	2683-2693	functional	_	
15-12	2694-2706	connectivity	_	
15-13	2707-2715	measures	_	
15-14	2716-2719	the	_	
15-15	2720-2728	temporal	_	
15-16	2729-2738	coherence	_	
15-17	2739-2746	between	_	
15-18	2747-2756	spatially	_	
15-19	2757-2765	separate	_	
15-20	2766-2773	regions	_	
15-21	2774-2776	of	_	
15-22	2777-2780	the	_	
15-23	2781-2786	brain	_	
15-24	2786-2787	.	_	

#Text=It is believed that examination of the functional interactions between brain networks in schizophrenia can be used to better characterize the disorder as well as further elucidate the underlying mechanisms of the disorder.
16-1	2788-2790	It	_	
16-2	2791-2793	is	_	
16-3	2794-2802	believed	_	
16-4	2803-2807	that	_	
16-5	2808-2819	examination	_	
16-6	2820-2822	of	_	
16-7	2823-2826	the	_	
16-8	2827-2837	functional	_	
16-9	2838-2850	interactions	_	
16-10	2851-2858	between	_	
16-11	2859-2864	brain	_	
16-12	2865-2873	networks	_	
16-13	2874-2876	in	_	
16-14	2877-2890	schizophrenia	_	
16-15	2891-2894	can	_	
16-16	2895-2897	be	_	
16-17	2898-2902	used	_	
16-18	2903-2905	to	_	
16-19	2906-2912	better	_	
16-20	2913-2925	characterize	_	
16-21	2926-2929	the	_	
16-22	2930-2938	disorder	_	
16-23	2939-2941	as	_	
16-24	2942-2946	well	_	
16-25	2947-2949	as	_	
16-26	2950-2957	further	_	
16-27	2958-2967	elucidate	_	
16-28	2968-2971	the	_	
16-29	2972-2982	underlying	_	
16-30	2983-2993	mechanisms	_	
16-31	2994-2996	of	_	
16-32	2997-3000	the	_	
16-33	3001-3009	disorder	_	
16-34	3009-3010	.	_	

#Text=Numerous functional magnetic resonance imaging (fMRI) studies examining functional connectivity in schizophrenia have been reported.
17-1	3011-3019	Numerous	_	
17-2	3020-3030	functional	_	
17-3	3031-3039	magnetic	_	
17-4	3040-3049	resonance	_	
17-5	3050-3057	imaging	_	
17-6	3058-3059	(	_	
17-7	3059-3063	fMRI	_	
17-8	3063-3064	)	_	
17-9	3065-3072	studies	_	
17-10	3073-3082	examining	_	
17-11	3083-3093	functional	_	
17-12	3094-3106	connectivity	_	
17-13	3107-3109	in	_	
17-14	3110-3123	schizophrenia	_	
17-15	3124-3128	have	_	
17-16	3129-3133	been	_	
17-17	3134-3142	reported	_	
17-18	3142-3143	.	_	

#Text=These studies have indicated that connectivity is altered in schizophrenia and may be manifested via the disorder's clinical symptoms.
18-1	3144-3149	These	_	
18-2	3150-3157	studies	_	
18-3	3158-3162	have	_	
18-4	3163-3172	indicated	_	
18-5	3173-3177	that	_	
18-6	3178-3190	connectivity	_	
18-7	3191-3193	is	_	
18-8	3194-3201	altered	_	
18-9	3202-3204	in	_	
18-10	3205-3218	schizophrenia	_	
18-11	3219-3222	and	_	
18-12	3223-3226	may	_	
18-13	3227-3229	be	_	
18-14	3230-3240	manifested	_	
18-15	3241-3244	via	_	
18-16	3245-3248	the	_	
18-17	3249-3259	disorder's	_	
18-18	3260-3268	clinical	_	
18-19	3269-3277	symptoms	_	
18-20	3277-3278	.	_	

#Text=Although reported fMRI functional connectivity abnormalities generally implicate alterations involving the task positive network, as well as the default mode network (DMN), connectivity abnormalities are heterogeneous across studies.
19-1	3279-3287	Although	_	
19-2	3288-3296	reported	_	
19-3	3297-3301	fMRI	_	
19-4	3302-3312	functional	_	
19-5	3313-3325	connectivity	_	
19-6	3326-3339	abnormalities	_	
19-7	3340-3349	generally	_	
19-8	3350-3359	implicate	_	
19-9	3360-3371	alterations	_	
19-10	3372-3381	involving	_	
19-11	3382-3385	the	_	
19-12	3386-3390	task	_	
19-13	3391-3399	positive	_	
19-14	3400-3407	network	_	
19-15	3407-3408	,	_	
19-16	3409-3411	as	_	
19-17	3412-3416	well	_	
19-18	3417-3419	as	_	
19-19	3420-3423	the	_	
19-20	3424-3431	default	_	
19-21	3432-3436	mode	_	
19-22	3437-3444	network	_	
19-23	3445-3446	(	_	
19-24	3446-3449	DMN	_	
19-25	3449-3450	)	_	
19-26	3450-3451	,	_	
19-27	3452-3464	connectivity	_	
19-28	3465-3478	abnormalities	_	
19-29	3479-3482	are	_	
19-30	3483-3496	heterogeneous	_	
19-31	3497-3503	across	_	
19-32	3504-3511	studies	_	
19-33	3511-3512	.	_	

#Text=Therefore, as Houck and colleagues have pointed out, although fMRI provides excellent spatial resolution, sole reliance on fMRI to explore dysconnectivity is limited by the slow temporal resolution of the hemodynamic response.
20-1	3513-3522	Therefore	_	
20-2	3522-3523	,	_	
20-3	3524-3526	as	_	
20-4	3527-3532	Houck	_	
20-5	3533-3536	and	_	
20-6	3537-3547	colleagues	_	
20-7	3548-3552	have	_	
20-8	3553-3560	pointed	_	
20-9	3561-3564	out	_	
20-10	3564-3565	,	_	
20-11	3566-3574	although	_	
20-12	3575-3579	fMRI	_	
20-13	3580-3588	provides	_	
20-14	3589-3598	excellent	_	
20-15	3599-3606	spatial	_	
20-16	3607-3617	resolution	_	
20-17	3617-3618	,	_	
20-18	3619-3623	sole	_	
20-19	3624-3632	reliance	_	
20-20	3633-3635	on	_	
20-21	3636-3640	fMRI	_	
20-22	3641-3643	to	_	
20-23	3644-3651	explore	_	
20-24	3652-3667	dysconnectivity	_	
20-25	3668-3670	is	_	
20-26	3671-3678	limited	_	
20-27	3679-3681	by	_	
20-28	3682-3685	the	_	
20-29	3686-3690	slow	_	
20-30	3691-3699	temporal	_	
20-31	3700-3710	resolution	_	
20-32	3711-3713	of	_	
20-33	3714-3717	the	_	
20-34	3718-3729	hemodynamic	_	
20-35	3730-3738	response	_	
20-36	3738-3739	.	_	

#Text=While fMRI measures hemodynamic changes, magnetoencephalography (MEG) enables the examination of the faster neural oscillations believed to underlie the blood oxygenation level dependent (BOLD) response of fMRI.
21-1	3740-3745	While	_	
21-2	3746-3750	fMRI	_	
21-3	3751-3759	measures	_	
21-4	3760-3771	hemodynamic	_	
21-5	3772-3779	changes	_	
21-6	3779-3780	,	_	
21-7	3781-3803	magnetoencephalography	_	
21-8	3804-3805	(	_	
21-9	3805-3808	MEG	_	
21-10	3808-3809	)	_	
21-11	3810-3817	enables	_	
21-12	3818-3821	the	_	
21-13	3822-3833	examination	_	
21-14	3834-3836	of	_	
21-15	3837-3840	the	_	
21-16	3841-3847	faster	_	
21-17	3848-3854	neural	_	
21-18	3855-3867	oscillations	_	
21-19	3868-3876	believed	_	
21-20	3877-3879	to	_	
21-21	3880-3888	underlie	_	
21-22	3889-3892	the	_	
21-23	3893-3898	blood	_	
21-24	3899-3910	oxygenation	_	
21-25	3911-3916	level	_	
21-26	3917-3926	dependent	_	
21-27	3927-3928	(	_	
21-28	3928-3932	BOLD	_	
21-29	3932-3933	)	_	
21-30	3934-3942	response	_	
21-31	3943-3945	of	_	
21-32	3946-3950	fMRI	_	
21-33	3950-3951	.	_	

#Text=However, just as fMRI has limited temporal resolution, the spatial resolution of MEG is limited due to the inferences necessary for signal localization and projection onto the brain.
22-1	3952-3959	However	_	
22-2	3959-3960	,	_	
22-3	3961-3965	just	_	
22-4	3966-3968	as	_	
22-5	3969-3973	fMRI	_	
22-6	3974-3977	has	_	
22-7	3978-3985	limited	_	
22-8	3986-3994	temporal	_	
22-9	3995-4005	resolution	_	
22-10	4005-4006	,	_	
22-11	4007-4010	the	_	
22-12	4011-4018	spatial	_	
22-13	4019-4029	resolution	_	
22-14	4030-4032	of	_	
22-15	4033-4036	MEG	_	
22-16	4037-4039	is	_	
22-17	4040-4047	limited	_	
22-18	4048-4051	due	_	
22-19	4052-4054	to	_	
22-20	4055-4058	the	_	
22-21	4059-4069	inferences	_	
22-22	4070-4079	necessary	_	
22-23	4080-4083	for	_	
22-24	4084-4090	signal	_	
22-25	4091-4103	localization	_	
22-26	4104-4107	and	_	
22-27	4108-4118	projection	_	
22-28	4119-4123	onto	_	
22-29	4124-4127	the	_	
22-30	4128-4133	brain	_	
22-31	4133-4134	.	_	

#Text=Hence, as the complementary modalities of fMRI and MEG respectively provide high spatial and temporal resolution, they can be used together to extend dysconnectivity findings in schizophrenia.
23-1	4135-4140	Hence	_	
23-2	4140-4141	,	_	
23-3	4142-4144	as	_	
23-4	4145-4148	the	_	
23-5	4149-4162	complementary	_	
23-6	4163-4173	modalities	_	
23-7	4174-4176	of	_	
23-8	4177-4181	fMRI	_	
23-9	4182-4185	and	_	
23-10	4186-4189	MEG	_	
23-11	4190-4202	respectively	_	
23-12	4203-4210	provide	_	
23-13	4211-4215	high	_	
23-14	4216-4223	spatial	_	
23-15	4224-4227	and	_	
23-16	4228-4236	temporal	_	
23-17	4237-4247	resolution	_	
23-18	4247-4248	,	_	
23-19	4249-4253	they	_	
23-20	4254-4257	can	_	
23-21	4258-4260	be	_	
23-22	4261-4265	used	_	
23-23	4266-4274	together	_	
23-24	4275-4277	to	_	
23-25	4278-4284	extend	_	
23-26	4285-4300	dysconnectivity	_	
23-27	4301-4309	findings	_	
23-28	4310-4312	in	_	
23-29	4313-4326	schizophrenia	_	
23-30	4326-4327	.	_	

#Text=Theoretical and experimental evidence implicate post-synaptic currents as a common origin of both the fMRI and MEG signals, suggesting that while these signals have different properties, they share a common underlying electrophysiological process.
24-1	4328-4339	Theoretical	_	
24-2	4340-4343	and	_	
24-3	4344-4356	experimental	_	
24-4	4357-4365	evidence	_	
24-5	4366-4375	implicate	_	
24-6	4376-4389	post-synaptic	_	
24-7	4390-4398	currents	_	
24-8	4399-4401	as	_	
24-9	4402-4403	a	_	
24-10	4404-4410	common	_	
24-11	4411-4417	origin	_	
24-12	4418-4420	of	_	
24-13	4421-4425	both	_	
24-14	4426-4429	the	_	
24-15	4430-4434	fMRI	_	
24-16	4435-4438	and	_	
24-17	4439-4442	MEG	_	
24-18	4443-4450	signals	_	
24-19	4450-4451	,	_	
24-20	4452-4462	suggesting	_	
24-21	4463-4467	that	_	
24-22	4468-4473	while	_	
24-23	4474-4479	these	_	
24-24	4480-4487	signals	_	
24-25	4488-4492	have	_	
24-26	4493-4502	different	_	
24-27	4503-4513	properties	_	
24-28	4513-4514	,	_	
24-29	4515-4519	they	_	
24-30	4520-4525	share	_	
24-31	4526-4527	a	_	
24-32	4528-4534	common	_	
24-33	4535-4545	underlying	_	
24-34	4546-4566	electrophysiological	_	
24-35	4567-4574	process	_	
24-36	4574-4575	.	_	

#Text=In addition, while low frequency oscillations are thought to support interactions between distant brain regions, high frequency oscillations are thought to be restricted to localized networks.
25-1	4576-4578	In	_	
25-2	4579-4587	addition	_	
25-3	4587-4588	,	_	
25-4	4589-4594	while	_	
25-5	4595-4598	low	_	
25-6	4599-4608	frequency	_	
25-7	4609-4621	oscillations	_	
25-8	4622-4625	are	_	
25-9	4626-4633	thought	_	
25-10	4634-4636	to	_	
25-11	4637-4644	support	_	
25-12	4645-4657	interactions	_	
25-13	4658-4665	between	_	
25-14	4666-4673	distant	_	
25-15	4674-4679	brain	_	
25-16	4680-4687	regions	_	
25-17	4687-4688	,	_	
25-18	4689-4693	high	_	
25-19	4694-4703	frequency	_	
25-20	4704-4716	oscillations	_	
25-21	4717-4720	are	_	
25-22	4721-4728	thought	_	
25-23	4729-4731	to	_	
25-24	4732-4734	be	_	
25-25	4735-4745	restricted	_	
25-26	4746-4748	to	_	
25-27	4749-4758	localized	_	
25-28	4759-4767	networks	_	
25-29	4767-4768	.	_	

#Text=Congruent with this notion, in non-human primates, a coupling between low-frequency oscillations (<20 Hz) and BOLD connectivity in a thalamo-cortical network was demonstrated during a resting state.
26-1	4769-4778	Congruent	_	
26-2	4779-4783	with	_	
26-3	4784-4788	this	_	
26-4	4789-4795	notion	_	
26-5	4795-4796	,	_	
26-6	4797-4799	in	_	
26-7	4800-4809	non-human	_	
26-8	4810-4818	primates	_	
26-9	4818-4819	,	_	
26-10	4820-4821	a	_	
26-11	4822-4830	coupling	_	
26-12	4831-4838	between	_	
26-13	4839-4852	low-frequency	_	
26-14	4853-4865	oscillations	_	
26-15	4866-4867	(	_	
26-16	4867-4868	<	_	
26-17	4868-4870	20	_	
26-18	4870-4871	 	_	
26-19	4871-4873	Hz	_	
26-20	4873-4874	)	_	
26-21	4875-4878	and	_	
26-22	4879-4883	BOLD	_	
26-23	4884-4896	connectivity	_	
26-24	4897-4899	in	_	
26-25	4900-4901	a	_	
26-26	4902-4918	thalamo-cortical	_	
26-27	4919-4926	network	_	
26-28	4927-4930	was	_	
26-29	4931-4943	demonstrated	_	
26-30	4944-4950	during	_	
26-31	4951-4952	a	_	
26-32	4953-4960	resting	_	
26-33	4961-4966	state	_	
26-34	4966-4967	.	_	

#Text=Furthermore, several studies have compared the spatial maps of functional connectivity obtained with BOLD and MEG and found a degree of spatial similarity between them.
27-1	4968-4979	Furthermore	_	
27-2	4979-4980	,	_	
27-3	4981-4988	several	_	
27-4	4989-4996	studies	_	
27-5	4997-5001	have	_	
27-6	5002-5010	compared	_	
27-7	5011-5014	the	_	
27-8	5015-5022	spatial	_	
27-9	5023-5027	maps	_	
27-10	5028-5030	of	_	
27-11	5031-5041	functional	_	
27-12	5042-5054	connectivity	_	
27-13	5055-5063	obtained	_	
27-14	5064-5068	with	_	
27-15	5069-5073	BOLD	_	
27-16	5074-5077	and	_	
27-17	5078-5081	MEG	_	
27-18	5082-5085	and	_	
27-19	5086-5091	found	_	
27-20	5092-5093	a	_	
27-21	5094-5100	degree	_	
27-22	5101-5103	of	_	
27-23	5104-5111	spatial	_	
27-24	5112-5122	similarity	_	
27-25	5123-5130	between	_	
27-26	5131-5135	them	_	
27-27	5135-5136	.	_	

#Text=Interestingly, the best spatial match between fMRI and MEG occurs with neural oscillations in the beta frequency.
28-1	5137-5150	Interestingly	_	
28-2	5150-5151	,	_	
28-3	5152-5155	the	_	
28-4	5156-5160	best	_	
28-5	5161-5168	spatial	_	
28-6	5169-5174	match	_	
28-7	5175-5182	between	_	
28-8	5183-5187	fMRI	_	
28-9	5188-5191	and	_	
28-10	5192-5195	MEG	_	
28-11	5196-5202	occurs	_	
28-12	5203-5207	with	_	
28-13	5208-5214	neural	_	
28-14	5215-5227	oscillations	_	
28-15	5228-5230	in	_	
28-16	5231-5234	the	_	
28-17	5235-5239	beta	_	
28-18	5240-5249	frequency	_	
28-19	5249-5250	.	_	

#Text=Recent multimodal functional connectivity studies have been implemented using complementary fMRI and MEG.
29-1	5251-5257	Recent	_	
29-2	5258-5268	multimodal	_	
29-3	5269-5279	functional	_	
29-4	5280-5292	connectivity	_	
29-5	5293-5300	studies	_	
29-6	5301-5305	have	_	
29-7	5306-5310	been	_	
29-8	5311-5322	implemented	_	
29-9	5323-5328	using	_	
29-10	5329-5342	complementary	_	
29-11	5343-5347	fMRI	_	
29-12	5348-5351	and	_	
29-13	5352-5355	MEG	_	
29-14	5355-5356	.	_	

#Text=Only three studies have evaluated MEG resting state functional connectivity in schizophrenia, and all three combined MEG with fMRI.
30-1	5357-5361	Only	_	
30-2	5362-5367	three	_	
30-3	5368-5375	studies	_	
30-4	5376-5380	have	_	
30-5	5381-5390	evaluated	_	
30-6	5391-5394	MEG	_	
30-7	5395-5402	resting	_	
30-8	5403-5408	state	_	
30-9	5409-5419	functional	_	
30-10	5420-5432	connectivity	_	
30-11	5433-5435	in	_	
30-12	5436-5449	schizophrenia	_	
30-13	5449-5450	,	_	
30-14	5451-5454	and	_	
30-15	5455-5458	all	_	
30-16	5459-5464	three	_	
30-17	5465-5473	combined	_	
30-18	5474-5477	MEG	_	
30-19	5478-5482	with	_	
30-20	5483-5487	fMRI	_	
30-21	5487-5488	.	_	

#Text=One study was limited to the evaluation of fronto-hippocampal functional connectivity.
31-1	5489-5492	One	_	
31-2	5493-5498	study	_	
31-3	5499-5502	was	_	
31-4	5503-5510	limited	_	
31-5	5511-5513	to	_	
31-6	5514-5517	the	_	
31-7	5518-5528	evaluation	_	
31-8	5529-5531	of	_	
31-9	5532-5550	fronto-hippocampal	_	
31-10	5551-5561	functional	_	
31-11	5562-5574	connectivity	_	
31-12	5574-5575	.	_	

#Text=Another study evaluated whole brain functional connectivity and reported a pattern of both hypo- and hyperconnectivity in frontal-DMN networks and within the frontal networks with MEG, and hypoconnectivity in temporal-occipital and frontal-occipital networks and within the occipital networks with fMRI in patients compared to controls.
32-1	5576-5583	Another	_	
32-2	5584-5589	study	_	
32-3	5590-5599	evaluated	_	
32-4	5600-5605	whole	_	
32-5	5606-5611	brain	_	
32-6	5612-5622	functional	_	
32-7	5623-5635	connectivity	_	
32-8	5636-5639	and	_	
32-9	5640-5648	reported	_	
32-10	5649-5650	a	_	
32-11	5651-5658	pattern	_	
32-12	5659-5661	of	_	
32-13	5662-5666	both	_	
32-14	5667-5671	hypo	_	
32-15	5671-5672	-	_	
32-16	5673-5676	and	_	
32-17	5677-5694	hyperconnectivity	_	
32-18	5695-5697	in	_	
32-19	5698-5709	frontal-DMN	_	
32-20	5710-5718	networks	_	
32-21	5719-5722	and	_	
32-22	5723-5729	within	_	
32-23	5730-5733	the	_	
32-24	5734-5741	frontal	_	
32-25	5742-5750	networks	_	
32-26	5751-5755	with	_	
32-27	5756-5759	MEG	_	
32-28	5759-5760	,	_	
32-29	5761-5764	and	_	
32-30	5765-5781	hypoconnectivity	_	
32-31	5782-5784	in	_	
32-32	5785-5803	temporal-occipital	_	
32-33	5804-5807	and	_	
32-34	5808-5825	frontal-occipital	_	
32-35	5826-5834	networks	_	
32-36	5835-5838	and	_	
32-37	5839-5845	within	_	
32-38	5846-5849	the	_	
32-39	5850-5859	occipital	_	
32-40	5860-5868	networks	_	
32-41	5869-5873	with	_	
32-42	5874-5878	fMRI	_	
32-43	5879-5881	in	_	
32-44	5882-5890	patients	_	
32-45	5891-5899	compared	_	
32-46	5900-5902	to	_	
32-47	5903-5911	controls	_	
32-48	5911-5912	.	_	

#Text=Using the same cohorts of chronic patients with schizophrenia and controls, the third study demonstrated improved classification of patients using combined fMRI/MEG methods, proving the importance of examining both the hemodynamic and electrophysiological functional connectivity effects when characterizing schizophrenia.
33-1	5913-5918	Using	_	
33-2	5919-5922	the	_	
33-3	5923-5927	same	_	
33-4	5928-5935	cohorts	_	
33-5	5936-5938	of	_	
33-6	5939-5946	chronic	_	
33-7	5947-5955	patients	_	
33-8	5956-5960	with	_	
33-9	5961-5974	schizophrenia	_	
33-10	5975-5978	and	_	
33-11	5979-5987	controls	_	
33-12	5987-5988	,	_	
33-13	5989-5992	the	_	
33-14	5993-5998	third	_	
33-15	5999-6004	study	_	
33-16	6005-6017	demonstrated	_	
33-17	6018-6026	improved	_	
33-18	6027-6041	classification	_	
33-19	6042-6044	of	_	
33-20	6045-6053	patients	_	
33-21	6054-6059	using	_	
33-22	6060-6068	combined	_	
33-23	6069-6073	fMRI	_	
33-24	6073-6074	/	_	
33-25	6074-6077	MEG	_	
33-26	6078-6085	methods	_	
33-27	6085-6086	,	_	
33-28	6087-6094	proving	_	
33-29	6095-6098	the	_	
33-30	6099-6109	importance	_	
33-31	6110-6112	of	_	
33-32	6113-6122	examining	_	
33-33	6123-6127	both	_	
33-34	6128-6131	the	_	
33-35	6132-6143	hemodynamic	_	
33-36	6144-6147	and	_	
33-37	6148-6168	electrophysiological	_	
33-38	6169-6179	functional	_	
33-39	6180-6192	connectivity	_	
33-40	6193-6200	effects	_	
33-41	6201-6205	when	_	
33-42	6206-6220	characterizing	_	
33-43	6221-6234	schizophrenia	_	
33-44	6234-6235	.	_	

#Text=In addition to characterizing schizophrenia using both hemodynamic and electrophysiological functional connectivity measures, it is important to examine the different stages of the disorder (e.g., premorbid, prodromal, onset/deterioration, residual) to further understand and characterize the pathophysiological mechanisms of schizophrenia.
34-1	6236-6238	In	_	
34-2	6239-6247	addition	_	
34-3	6248-6250	to	_	
34-4	6251-6265	characterizing	_	
34-5	6266-6279	schizophrenia	_	
34-6	6280-6285	using	_	
34-7	6286-6290	both	_	
34-8	6291-6302	hemodynamic	_	
34-9	6303-6306	and	_	
34-10	6307-6327	electrophysiological	_	
34-11	6328-6338	functional	_	
34-12	6339-6351	connectivity	_	
34-13	6352-6360	measures	_	
34-14	6360-6361	,	_	
34-15	6362-6364	it	_	
34-16	6365-6367	is	_	
34-17	6368-6377	important	_	
34-18	6378-6380	to	_	
34-19	6381-6388	examine	_	
34-20	6389-6392	the	_	
34-21	6393-6402	different	_	
34-22	6403-6409	stages	_	
34-23	6410-6412	of	_	
34-24	6413-6416	the	_	
34-25	6417-6425	disorder	_	
34-26	6426-6427	(	_	
34-27	6427-6430	e.g	_	
34-28	6430-6431	.	_	
34-29	6431-6432	,	_	
34-30	6433-6442	premorbid	_	
34-31	6442-6443	,	_	
34-32	6444-6453	prodromal	_	
34-33	6453-6454	,	_	
34-34	6455-6460	onset	_	
34-35	6460-6461	/	_	
34-36	6461-6474	deterioration	_	
34-37	6474-6475	,	_	
34-38	6476-6484	residual	_	
34-39	6484-6485	)	_	
34-40	6486-6488	to	_	
34-41	6489-6496	further	_	
34-42	6497-6507	understand	_	
34-43	6508-6511	and	_	
34-44	6512-6524	characterize	_	
34-45	6525-6528	the	_	
34-46	6529-6547	pathophysiological	_	
34-47	6548-6558	mechanisms	_	
34-48	6559-6561	of	_	
34-49	6562-6575	schizophrenia	_	
34-50	6575-6576	.	_	

#Text=While examining all stages of the disorder are important, examination of first-episode patients with schizophrenia is especially important as studies have demonstrated that the early stages of the disorder are critical in determining the overall course and outcome of the disorder.
35-1	6577-6582	While	_	
35-2	6583-6592	examining	_	
35-3	6593-6596	all	_	
35-4	6597-6603	stages	_	
35-5	6604-6606	of	_	
35-6	6607-6610	the	_	
35-7	6611-6619	disorder	_	
35-8	6620-6623	are	_	
35-9	6624-6633	important	_	
35-10	6633-6634	,	_	
35-11	6635-6646	examination	_	
35-12	6647-6649	of	_	
35-13	6650-6663	first-episode	_	
35-14	6664-6672	patients	_	
35-15	6673-6677	with	_	
35-16	6678-6691	schizophrenia	_	
35-17	6692-6694	is	_	
35-18	6695-6705	especially	_	
35-19	6706-6715	important	_	
35-20	6716-6718	as	_	
35-21	6719-6726	studies	_	
35-22	6727-6731	have	_	
35-23	6732-6744	demonstrated	_	
35-24	6745-6749	that	_	
35-25	6750-6753	the	_	
35-26	6754-6759	early	_	
35-27	6760-6766	stages	_	
35-28	6767-6769	of	_	
35-29	6770-6773	the	_	
35-30	6774-6782	disorder	_	
35-31	6783-6786	are	_	
35-32	6787-6795	critical	_	
35-33	6796-6798	in	_	
35-34	6799-6810	determining	_	
35-35	6811-6814	the	_	
35-36	6815-6822	overall	_	
35-37	6823-6829	course	_	
35-38	6830-6833	and	_	
35-39	6834-6841	outcome	_	
35-40	6842-6844	of	_	
35-41	6845-6848	the	_	
35-42	6849-6857	disorder	_	
35-43	6857-6858	.	_	

#Text=Moreover, studying first-episode patients allows for the examination of intrinsic abnormalities of the disorder rather than the confounding effects (e.g., medication, disorder chronicity on brain structure/function) introduced when investigating later stages of the illness.
36-1	6859-6867	Moreover	_	
36-2	6867-6868	,	_	
36-3	6869-6877	studying	_	
36-4	6878-6891	first-episode	_	
36-5	6892-6900	patients	_	
36-6	6901-6907	allows	_	
36-7	6908-6911	for	_	
36-8	6912-6915	the	_	
36-9	6916-6927	examination	_	
36-10	6928-6930	of	_	
36-11	6931-6940	intrinsic	_	
36-12	6941-6954	abnormalities	_	
36-13	6955-6957	of	_	
36-14	6958-6961	the	_	
36-15	6962-6970	disorder	_	
36-16	6971-6977	rather	_	
36-17	6978-6982	than	_	
36-18	6983-6986	the	_	
36-19	6987-6998	confounding	_	
36-20	6999-7006	effects	_	
36-21	7007-7008	(	_	
36-22	7008-7011	e.g	_	
36-23	7011-7012	.	_	
36-24	7012-7013	,	_	
36-25	7014-7024	medication	_	
36-26	7024-7025	,	_	
36-27	7026-7034	disorder	_	
36-28	7035-7045	chronicity	_	
36-29	7046-7048	on	_	
36-30	7049-7054	brain	_	
36-31	7055-7064	structure	_	
36-32	7064-7065	/	_	
36-33	7065-7073	function	_	
36-34	7073-7074	)	_	
36-35	7075-7085	introduced	_	
36-36	7086-7090	when	_	
36-37	7091-7104	investigating	_	
36-38	7105-7110	later	_	
36-39	7111-7117	stages	_	
36-40	7118-7120	of	_	
36-41	7121-7124	the	_	
36-42	7125-7132	illness	_	
36-43	7132-7133	.	_	

#Text=The purpose of this study is to examine resting-state functional connectivity in a sample of healthy controls and first-episode patients with schizophrenia using both 7 Tesla (7 T) fMRI and MEG.
37-1	7134-7137	The	_	
37-2	7138-7145	purpose	_	
37-3	7146-7148	of	_	
37-4	7149-7153	this	_	
37-5	7154-7159	study	_	
37-6	7160-7162	is	_	
37-7	7163-7165	to	_	
37-8	7166-7173	examine	_	
37-9	7174-7187	resting-state	_	
37-10	7188-7198	functional	_	
37-11	7199-7211	connectivity	_	
37-12	7212-7214	in	_	
37-13	7215-7216	a	_	
37-14	7217-7223	sample	_	
37-15	7224-7226	of	_	
37-16	7227-7234	healthy	_	
37-17	7235-7243	controls	_	
37-18	7244-7247	and	_	
37-19	7248-7261	first-episode	_	
37-20	7262-7270	patients	_	
37-21	7271-7275	with	_	
37-22	7276-7289	schizophrenia	_	
37-23	7290-7295	using	_	
37-24	7296-7300	both	_	
37-25	7301-7302	7	_	
37-26	7303-7308	Tesla	_	
37-27	7309-7310	(	_	
37-28	7310-7311	7	_	
37-29	7311-7312	 	_	
37-30	7312-7313	T	_	
37-31	7313-7314	)	_	
37-32	7315-7319	fMRI	_	
37-33	7320-7323	and	_	
37-34	7324-7327	MEG	_	
37-35	7327-7328	.	_	

#Text=Using independent component analyses to extract resting-state networks from both fMRI and MEG, we hypothesize that patients will exhibit connectivity alterations in comparison to controls in both resting state fMRI and MEG mapping to task positive and default mode networks.
38-1	7329-7334	Using	_	
38-2	7335-7346	independent	_	
38-3	7347-7356	component	_	
38-4	7357-7365	analyses	_	
38-5	7366-7368	to	_	
38-6	7369-7376	extract	_	
38-7	7377-7390	resting-state	_	
38-8	7391-7399	networks	_	
38-9	7400-7404	from	_	
38-10	7405-7409	both	_	
38-11	7410-7414	fMRI	_	
38-12	7415-7418	and	_	
38-13	7419-7422	MEG	_	
38-14	7422-7423	,	_	
38-15	7424-7426	we	_	
38-16	7427-7438	hypothesize	_	
38-17	7439-7443	that	_	
38-18	7444-7452	patients	_	
38-19	7453-7457	will	_	
38-20	7458-7465	exhibit	_	
38-21	7466-7478	connectivity	_	
38-22	7479-7490	alterations	_	
38-23	7491-7493	in	_	
38-24	7494-7504	comparison	_	
38-25	7505-7507	to	_	
38-26	7508-7516	controls	_	
38-27	7517-7519	in	_	
38-28	7520-7524	both	_	
38-29	7525-7532	resting	_	
38-30	7533-7538	state	_	
38-31	7539-7543	fMRI	_	
38-32	7544-7547	and	_	
38-33	7548-7551	MEG	_	
38-34	7552-7559	mapping	_	
38-35	7560-7562	to	_	
38-36	7563-7567	task	_	
38-37	7568-7576	positive	_	
38-38	7577-7580	and	_	
38-39	7581-7588	default	_	
38-40	7589-7593	mode	_	
38-41	7594-7602	networks	_	
38-42	7602-7603	.	_	

#Text=Because low frequency oscillations are thought to support interactions between distant regions, we further hypothesize that functional connectivity alterations will be more similar between fMRI and MEG in the low frequency bands.
39-1	7604-7611	Because	_	
39-2	7612-7615	low	_	
39-3	7616-7625	frequency	_	
39-4	7626-7638	oscillations	_	
39-5	7639-7642	are	_	
39-6	7643-7650	thought	_	
39-7	7651-7653	to	_	
39-8	7654-7661	support	_	
39-9	7662-7674	interactions	_	
39-10	7675-7682	between	_	
39-11	7683-7690	distant	_	
39-12	7691-7698	regions	_	
39-13	7698-7699	,	_	
39-14	7700-7702	we	_	
39-15	7703-7710	further	_	
39-16	7711-7722	hypothesize	_	
39-17	7723-7727	that	_	
39-18	7728-7738	functional	_	
39-19	7739-7751	connectivity	_	
39-20	7752-7763	alterations	_	
39-21	7764-7768	will	_	
39-22	7769-7771	be	_	
39-23	7772-7776	more	_	
39-24	7777-7784	similar	_	
39-25	7785-7792	between	_	
39-26	7793-7797	fMRI	_	
39-27	7798-7801	and	_	
39-28	7802-7805	MEG	_	
39-29	7806-7808	in	_	
39-30	7809-7812	the	_	
39-31	7813-7816	low	_	
39-32	7817-7826	frequency	_	
39-33	7827-7832	bands	_	
39-34	7832-7833	.	_	

#Text=Likewise, we also hypothesize that connectivity alterations examined in MEG will vary with different frequency bands.
40-1	7834-7842	Likewise	_	
40-2	7842-7843	,	_	
40-3	7844-7846	we	_	
40-4	7847-7851	also	_	
40-5	7852-7863	hypothesize	_	
40-6	7864-7868	that	_	
40-7	7869-7881	connectivity	_	
40-8	7882-7893	alterations	_	
40-9	7894-7902	examined	_	
40-10	7903-7905	in	_	
40-11	7906-7909	MEG	_	
40-12	7910-7914	will	_	
40-13	7915-7919	vary	_	
40-14	7920-7924	with	_	
40-15	7925-7934	different	_	
40-16	7935-7944	frequency	_	
40-17	7945-7950	bands	_	
40-18	7950-7951	.	_	

#Text=The consistent finding that patients tend to exhibit aberrant spontaneous brain activity in the theta and delta EEG/MEG frequency bands, also suggests that MEG functional connectivity differences between patients and controls will be strongest at these low frequencies.
41-1	7952-7955	The	_	
41-2	7956-7966	consistent	_	
41-3	7967-7974	finding	_	
41-4	7975-7979	that	_	
41-5	7980-7988	patients	_	
41-6	7989-7993	tend	_	
41-7	7994-7996	to	_	
41-8	7997-8004	exhibit	_	
41-9	8005-8013	aberrant	_	
41-10	8014-8025	spontaneous	_	
41-11	8026-8031	brain	_	
41-12	8032-8040	activity	_	
41-13	8041-8043	in	_	
41-14	8044-8047	the	_	
41-15	8048-8053	theta	_	
41-16	8054-8057	and	_	
41-17	8058-8063	delta	_	
41-18	8064-8067	EEG	_	
41-19	8067-8068	/	_	
41-20	8068-8071	MEG	_	
41-21	8072-8081	frequency	_	
41-22	8082-8087	bands	_	
41-23	8087-8088	,	_	
41-24	8089-8093	also	_	
41-25	8094-8102	suggests	_	
41-26	8103-8107	that	_	
41-27	8108-8111	MEG	_	
41-28	8112-8122	functional	_	
41-29	8123-8135	connectivity	_	
41-30	8136-8147	differences	_	
41-31	8148-8155	between	_	
41-32	8156-8164	patients	_	
41-33	8165-8168	and	_	
41-34	8169-8177	controls	_	
41-35	8178-8182	will	_	
41-36	8183-8185	be	_	
41-37	8186-8195	strongest	_	
41-38	8196-8198	at	_	
41-39	8199-8204	these	_	
41-40	8205-8208	low	_	
41-41	8209-8220	frequencies	_	
41-42	8220-8221	.	_	

#Text=Materials and methods
#Text=Participants
#Text=Minimally treated first-episode patients with schizophrenia were recruited from the University of Alabama at Birmingham (UAB) emergency room, inpatient units, and various outpatient clinics.
42-1	8222-8231	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[10]	
42-2	8232-8235	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[10]	
42-3	8236-8243	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[10]	
42-4	8244-8256	Participants	_	
42-5	8257-8266	Minimally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-6	8267-8274	treated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-7	8275-8288	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[12]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[13]	
42-8	8289-8297	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[12]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[13]	
42-9	8298-8302	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[12]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[13]	
42-10	8303-8316	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[12]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[13]	
42-11	8317-8321	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-12	8322-8331	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-13	8332-8336	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-14	8337-8340	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-15	8341-8351	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-16	8352-8354	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-17	8355-8362	Alabama	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-18	8363-8365	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-19	8366-8376	Birmingham	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-20	8377-8378	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-21	8378-8381	UAB	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-22	8381-8382	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-23	8383-8392	emergency	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-24	8393-8397	room	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-25	8397-8398	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-26	8399-8408	inpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-27	8409-8414	units	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-28	8414-8415	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-29	8416-8419	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-30	8420-8427	various	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-31	8428-8438	outpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-32	8439-8446	clinics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-33	8446-8447	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Informed consent to participate in this UAB Institutional Review Board (IRB) approved study was obtained following evaluation of competency to provide informed consent.
43-1	8448-8456	Informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-2	8457-8464	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-3	8465-8467	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-4	8468-8479	participate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-5	8480-8482	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-6	8483-8487	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-7	8488-8491	UAB	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-8	8492-8505	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-9	8506-8512	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-10	8513-8518	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-11	8519-8520	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-12	8520-8523	IRB	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-13	8523-8524	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-14	8525-8533	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-15	8534-8539	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-16	8540-8543	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-17	8544-8552	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-18	8553-8562	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-19	8563-8573	evaluation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-20	8574-8576	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-21	8577-8587	competency	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-22	8588-8590	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-23	8591-8598	provide	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-24	8599-8607	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-25	8608-8615	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
43-26	8615-8616	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	

#Text=Additionally, healthy controls matched on age, gender, parental socioeconomic status (SES), years of education, and smoking status were enrolled in the study.
44-1	8617-8629	Additionally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-2	8629-8630	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-3	8631-8638	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[16]	
44-4	8639-8647	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[16]	
44-5	8648-8655	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-6	8656-8658	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-7	8659-8662	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-8	8662-8663	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-9	8664-8670	gender	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-10	8670-8671	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-11	8672-8680	parental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-12	8681-8694	socioeconomic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-13	8695-8701	status	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-14	8702-8703	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-15	8703-8706	SES	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-16	8706-8707	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-17	8707-8708	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-18	8709-8714	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-19	8715-8717	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-20	8718-8727	education	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-21	8727-8728	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-22	8729-8732	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-23	8733-8740	smoking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-24	8741-8747	status	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-25	8748-8752	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-26	8753-8761	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-27	8762-8764	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-28	8765-8768	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-29	8769-8774	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-30	8774-8775	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	

#Text=Diagnoses were established with a review of medical records and evaluation by two board certified psychiatrists (ACL and NVK) and confirmed using the Diagnostic Interview for Genetic Studies.
45-1	8776-8785	Diagnoses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-2	8786-8790	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-3	8791-8802	established	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-4	8803-8807	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-5	8808-8809	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-6	8810-8816	review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-7	8817-8819	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-8	8820-8827	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-9	8828-8835	records	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-10	8836-8839	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-11	8840-8850	evaluation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-12	8851-8853	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-13	8854-8857	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-14	8858-8863	board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-15	8864-8873	certified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-16	8874-8887	psychiatrists	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-17	8888-8889	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-18	8889-8892	ACL	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-19	8893-8896	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-20	8897-8900	NVK	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-21	8900-8901	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-22	8902-8905	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-23	8906-8915	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-24	8916-8921	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-25	8922-8925	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-26	8926-8936	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[18]	
45-27	8937-8946	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[18]	
45-28	8947-8950	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[18]	
45-29	8951-8958	Genetic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[18]	
45-30	8959-8966	Studies	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[18]	
45-31	8966-8967	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=Exclusion criteria for this study included the presence of major medical or neurological conditions, history of head trauma with loss of consciousness, substance abuse within six months of imaging (excluding nicotine), pregnancy, MRI contraindications, and use of medication altering brain function.
46-1	8968-8977	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-2	8978-8986	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-3	8987-8990	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-4	8991-8995	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-5	8996-9001	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-6	9002-9010	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-7	9011-9014	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-8	9015-9023	presence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-9	9024-9026	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-10	9027-9032	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-11	9033-9040	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-12	9041-9043	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-13	9044-9056	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-14	9057-9067	conditions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-15	9067-9068	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-16	9069-9076	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-17	9077-9079	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-18	9080-9084	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-19	9085-9091	trauma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-20	9092-9096	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-21	9097-9101	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-22	9102-9104	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-23	9105-9118	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-24	9118-9119	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-25	9120-9129	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-26	9130-9135	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-27	9136-9142	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-28	9143-9146	six	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-29	9147-9153	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-30	9154-9156	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-31	9157-9164	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-32	9165-9166	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-33	9166-9175	excluding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-34	9176-9184	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-35	9184-9185	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-36	9185-9186	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-37	9187-9196	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-38	9196-9197	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-39	9198-9201	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-40	9202-9219	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-41	9219-9220	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-42	9221-9224	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-43	9225-9228	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-44	9229-9231	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-45	9232-9242	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-46	9243-9251	altering	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-47	9252-9257	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-48	9258-9266	function	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
46-49	9266-9267	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=Exclusion criteria for healthy controls also included a personal history of Axis I disorders or in first-degree relatives.
47-1	9268-9277	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-2	9278-9286	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-3	9287-9290	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-4	9291-9298	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]	
47-5	9299-9307	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]	
47-6	9308-9312	also	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-7	9313-9321	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-8	9322-9323	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-9	9324-9332	personal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-10	9333-9340	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-11	9341-9343	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-12	9344-9348	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-13	9349-9350	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-14	9351-9360	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-15	9361-9363	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-16	9364-9366	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-17	9367-9379	first-degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-18	9380-9389	relatives	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-19	9389-9390	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	

#Text=A total of 23 first-episode patients with schizophrenia were enrolled in the study.
48-1	9391-9392	A	_	
48-2	9393-9398	total	_	
48-3	9399-9401	of	_	
48-4	9402-9404	23	_	
48-5	9405-9418	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[22]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[23]	
48-6	9419-9427	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[22]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[23]	
48-7	9428-9432	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[22]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[23]	
48-8	9433-9446	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[22]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[23]	
48-9	9447-9451	were	_	
48-10	9452-9460	enrolled	_	
48-11	9461-9463	in	_	
48-12	9464-9467	the	_	
48-13	9468-9473	study	_	
48-14	9473-9474	.	_	

#Text=Of these, fMRI resting-state data for 19 patients remained for analysis as one subject was too large, one subject was unable to complete the scan due to scanner intolerability, one subject was excluded due to poor scan quality, and one subject did not complete a resting-state fMRI scan.
49-1	9475-9477	Of	_	
49-2	9478-9483	these	_	
49-3	9483-9484	,	_	
49-4	9485-9489	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[24]	
49-5	9490-9503	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[24]	
49-6	9504-9508	data	_	
49-7	9509-9512	for	_	
49-8	9513-9515	19	_	
49-9	9516-9524	patients	_	
49-10	9525-9533	remained	_	
49-11	9534-9537	for	_	
49-12	9538-9546	analysis	_	
49-13	9547-9549	as	_	
49-14	9550-9553	one	_	
49-15	9554-9561	subject	_	
49-16	9562-9565	was	_	
49-17	9566-9569	too	_	
49-18	9570-9575	large	_	
49-19	9575-9576	,	_	
49-20	9577-9580	one	_	
49-21	9581-9588	subject	_	
49-22	9589-9592	was	_	
49-23	9593-9599	unable	_	
49-24	9600-9602	to	_	
49-25	9603-9611	complete	_	
49-26	9612-9615	the	_	
49-27	9616-9620	scan	_	
49-28	9621-9624	due	_	
49-29	9625-9627	to	_	
49-30	9628-9635	scanner	_	
49-31	9636-9650	intolerability	_	
49-32	9650-9651	,	_	
49-33	9652-9655	one	_	
49-34	9656-9663	subject	_	
49-35	9664-9667	was	_	
49-36	9668-9676	excluded	_	
49-37	9677-9680	due	_	
49-38	9681-9683	to	_	
49-39	9684-9688	poor	_	
49-40	9689-9693	scan	_	
49-41	9694-9701	quality	_	
49-42	9701-9702	,	_	
49-43	9703-9706	and	_	
49-44	9707-9710	one	_	
49-45	9711-9718	subject	_	
49-46	9719-9722	did	_	
49-47	9723-9726	not	_	
49-48	9727-9735	complete	_	
49-49	9736-9737	a	_	
49-50	9738-9751	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[25]	
49-51	9752-9756	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[25]	
49-52	9757-9761	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[25]	
49-53	9761-9762	.	_	

#Text=MEG data for 19 patients remained for analysis as one subject was too large, one subject was lost to follow-up, one subject was hospitalized long-term, and data for one subject lacked head position sensor information.
50-1	9763-9766	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography	
50-2	9767-9771	data	_	
50-3	9772-9775	for	_	
50-4	9776-9778	19	_	
50-5	9779-9787	patients	_	
50-6	9788-9796	remained	_	
50-7	9797-9800	for	_	
50-8	9801-9809	analysis	_	
50-9	9810-9812	as	_	
50-10	9813-9816	one	_	
50-11	9817-9824	subject	_	
50-12	9825-9828	was	_	
50-13	9829-9832	too	_	
50-14	9833-9838	large	_	
50-15	9838-9839	,	_	
50-16	9840-9843	one	_	
50-17	9844-9851	subject	_	
50-18	9852-9855	was	_	
50-19	9856-9860	lost	_	
50-20	9861-9863	to	_	
50-21	9864-9873	follow-up	_	
50-22	9873-9874	,	_	
50-23	9875-9878	one	_	
50-24	9879-9886	subject	_	
50-25	9887-9890	was	_	
50-26	9891-9903	hospitalized	_	
50-27	9904-9913	long-term	_	
50-28	9913-9914	,	_	
50-29	9915-9918	and	_	
50-30	9919-9923	data	_	
50-31	9924-9927	for	_	
50-32	9928-9931	one	_	
50-33	9932-9939	subject	_	
50-34	9940-9946	lacked	_	
50-35	9947-9951	head	_	
50-36	9952-9960	position	_	
50-37	9961-9967	sensor	_	
50-38	9968-9979	information	_	
50-39	9979-9980	.	_	

#Text=A total of 24 matched healthy controls were enrolled in the study.
51-1	9981-9982	A	_	
51-2	9983-9988	total	_	
51-3	9989-9991	of	_	
51-4	9992-9994	24	_	
51-5	9995-10002	matched	_	
51-6	10003-10010	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]	
51-7	10011-10019	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]	
51-8	10020-10024	were	_	
51-9	10025-10033	enrolled	_	
51-10	10034-10036	in	_	
51-11	10037-10040	the	_	
51-12	10041-10046	study	_	
51-13	10046-10047	.	_	

#Text=Of the 24 controls enrolled, fMRI resting-state data for 21 subjects remained for analysis as three subjects did not complete a resting-state fMRI scan.
52-1	10048-10050	Of	_	
52-2	10051-10054	the	_	
52-3	10055-10057	24	_	
52-4	10058-10066	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
52-5	10067-10075	enrolled	_	
52-6	10075-10076	,	_	
52-7	10077-10081	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[27]	
52-8	10082-10095	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[27]	
52-9	10096-10100	data	_	
52-10	10101-10104	for	_	
52-11	10105-10107	21	_	
52-12	10108-10116	subjects	_	
52-13	10117-10125	remained	_	
52-14	10126-10129	for	_	
52-15	10130-10138	analysis	_	
52-16	10139-10141	as	_	
52-17	10142-10147	three	_	
52-18	10148-10156	subjects	_	
52-19	10157-10160	did	_	
52-20	10161-10164	not	_	
52-21	10165-10173	complete	_	
52-22	10174-10175	a	_	
52-23	10176-10189	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[28]	
52-24	10190-10194	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[28]	
52-25	10195-10199	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[28]	
52-26	10199-10200	.	_	

#Text=MEG data for 24 controls remained for MEG analysis.
53-1	10201-10204	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography	
53-2	10205-10209	data	_	
53-3	10210-10213	for	_	
53-4	10214-10216	24	_	
53-5	10217-10225	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
53-6	10226-10234	remained	_	
53-7	10235-10238	for	_	
53-8	10239-10242	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography	
53-9	10243-10251	analysis	_	
53-10	10251-10252	.	_	

#Text=Symptom severity was assessed using the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Negative Symptoms (SANS), and the Scale for the Assessment of Positive Symptoms (SAPS).
54-1	10253-10260	Symptom	_	
54-2	10261-10269	severity	_	
54-3	10270-10273	was	_	
54-4	10274-10282	assessed	_	
54-5	10283-10288	using	_	
54-6	10289-10292	the	_	
54-7	10293-10298	Brief	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[29]	
54-8	10299-10310	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[29]	
54-9	10311-10317	Rating	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[29]	
54-10	10318-10323	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[29]	
54-11	10324-10325	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[29]	
54-12	10325-10329	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[29]	
54-13	10329-10330	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[29]	
54-14	10330-10331	,	_	
54-15	10332-10335	the	_	
54-16	10336-10341	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[30]	
54-17	10342-10345	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[30]	
54-18	10346-10349	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[30]	
54-19	10350-10360	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[30]	
54-20	10361-10363	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[30]	
54-21	10364-10372	Negative	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[30]	
54-22	10373-10381	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[30]	
54-23	10382-10383	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[30]	
54-24	10383-10387	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[30]	
54-25	10387-10388	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[30]	
54-26	10388-10389	,	_	
54-27	10390-10393	and	_	
54-28	10394-10397	the	_	
54-29	10398-10403	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[31]	
54-30	10404-10407	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[31]	
54-31	10408-10411	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[31]	
54-32	10412-10422	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[31]	
54-33	10423-10425	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[31]	
54-34	10426-10434	Positive	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[31]	
54-35	10435-10443	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[31]	
54-36	10444-10445	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[31]	
54-37	10445-10449	SAPS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[31]	
54-38	10449-10450	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[31]	
54-39	10450-10451	.	_	

#Text=The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) was used to assess cognitive function for healthy controls and patients.
55-1	10452-10455	The	_	
55-2	10456-10466	Repeatable	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
55-3	10467-10474	Battery	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
55-4	10475-10478	for	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
55-5	10479-10482	the	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
55-6	10483-10493	Assessment	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
55-7	10494-10496	of	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
55-8	10497-10515	Neuropsychological	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
55-9	10516-10522	Status	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
55-10	10523-10524	(	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
55-11	10524-10529	RBANS	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
55-12	10529-10530	)	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
55-13	10531-10534	was	_	
55-14	10535-10539	used	_	
55-15	10540-10542	to	_	
55-16	10543-10549	assess	_	
55-17	10550-10559	cognitive	_	
55-18	10560-10568	function	_	
55-19	10569-10572	for	_	
55-20	10573-10580	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[33]	
55-21	10581-10589	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[33]	
55-22	10590-10593	and	_	
55-23	10594-10602	patients	_	
55-24	10602-10603	.	_	

#Text=Functional MRI analysis
#Text=fMRI scanning parameters
#Text=All scans were performed at the Auburn University MRI Research Center on a whole-body 7 T Siemens MAGNETOM MRI scanner (Siemens Healthineers, Erlangen, Germany), with a 32-channel head coil.
56-1	10604-10614	Functional	_	
56-2	10615-10618	MRI	_	
56-3	10619-10627	analysis	_	
56-4	10628-10632	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
56-5	10633-10641	scanning	_	
56-6	10642-10652	parameters	_	
56-7	10653-10656	All	_	
56-8	10657-10662	scans	_	
56-9	10663-10667	were	_	
56-10	10668-10677	performed	_	
56-11	10678-10680	at	_	
56-12	10681-10684	the	_	
56-13	10685-10691	Auburn	_	
56-14	10692-10702	University	_	
56-15	10703-10706	MRI	_	
56-16	10707-10715	Research	_	
56-17	10716-10722	Center	_	
56-18	10723-10725	on	_	
56-19	10726-10727	a	_	
56-20	10728-10738	whole-body	_	
56-21	10739-10740	7	_	
56-22	10740-10741	 	_	
56-23	10741-10742	T	_	
56-24	10743-10750	Siemens	_	
56-25	10751-10759	MAGNETOM	_	
56-26	10760-10763	MRI	_	
56-27	10764-10771	scanner	_	
56-28	10772-10773	(	_	
56-29	10773-10780	Siemens	_	
56-30	10781-10793	Healthineers	_	
56-31	10793-10794	,	_	
56-32	10795-10803	Erlangen	_	
56-33	10803-10804	,	_	
56-34	10805-10812	Germany	_	
56-35	10812-10813	)	_	
56-36	10813-10814	,	_	
56-37	10815-10819	with	_	
56-38	10820-10821	a	_	
56-39	10822-10824	32	_	
56-40	10824-10825	-	_	
56-41	10825-10832	channel	_	
56-42	10833-10837	head	_	
56-43	10838-10842	coil	_	
56-44	10842-10843	.	_	

#Text=High-resolution structural scans were acquired using a 3-dimensional T1-weighted magnetization-prepared rapid acquisition gradient-echo sequence (MPRAGE; 256 slices, repetition time/echo time/inversion time [TR/TE/TI] = 2000/2.89/1050 ms, 7° flip angle, 190 mm field of view, 0.7 mm isotropic voxels, base resolution = 256, sagittal acquisition, GRAPPA acceleration factor = 2).
57-1	10844-10859	High-resolution	_	
57-2	10860-10870	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
57-3	10871-10876	scans	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
57-4	10877-10881	were	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
57-5	10882-10890	acquired	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
57-6	10891-10896	using	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
57-7	10897-10898	a	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
57-8	10899-10900	3	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
57-9	10900-10901	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
57-10	10901-10912	dimensional	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
57-11	10913-10915	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
57-12	10915-10916	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
57-13	10916-10924	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
57-14	10925-10947	magnetization-prepared	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
57-15	10948-10953	rapid	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
57-16	10954-10965	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
57-17	10966-10979	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
57-18	10980-10988	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]	
57-19	10989-10990	(	_	
57-20	10990-10996	MPRAGE	_	
57-21	10996-10997	;	_	
57-22	10998-11001	256	_	
57-23	11002-11008	slices	_	
57-24	11008-11009	,	_	
57-25	11010-11020	repetition	_	
57-26	11021-11025	time	_	
57-27	11025-11026	/	_	
57-28	11026-11030	echo	_	
57-29	11031-11035	time	_	
57-30	11035-11036	/	_	
57-31	11036-11045	inversion	_	
57-32	11046-11050	time	_	
57-33	11051-11052	[	_	
57-34	11052-11054	TR	_	
57-35	11054-11055	/	_	
57-36	11055-11057	TE	_	
57-37	11057-11058	/	_	
57-38	11058-11060	TI	_	
57-39	11060-11061	]	_	
57-40	11061-11062	 	_	
57-41	11062-11063	=	_	
57-42	11063-11064	 	_	
57-43	11064-11068	2000	_	
57-44	11068-11069	/	_	
57-45	11069-11073	2.89	_	
57-46	11073-11074	/	_	
57-47	11074-11078	1050	_	
57-48	11078-11079	 	_	
57-49	11079-11081	ms	_	
57-50	11081-11082	,	_	
57-51	11083-11084	7	_	
57-52	11084-11085	°	_	
57-53	11086-11090	flip	_	
57-54	11091-11096	angle	_	
57-55	11096-11097	,	_	
57-56	11098-11101	190	_	
57-57	11101-11102	 	_	
57-58	11102-11104	mm	_	
57-59	11105-11110	field	_	
57-60	11111-11113	of	_	
57-61	11114-11118	view	_	
57-62	11118-11119	,	_	
57-63	11120-11123	0.7	_	
57-64	11123-11124	 	_	
57-65	11124-11126	mm	_	
57-66	11127-11136	isotropic	_	
57-67	11137-11143	voxels	_	
57-68	11143-11144	,	_	
57-69	11145-11149	base	_	
57-70	11150-11160	resolution	_	
57-71	11160-11161	 	_	
57-72	11161-11162	=	_	
57-73	11162-11163	 	_	
57-74	11163-11166	256	_	
57-75	11166-11167	,	_	
57-76	11168-11176	sagittal	_	
57-77	11177-11188	acquisition	_	
57-78	11188-11189	,	_	
57-79	11190-11196	GRAPPA	_	
57-80	11197-11209	acceleration	_	
57-81	11210-11216	factor	_	
57-82	11216-11217	 	_	
57-83	11217-11218	=	_	
57-84	11218-11219	 	_	
57-85	11219-11220	2	_	
57-86	11220-11221	)	_	
57-87	11221-11222	.	_	

#Text=Resting-state fMRI scans were acquired using a gradient recalled echo-planar imaging sequence (TR/TE = 3000/28 ms, 70° flip angle, 200 mm field of view, 37 slices, 0.85 mm × 0.85 mm × 1.8 mm voxels, iPAT GRAPPA acceleration factor = 3, base resolution = 234, interleaved acquisition, A > P phase encode direction, 1 ms echo spacing, gap = 1.08 mm).
58-1	11223-11236	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
58-2	11237-11241	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
58-3	11242-11247	scans	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]	
58-4	11248-11252	were	_	
58-5	11253-11261	acquired	_	
58-6	11262-11267	using	_	
58-7	11268-11269	a	_	
58-8	11270-11278	gradient	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[36]	
58-9	11279-11287	recalled	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[36]	
58-10	11288-11299	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[36]	
58-11	11300-11307	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[36]	
58-12	11308-11316	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[36]	
58-13	11317-11318	(	_	
58-14	11318-11320	TR	_	
58-15	11320-11321	/	_	
58-16	11321-11323	TE	_	
58-17	11323-11324	 	_	
58-18	11324-11325	=	_	
58-19	11325-11326	 	_	
58-20	11326-11330	3000	_	
58-21	11330-11331	/	_	
58-22	11331-11333	28	_	
58-23	11333-11334	 	_	
58-24	11334-11336	ms	_	
58-25	11336-11337	,	_	
58-26	11338-11340	70	_	
58-27	11340-11341	°	_	
58-28	11342-11346	flip	_	
58-29	11347-11352	angle	_	
58-30	11352-11353	,	_	
58-31	11354-11357	200	_	
58-32	11357-11358	 	_	
58-33	11358-11360	mm	_	
58-34	11361-11366	field	_	
58-35	11367-11369	of	_	
58-36	11370-11374	view	_	
58-37	11374-11375	,	_	
58-38	11376-11378	37	_	
58-39	11379-11385	slices	_	
58-40	11385-11386	,	_	
58-41	11387-11391	0.85	_	
58-42	11391-11392	 	_	
58-43	11392-11394	mm	_	
58-44	11394-11395	 	_	
58-45	11395-11396	×	_	
58-46	11396-11397	 	_	
58-47	11397-11401	0.85	_	
58-48	11401-11402	 	_	
58-49	11402-11404	mm	_	
58-50	11404-11405	 	_	
58-51	11405-11406	×	_	
58-52	11406-11407	 	_	
58-53	11407-11410	1.8	_	
58-54	11410-11411	 	_	
58-55	11411-11413	mm	_	
58-56	11414-11420	voxels	_	
58-57	11420-11421	,	_	
58-58	11422-11426	iPAT	_	
58-59	11427-11433	GRAPPA	_	
58-60	11434-11446	acceleration	_	
58-61	11447-11453	factor	_	
58-62	11453-11454	 	_	
58-63	11454-11455	=	_	
58-64	11455-11456	 	_	
58-65	11456-11457	3	_	
58-66	11457-11458	,	_	
58-67	11459-11463	base	_	
58-68	11464-11474	resolution	_	
58-69	11474-11475	 	_	
58-70	11475-11476	=	_	
58-71	11476-11477	 	_	
58-72	11477-11480	234	_	
58-73	11480-11481	,	_	
58-74	11482-11493	interleaved	_	
58-75	11494-11505	acquisition	_	
58-76	11505-11506	,	_	
58-77	11507-11508	A	_	
58-78	11508-11509	 	_	
58-79	11509-11510	>	_	
58-80	11510-11511	 	_	
58-81	11511-11512	P	_	
58-82	11513-11518	phase	_	
58-83	11519-11525	encode	_	
58-84	11526-11535	direction	_	
58-85	11535-11536	,	_	
58-86	11537-11538	1	_	
58-87	11538-11539	 	_	
58-88	11539-11541	ms	_	
58-89	11542-11546	echo	_	
58-90	11547-11554	spacing	_	
58-91	11554-11555	,	_	
58-92	11556-11559	gap	_	
58-93	11559-11560	 	_	
58-94	11560-11561	=	_	
58-95	11561-11562	 	_	
58-96	11562-11566	1.08	_	
58-97	11566-11567	 	_	
58-98	11567-11569	mm	_	
58-99	11569-11570	)	_	
58-100	11570-11571	.	_	

#Text=Six-minute resting-state scans consisted of 120 volumes.
59-1	11572-11582	Six-minute	_	
59-2	11583-11596	resting-state	_	
59-3	11597-11602	scans	_	
59-4	11603-11612	consisted	_	
59-5	11613-11615	of	_	
59-6	11616-11619	120	_	
59-7	11620-11627	volumes	_	
59-8	11627-11628	.	_	

#Text=Field maps were acquired using a gradient-recalled echo (GRE) sequence (TR/TE1/TE2 = 400/4.92/7.38 ms, 60° flip angle, 200 mm field of view, 36 slices, 3.1 mm × 3.1 mm × 3.0 mm voxels, base resolution = 64, interleaved acquisition, gap = 0.75 mm).
#Text=fMRI preprocessing
#Text=Data preprocessing of resting-state scans was performed with SPM12 (Wellcome Trust Centre for Neuroimaging, London, UK; http://www.fil.ion.ucl.ac.uk/spm/) and the “CONN” Connectivity Toolbox using standard preprocessing steps.
60-1	11629-11634	Field	_	
60-2	11635-11639	maps	_	
60-3	11640-11644	were	_	
60-4	11645-11653	acquired	_	
60-5	11654-11659	using	_	
60-6	11660-11661	a	_	
60-7	11662-11679	gradient-recalled	_	
60-8	11680-11684	echo	_	
60-9	11685-11686	(	_	
60-10	11686-11689	GRE	_	
60-11	11689-11690	)	_	
60-12	11691-11699	sequence	_	
60-13	11700-11701	(	_	
60-14	11701-11703	TR	_	
60-15	11703-11704	/	_	
60-16	11704-11707	TE1	_	
60-17	11707-11708	/	_	
60-18	11708-11711	TE2	_	
60-19	11711-11712	 	_	
60-20	11712-11713	=	_	
60-21	11713-11714	 	_	
60-22	11714-11717	400	_	
60-23	11717-11718	/	_	
60-24	11718-11722	4.92	_	
60-25	11722-11723	/	_	
60-26	11723-11727	7.38	_	
60-27	11727-11728	 	_	
60-28	11728-11730	ms	_	
60-29	11730-11731	,	_	
60-30	11732-11734	60	_	
60-31	11734-11735	°	_	
60-32	11736-11740	flip	_	
60-33	11741-11746	angle	_	
60-34	11746-11747	,	_	
60-35	11748-11751	200	_	
60-36	11751-11752	 	_	
60-37	11752-11754	mm	_	
60-38	11755-11760	field	_	
60-39	11761-11763	of	_	
60-40	11764-11768	view	_	
60-41	11768-11769	,	_	
60-42	11770-11772	36	_	
60-43	11773-11779	slices	_	
60-44	11779-11780	,	_	
60-45	11781-11784	3.1	_	
60-46	11784-11785	 	_	
60-47	11785-11787	mm	_	
60-48	11787-11788	 	_	
60-49	11788-11789	×	_	
60-50	11789-11790	 	_	
60-51	11790-11793	3.1	_	
60-52	11793-11794	 	_	
60-53	11794-11796	mm	_	
60-54	11796-11797	 	_	
60-55	11797-11798	×	_	
60-56	11798-11799	 	_	
60-57	11799-11802	3.0	_	
60-58	11802-11803	 	_	
60-59	11803-11805	mm	_	
60-60	11806-11812	voxels	_	
60-61	11812-11813	,	_	
60-62	11814-11818	base	_	
60-63	11819-11829	resolution	_	
60-64	11829-11830	 	_	
60-65	11830-11831	=	_	
60-66	11831-11832	 	_	
60-67	11832-11834	64	_	
60-68	11834-11835	,	_	
60-69	11836-11847	interleaved	_	
60-70	11848-11859	acquisition	_	
60-71	11859-11860	,	_	
60-72	11861-11864	gap	_	
60-73	11864-11865	 	_	
60-74	11865-11866	=	_	
60-75	11866-11867	 	_	
60-76	11867-11871	0.75	_	
60-77	11871-11872	 	_	
60-78	11872-11874	mm	_	
60-79	11874-11875	)	_	
60-80	11875-11876	.	_	
60-81	11877-11881	fMRI	_	
60-82	11882-11895	preprocessing	_	
60-83	11896-11900	Data	_	
60-84	11901-11914	preprocessing	_	
60-85	11915-11917	of	_	
60-86	11918-11931	resting-state	_	
60-87	11932-11937	scans	_	
60-88	11938-11941	was	_	
60-89	11942-11951	performed	_	
60-90	11952-11956	with	_	
60-91	11957-11962	SPM12	_	
60-92	11963-11964	(	_	
60-93	11964-11972	Wellcome	_	
60-94	11973-11978	Trust	_	
60-95	11979-11985	Centre	_	
60-96	11986-11989	for	_	
60-97	11990-12002	Neuroimaging	_	
60-98	12002-12003	,	_	
60-99	12004-12010	London	_	
60-100	12010-12011	,	_	
60-101	12012-12014	UK	_	
60-102	12014-12015	;	_	
60-103	12016-12020	http	_	
60-104	12020-12021	:	_	
60-105	12021-12022	/	_	
60-106	12022-12023	/	_	
60-107	12023-12044	www.fil.ion.ucl.ac.uk	_	
60-108	12044-12045	/	_	
60-109	12045-12048	spm	_	
60-110	12048-12049	/	_	
60-111	12049-12050	)	_	
60-112	12051-12054	and	_	
60-113	12055-12058	the	_	
60-114	12059-12060	“	_	
60-115	12060-12064	CONN	_	
60-116	12064-12065	”	_	
60-117	12066-12078	Connectivity	_	
60-118	12079-12086	Toolbox	_	
60-119	12087-12092	using	_	
60-120	12093-12101	standard	_	
60-121	12102-12115	preprocessing	_	
60-122	12116-12121	steps	_	
60-123	12121-12122	.	_	

#Text=More specifically, preprocessing steps included realignment and unwarping using phase maps, slice timing correction, coregistration to anatomical space using the T1-weighted MPRAGE structural image and using the first functional image as reference, normalization to Montreal Neurological Institute (MNI) space using the first functional volume as reference, artifact detection, and Gaussian smoothing [5 mm full-width half-maximum (FWHM)].
61-1	12123-12127	More	_	
61-2	12128-12140	specifically	_	
61-3	12140-12141	,	_	
61-4	12142-12155	preprocessing	_	
61-5	12156-12161	steps	_	
61-6	12162-12170	included	_	
61-7	12171-12182	realignment	_	
61-8	12183-12186	and	_	
61-9	12187-12196	unwarping	_	
61-10	12197-12202	using	_	
61-11	12203-12208	phase	_	
61-12	12209-12213	maps	_	
61-13	12213-12214	,	_	
61-14	12215-12220	slice	_	
61-15	12221-12227	timing	_	
61-16	12228-12238	correction	_	
61-17	12238-12239	,	_	
61-18	12240-12254	coregistration	_	
61-19	12255-12257	to	_	
61-20	12258-12268	anatomical	_	
61-21	12269-12274	space	_	
61-22	12275-12280	using	_	
61-23	12281-12284	the	_	
61-24	12285-12287	T1	_	
61-25	12287-12288	-	_	
61-26	12288-12296	weighted	_	
61-27	12297-12303	MPRAGE	_	
61-28	12304-12314	structural	_	
61-29	12315-12320	image	_	
61-30	12321-12324	and	_	
61-31	12325-12330	using	_	
61-32	12331-12334	the	_	
61-33	12335-12340	first	_	
61-34	12341-12351	functional	_	
61-35	12352-12357	image	_	
61-36	12358-12360	as	_	
61-37	12361-12370	reference	_	
61-38	12370-12371	,	_	
61-39	12372-12385	normalization	_	
61-40	12386-12388	to	_	
61-41	12389-12397	Montreal	_	
61-42	12398-12410	Neurological	_	
61-43	12411-12420	Institute	_	
61-44	12421-12422	(	_	
61-45	12422-12425	MNI	_	
61-46	12425-12426	)	_	
61-47	12427-12432	space	_	
61-48	12433-12438	using	_	
61-49	12439-12442	the	_	
61-50	12443-12448	first	_	
61-51	12449-12459	functional	_	
61-52	12460-12466	volume	_	
61-53	12467-12469	as	_	
61-54	12470-12479	reference	_	
61-55	12479-12480	,	_	
61-56	12481-12489	artifact	_	
61-57	12490-12499	detection	_	
61-58	12499-12500	,	_	
61-59	12501-12504	and	_	
61-60	12505-12513	Gaussian	_	
61-61	12514-12523	smoothing	_	
61-62	12524-12525	[	_	
61-63	12525-12526	5	_	
61-64	12526-12527	 	_	
61-65	12527-12529	mm	_	
61-66	12530-12540	full-width	_	
61-67	12541-12553	half-maximum	_	
61-68	12554-12555	(	_	
61-69	12555-12559	FWHM	_	
61-70	12559-12560	)	_	
61-71	12560-12561	]	_	
61-72	12561-12562	.	_	

#Text=Resulting preprocessed functional resting-state data maintained a spatial resolution of 0.855 mm × 0.855 mm × 2.88 mm.
#Text=fMRI group independent component analysis
#Text=The Group ICA of fMRI Toolbox (GIFT; http://mialab.mrn.org/software/gift) was used to perform group-level spatial independent component analysis (ICA).
62-1	12563-12572	Resulting	_	
62-2	12573-12585	preprocessed	_	
62-3	12586-12596	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[37]	
62-4	12597-12610	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[37]	
62-5	12611-12615	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[37]	
62-6	12616-12626	maintained	_	
62-7	12627-12628	a	_	
62-8	12629-12636	spatial	_	
62-9	12637-12647	resolution	_	
62-10	12648-12650	of	_	
62-11	12651-12656	0.855	_	
62-12	12656-12657	 	_	
62-13	12657-12659	mm	_	
62-14	12659-12660	 	_	
62-15	12660-12661	×	_	
62-16	12661-12662	 	_	
62-17	12662-12667	0.855	_	
62-18	12667-12668	 	_	
62-19	12668-12670	mm	_	
62-20	12670-12671	 	_	
62-21	12671-12672	×	_	
62-22	12672-12673	 	_	
62-23	12673-12677	2.88	_	
62-24	12677-12678	 	_	
62-25	12678-12680	mm	_	
62-26	12680-12681	.	_	
62-27	12682-12686	fMRI	_	
62-28	12687-12692	group	_	
62-29	12693-12704	independent	_	
62-30	12705-12714	component	_	
62-31	12715-12723	analysis	_	
62-32	12724-12727	The	_	
62-33	12728-12733	Group	_	
62-34	12734-12737	ICA	_	
62-35	12738-12740	of	_	
62-36	12741-12745	fMRI	_	
62-37	12746-12753	Toolbox	_	
62-38	12754-12755	(	_	
62-39	12755-12759	GIFT	_	
62-40	12759-12760	;	_	
62-41	12761-12765	http	_	
62-42	12765-12766	:	_	
62-43	12766-12767	/	_	
62-44	12767-12768	/	_	
62-45	12768-12782	mialab.mrn.org	_	
62-46	12782-12783	/	_	
62-47	12783-12791	software	_	
62-48	12791-12792	/	_	
62-49	12792-12796	gift	_	
62-50	12796-12797	)	_	
62-51	12798-12801	was	_	
62-52	12802-12806	used	_	
62-53	12807-12809	to	_	
62-54	12810-12817	perform	_	
62-55	12818-12829	group-level	_	
62-56	12830-12837	spatial	_	
62-57	12838-12849	independent	_	
62-58	12850-12859	component	_	
62-59	12860-12868	analysis	_	
62-60	12869-12870	(	_	
62-61	12870-12873	ICA	_	
62-62	12873-12874	)	_	
62-63	12874-12875	.	_	

#Text=A subject-specific data reduction principal component analysis (PCA) first reduced the data to 75 principal components followed by a group data reduction retaining 50 principal components.
63-1	12876-12877	A	_	
63-2	12878-12894	subject-specific	_	
63-3	12895-12899	data	_	
63-4	12900-12909	reduction	_	
63-5	12910-12919	principal	_	
63-6	12920-12929	component	_	
63-7	12930-12938	analysis	_	
63-8	12939-12940	(	_	
63-9	12940-12943	PCA	_	
63-10	12943-12944	)	_	
63-11	12945-12950	first	_	
63-12	12951-12958	reduced	_	
63-13	12959-12962	the	_	
63-14	12963-12967	data	_	
63-15	12968-12970	to	_	
63-16	12971-12973	75	_	
63-17	12974-12983	principal	_	
63-18	12984-12994	components	_	
63-19	12995-13003	followed	_	
63-20	13004-13006	by	_	
63-21	13007-13008	a	_	
63-22	13009-13014	group	_	
63-23	13015-13019	data	_	
63-24	13020-13029	reduction	_	
63-25	13030-13039	retaining	_	
63-26	13040-13042	50	_	
63-27	13043-13052	principal	_	
63-28	13053-13063	components	_	
63-29	13063-13064	.	_	

#Text=In order to carry out PCA in a memory efficient-manner, PCA was carried out using the expectation maximization algorithm.
64-1	13065-13067	In	_	
64-2	13068-13073	order	_	
64-3	13074-13076	to	_	
64-4	13077-13082	carry	_	
64-5	13083-13086	out	_	
64-6	13087-13090	PCA	_	
64-7	13091-13093	in	_	
64-8	13094-13095	a	_	
64-9	13096-13102	memory	_	
64-10	13103-13119	efficient-manner	_	
64-11	13119-13120	,	_	
64-12	13121-13124	PCA	_	
64-13	13125-13128	was	_	
64-14	13129-13136	carried	_	
64-15	13137-13140	out	_	
64-16	13141-13146	using	_	
64-17	13147-13150	the	_	
64-18	13151-13162	expectation	_	
64-19	13163-13175	maximization	_	
64-20	13176-13185	algorithm	_	
64-21	13185-13186	.	_	

#Text=The infomax algorithm was then utilized for group-level spatial ICA to generate 50 spatially independent components (ICs) (See Supplementary Fig. 1 for estimation of the number of ICs using minimum description length criteria).
65-1	13187-13190	The	_	
65-2	13191-13198	infomax	_	
65-3	13199-13208	algorithm	_	
65-4	13209-13212	was	_	
65-5	13213-13217	then	_	
65-6	13218-13226	utilized	_	
65-7	13227-13230	for	_	
65-8	13231-13242	group-level	_	
65-9	13243-13250	spatial	_	
65-10	13251-13254	ICA	_	
65-11	13255-13257	to	_	
65-12	13258-13266	generate	_	
65-13	13267-13269	50	_	
65-14	13270-13279	spatially	_	
65-15	13280-13291	independent	_	
65-16	13292-13302	components	_	
65-17	13303-13304	(	_	
65-18	13304-13307	ICs	_	
65-19	13307-13308	)	_	
65-20	13309-13310	(	_	
65-21	13310-13313	See	_	
65-22	13314-13327	Supplementary	_	
65-23	13328-13331	Fig	_	
65-24	13331-13332	.	_	
65-25	13333-13334	1	_	
65-26	13335-13338	for	_	
65-27	13339-13349	estimation	_	
65-28	13350-13352	of	_	
65-29	13353-13356	the	_	
65-30	13357-13363	number	_	
65-31	13364-13366	of	_	
65-32	13367-13370	ICs	_	
65-33	13371-13376	using	_	
65-34	13377-13384	minimum	_	
65-35	13385-13396	description	_	
65-36	13397-13403	length	_	
65-37	13404-13412	criteria	_	
65-38	13412-13413	)	_	
65-39	13413-13414	.	_	

#Text=In order to measure component stability/quality, the infomax ICA algorithm was repeated 20 times in ICASSO and the most representative run was used in subsequent steps.
66-1	13415-13417	In	_	
66-2	13418-13423	order	_	
66-3	13424-13426	to	_	
66-4	13427-13434	measure	_	
66-5	13435-13444	component	_	
66-6	13445-13454	stability	_	
66-7	13454-13455	/	_	
66-8	13455-13462	quality	_	
66-9	13462-13463	,	_	
66-10	13464-13467	the	_	
66-11	13468-13475	infomax	_	
66-12	13476-13479	ICA	_	
66-13	13480-13489	algorithm	_	
66-14	13490-13493	was	_	
66-15	13494-13502	repeated	_	
66-16	13503-13505	20	_	
66-17	13506-13511	times	_	
66-18	13512-13514	in	_	
66-19	13515-13521	ICASSO	_	
66-20	13522-13525	and	_	
66-21	13526-13529	the	_	
66-22	13530-13534	most	_	
66-23	13535-13549	representative	_	
66-24	13550-13553	run	_	
66-25	13554-13557	was	_	
66-26	13558-13562	used	_	
66-27	13563-13565	in	_	
66-28	13566-13576	subsequent	_	
66-29	13577-13582	steps	_	
66-30	13582-13583	.	_	

#Text=Subject-specific spatial maps and time courses were estimated using GICA back-reconstruction.
#Text=fMRI component identification
#Text=Composite fMRI and MEG spatial maps.
67-1	13584-13600	Subject-specific	_	
67-2	13601-13608	spatial	_	
67-3	13609-13613	maps	_	
67-4	13614-13617	and	_	
67-5	13618-13622	time	_	
67-6	13623-13630	courses	_	
67-7	13631-13635	were	_	
67-8	13636-13645	estimated	_	
67-9	13646-13651	using	_	
67-10	13652-13656	GICA	_	
67-11	13657-13676	back-reconstruction	_	
67-12	13676-13677	.	_	
67-13	13678-13682	fMRI	_	
67-14	13683-13692	component	_	
67-15	13693-13707	identification	_	
67-16	13708-13717	Composite	_	
67-17	13718-13722	fMRI	_	
67-18	13723-13726	and	_	
67-19	13727-13730	MEG	_	
67-20	13731-13738	spatial	_	
67-21	13739-13743	maps	_	
67-22	13743-13744	.	_	

#Text=Composite maps of the 30 fMRI (left column) and 33 MEG (right column) resting-state independent component spatial maps.
68-1	13745-13754	Composite	_	
68-2	13755-13759	maps	_	
68-3	13760-13762	of	_	
68-4	13763-13766	the	_	
68-5	13767-13769	30	_	
68-6	13770-13774	fMRI	_	
68-7	13775-13776	(	_	
68-8	13776-13780	left	_	
68-9	13781-13787	column	_	
68-10	13787-13788	)	_	
68-11	13789-13792	and	_	
68-12	13793-13795	33	_	
68-13	13796-13799	MEG	_	
68-14	13800-13801	(	_	
68-15	13801-13806	right	_	
68-16	13807-13813	column	_	
68-17	13813-13814	)	_	
68-18	13815-13828	resting-state	_	
68-19	13829-13840	independent	_	
68-20	13841-13850	component	_	
68-21	13851-13858	spatial	_	
68-22	13859-13863	maps	_	
68-23	13863-13864	.	_	

#Text=Components are categorized into auditory, sensorimotor, visual, task positive, default-mode, and subcortical networks.
69-1	13865-13875	Components	_	
69-2	13876-13879	are	_	
69-3	13880-13891	categorized	_	
69-4	13892-13896	into	_	
69-5	13897-13905	auditory	_	
69-6	13905-13906	,	_	
69-7	13907-13919	sensorimotor	_	
69-8	13919-13920	,	_	
69-9	13921-13927	visual	_	
69-10	13927-13928	,	_	
69-11	13929-13933	task	_	
69-12	13934-13942	positive	_	
69-13	13942-13943	,	_	
69-14	13944-13956	default-mode	_	
69-15	13956-13957	,	_	
69-16	13958-13961	and	_	
69-17	13962-13973	subcortical	_	
69-18	13974-13982	networks	_	
69-19	13982-13983	.	_	

#Text=Colors in each map represent a different component and are indicated with the component number.
70-1	13984-13990	Colors	_	
70-2	13991-13993	in	_	
70-3	13994-13998	each	_	
70-4	13999-14002	map	_	
70-5	14003-14012	represent	_	
70-6	14013-14014	a	_	
70-7	14015-14024	different	_	
70-8	14025-14034	component	_	
70-9	14035-14038	and	_	
70-10	14039-14042	are	_	
70-11	14043-14052	indicated	_	
70-12	14053-14057	with	_	
70-13	14058-14061	the	_	
70-14	14062-14071	component	_	
70-15	14072-14078	number	_	
70-16	14078-14079	.	_	

#Text=The number of components in each network is indicated behind the network name.
71-1	14080-14083	The	_	
71-2	14084-14090	number	_	
71-3	14091-14093	of	_	
71-4	14094-14104	components	_	
71-5	14105-14107	in	_	
71-6	14108-14112	each	_	
71-7	14113-14120	network	_	
71-8	14121-14123	is	_	
71-9	14124-14133	indicated	_	
71-10	14134-14140	behind	_	
71-11	14141-14144	the	_	
71-12	14145-14152	network	_	
71-13	14153-14157	name	_	
71-14	14157-14158	.	_	

#Text=Peak activations of individual components can be found in Table S1 (fMRI) and Table S2 (MEG) in Supplementary Material.
72-1	14159-14163	Peak	_	
72-2	14164-14175	activations	_	
72-3	14176-14178	of	_	
72-4	14179-14189	individual	_	
72-5	14190-14200	components	_	
72-6	14201-14204	can	_	
72-7	14205-14207	be	_	
72-8	14208-14213	found	_	
72-9	14214-14216	in	_	
72-10	14217-14222	Table	_	
72-11	14223-14225	S1	_	
72-12	14226-14227	(	_	
72-13	14227-14231	fMRI	_	
72-14	14231-14232	)	_	
72-15	14233-14236	and	_	
72-16	14237-14242	Table	_	
72-17	14243-14245	S2	_	
72-18	14246-14247	(	_	
72-19	14247-14250	MEG	_	
72-20	14250-14251	)	_	
72-21	14252-14254	in	_	
72-22	14255-14268	Supplementary	_	
72-23	14269-14277	Material	_	
72-24	14277-14278	.	_	

#Text=Fig. 1
#Text=In accordance with previous studies, ICs were classified as resting-state networks (RSNs), rather than artifacts, based on spectral properties and functional relevance.
73-1	14279-14282	Fig	_	
73-2	14282-14283	.	_	
73-3	14284-14285	1	_	
73-4	14286-14288	In	_	
73-5	14289-14299	accordance	_	
73-6	14300-14304	with	_	
73-7	14305-14313	previous	_	
73-8	14314-14321	studies	_	
73-9	14321-14322	,	_	
73-10	14323-14326	ICs	_	
73-11	14327-14331	were	_	
73-12	14332-14342	classified	_	
73-13	14343-14345	as	_	
73-14	14346-14359	resting-state	_	
73-15	14360-14368	networks	_	
73-16	14369-14370	(	_	
73-17	14370-14374	RSNs	_	
73-18	14374-14375	)	_	
73-19	14375-14376	,	_	
73-20	14377-14383	rather	_	
73-21	14384-14388	than	_	
73-22	14389-14398	artifacts	_	
73-23	14398-14399	,	_	
73-24	14400-14405	based	_	
73-25	14406-14408	on	_	
73-26	14409-14417	spectral	_	
73-27	14418-14428	properties	_	
73-28	14429-14432	and	_	
73-29	14433-14443	functional	_	
73-30	14444-14453	relevance	_	
73-31	14453-14454	.	_	

#Text=The power spectra for each component were characterized by dynamic range and the ratio of low frequency to high frequency power.
74-1	14455-14458	The	_	
74-2	14459-14464	power	_	
74-3	14465-14472	spectra	_	
74-4	14473-14476	for	_	
74-5	14477-14481	each	_	
74-6	14482-14491	component	_	
74-7	14492-14496	were	_	
74-8	14497-14510	characterized	_	
74-9	14511-14513	by	_	
74-10	14514-14521	dynamic	_	
74-11	14522-14527	range	_	
74-12	14528-14531	and	_	
74-13	14532-14535	the	_	
74-14	14536-14541	ratio	_	
74-15	14542-14544	of	_	
74-16	14545-14548	low	_	
74-17	14549-14558	frequency	_	
74-18	14559-14561	to	_	
74-19	14562-14566	high	_	
74-20	14567-14576	frequency	_	
74-21	14577-14582	power	_	
74-22	14582-14583	.	_	

#Text=Dynamic range can be defined as the difference between maximum power and minimum power at frequencies to the right of the power spectra peak.
75-1	14584-14591	Dynamic	_	
75-2	14592-14597	range	_	
75-3	14598-14601	can	_	
75-4	14602-14604	be	_	
75-5	14605-14612	defined	_	
75-6	14613-14615	as	_	
75-7	14616-14619	the	_	
75-8	14620-14630	difference	_	
75-9	14631-14638	between	_	
75-10	14639-14646	maximum	_	
75-11	14647-14652	power	_	
75-12	14653-14656	and	_	
75-13	14657-14664	minimum	_	
75-14	14665-14670	power	_	
75-15	14671-14673	at	_	
75-16	14674-14685	frequencies	_	
75-17	14686-14688	to	_	
75-18	14689-14692	the	_	
75-19	14693-14698	right	_	
75-20	14699-14701	of	_	
75-21	14702-14705	the	_	
75-22	14706-14711	power	_	
75-23	14712-14719	spectra	_	
75-24	14720-14724	peak	_	
75-25	14724-14725	.	_	

#Text=The ratio of low frequency to high frequency power can be defined as the ratio of integral spectral power below 0.1 Hz to integral spectral power between 0.15 and 0.167 Hz.
76-1	14726-14729	The	_	
76-2	14730-14735	ratio	_	
76-3	14736-14738	of	_	
76-4	14739-14742	low	_	
76-5	14743-14752	frequency	_	
76-6	14753-14755	to	_	
76-7	14756-14760	high	_	
76-8	14761-14770	frequency	_	
76-9	14771-14776	power	_	
76-10	14777-14780	can	_	
76-11	14781-14783	be	_	
76-12	14784-14791	defined	_	
76-13	14792-14794	as	_	
76-14	14795-14798	the	_	
76-15	14799-14804	ratio	_	
76-16	14805-14807	of	_	
76-17	14808-14816	integral	_	
76-18	14817-14825	spectral	_	
76-19	14826-14831	power	_	
76-20	14832-14837	below	_	
76-21	14838-14841	0.1	_	
76-22	14841-14842	 	_	
76-23	14842-14844	Hz	_	
76-24	14845-14847	to	_	
76-25	14848-14856	integral	_	
76-26	14857-14865	spectral	_	
76-27	14866-14871	power	_	
76-28	14872-14879	between	_	
76-29	14880-14884	0.15	_	
76-30	14885-14888	and	_	
76-31	14889-14894	0.167	_	
76-32	14894-14895	 	_	
76-33	14895-14897	Hz	_	
76-34	14897-14898	.	_	

#Text=Components were also evaluated for functional relevance via visual inspection.
77-1	14899-14909	Components	_	
77-2	14910-14914	were	_	
77-3	14915-14919	also	_	
77-4	14920-14929	evaluated	_	
77-5	14930-14933	for	_	
77-6	14934-14944	functional	_	
77-7	14945-14954	relevance	_	
77-8	14955-14958	via	_	
77-9	14959-14965	visual	_	
77-10	14966-14976	inspection	_	
77-11	14976-14977	.	_	

#Text=Components were inspected and classified as non-artifactual or RSNs based on the following criteria: (1) peak activations should occur primarily in grey matter and correspond anatomically to known functional brain networks, (2) low spatial overlap with vascular, ventricular, motion and susceptibility artifacts, (3) time courses predominantly characterized by low frequency fluctuations.
78-1	14978-14988	Components	_	
78-2	14989-14993	were	_	
78-3	14994-15003	inspected	_	
78-4	15004-15007	and	_	
78-5	15008-15018	classified	_	
78-6	15019-15021	as	_	
78-7	15022-15037	non-artifactual	_	
78-8	15038-15040	or	_	
78-9	15041-15045	RSNs	_	
78-10	15046-15051	based	_	
78-11	15052-15054	on	_	
78-12	15055-15058	the	_	
78-13	15059-15068	following	_	
78-14	15069-15077	criteria	_	
78-15	15077-15078	:	_	
78-16	15079-15080	(	_	
78-17	15080-15081	1	_	
78-18	15081-15082	)	_	
78-19	15083-15087	peak	_	
78-20	15088-15099	activations	_	
78-21	15100-15106	should	_	
78-22	15107-15112	occur	_	
78-23	15113-15122	primarily	_	
78-24	15123-15125	in	_	
78-25	15126-15130	grey	_	
78-26	15131-15137	matter	_	
78-27	15138-15141	and	_	
78-28	15142-15152	correspond	_	
78-29	15153-15165	anatomically	_	
78-30	15166-15168	to	_	
78-31	15169-15174	known	_	
78-32	15175-15185	functional	_	
78-33	15186-15191	brain	_	
78-34	15192-15200	networks	_	
78-35	15200-15201	,	_	
78-36	15202-15203	(	_	
78-37	15203-15204	2	_	
78-38	15204-15205	)	_	
78-39	15206-15209	low	_	
78-40	15210-15217	spatial	_	
78-41	15218-15225	overlap	_	
78-42	15226-15230	with	_	
78-43	15231-15239	vascular	_	
78-44	15239-15240	,	_	
78-45	15241-15252	ventricular	_	
78-46	15252-15253	,	_	
78-47	15254-15260	motion	_	
78-48	15261-15264	and	_	
78-49	15265-15279	susceptibility	_	
78-50	15280-15289	artifacts	_	
78-51	15289-15290	,	_	
78-52	15291-15292	(	_	
78-53	15292-15293	3	_	
78-54	15293-15294	)	_	
78-55	15295-15299	time	_	
78-56	15300-15307	courses	_	
78-57	15308-15321	predominantly	_	
78-58	15322-15335	characterized	_	
78-59	15336-15338	by	_	
78-60	15339-15342	low	_	
78-61	15343-15352	frequency	_	
78-62	15353-15365	fluctuations	_	
78-63	15365-15366	.	_	

#Text=Of the 50 components extracted, 30 were identified as RSNs (Fig. 1).
79-1	15367-15369	Of	_	
79-2	15370-15373	the	_	
79-3	15374-15376	50	_	
79-4	15377-15387	components	_	
79-5	15388-15397	extracted	_	
79-6	15397-15398	,	_	
79-7	15399-15401	30	_	
79-8	15402-15406	were	_	
79-9	15407-15417	identified	_	
79-10	15418-15420	as	_	
79-11	15421-15425	RSNs	_	
79-12	15426-15427	(	_	
79-13	15427-15430	Fig	_	
79-14	15430-15431	.	_	
79-15	15432-15433	1	_	
79-16	15433-15434	)	_	
79-17	15434-15435	.	_	

#Text=MEG analysis
#Text=MEG scanning parameters
#Text=Resting-state MEG recordings were collected in a shielded room below ground level using a 148-channel whole head magnetometer (MagnesTM 2500 WH, 4-D Neuroimaging) at the University of Alabama at Birmingham.
80-1	15436-15439	MEG	_	
80-2	15440-15448	analysis	_	
80-3	15449-15452	MEG	_	
80-4	15453-15461	scanning	_	
80-5	15462-15472	parameters	_	
80-6	15473-15486	Resting-state	_	
80-7	15487-15490	MEG	_	
80-8	15491-15501	recordings	_	
80-9	15502-15506	were	_	
80-10	15507-15516	collected	_	
80-11	15517-15519	in	_	
80-12	15520-15521	a	_	
80-13	15522-15530	shielded	_	
80-14	15531-15535	room	_	
80-15	15536-15541	below	_	
80-16	15542-15548	ground	_	
80-17	15549-15554	level	_	
80-18	15555-15560	using	_	
80-19	15561-15562	a	_	
80-20	15563-15566	148	_	
80-21	15566-15567	-	_	
80-22	15567-15574	channel	_	
80-23	15575-15580	whole	_	
80-24	15581-15585	head	_	
80-25	15586-15598	magnetometer	_	
80-26	15599-15600	(	_	
80-27	15600-15608	MagnesTM	_	
80-28	15609-15613	2500	_	
80-29	15614-15616	WH	_	
80-30	15616-15617	,	_	
80-31	15618-15619	4	_	
80-32	15619-15620	-	_	
80-33	15620-15621	D	_	
80-34	15622-15634	Neuroimaging	_	
80-35	15634-15635	)	_	
80-36	15636-15638	at	_	
80-37	15639-15642	the	_	
80-38	15643-15653	University	_	
80-39	15654-15656	of	_	
80-40	15657-15664	Alabama	_	
80-41	15665-15667	at	_	
80-42	15668-15678	Birmingham	_	
80-43	15678-15679	.	_	

#Text=Recordings were sampled at a rate of 1000 Hz, with a bandpass filter of 0.1 to 200 Hz.
81-1	15680-15690	Recordings	_	
81-2	15691-15695	were	_	
81-3	15696-15703	sampled	_	
81-4	15704-15706	at	_	
81-5	15707-15708	a	_	
81-6	15709-15713	rate	_	
81-7	15714-15716	of	_	
81-8	15717-15721	1000	_	
81-9	15721-15722	 	_	
81-10	15722-15724	Hz	_	
81-11	15724-15725	,	_	
81-12	15726-15730	with	_	
81-13	15731-15732	a	_	
81-14	15733-15741	bandpass	_	
81-15	15742-15748	filter	_	
81-16	15749-15751	of	_	
81-17	15752-15755	0.1	_	
81-18	15756-15758	to	_	
81-19	15759-15762	200	_	
81-20	15762-15763	 	_	
81-21	15763-15765	Hz	_	
81-22	15765-15766	.	_	

#Text=Fiducial head-sensor coils were used to ensure the subject's head did not move during a scan.
82-1	15767-15775	Fiducial	_	
82-2	15776-15787	head-sensor	_	
82-3	15788-15793	coils	_	
82-4	15794-15798	were	_	
82-5	15799-15803	used	_	
82-6	15804-15806	to	_	
82-7	15807-15813	ensure	_	
82-8	15814-15817	the	_	
82-9	15818-15827	subject's	_	
82-10	15828-15832	head	_	
82-11	15833-15836	did	_	
82-12	15837-15840	not	_	
82-13	15841-15845	move	_	
82-14	15846-15852	during	_	
82-15	15853-15854	a	_	
82-16	15855-15859	scan	_	
82-17	15859-15860	.	_	

#Text=Additional head-sensor data were collected using a 3D digitizer and later used for registration between each subject's MEG and anatomical MRI.
83-1	15861-15871	Additional	_	
83-2	15872-15883	head-sensor	_	
83-3	15884-15888	data	_	
83-4	15889-15893	were	_	
83-5	15894-15903	collected	_	
83-6	15904-15909	using	_	
83-7	15910-15911	a	_	
83-8	15912-15914	3D	_	
83-9	15915-15924	digitizer	_	
83-10	15925-15928	and	_	
83-11	15929-15934	later	_	
83-12	15935-15939	used	_	
83-13	15940-15943	for	_	
83-14	15944-15956	registration	_	
83-15	15957-15964	between	_	
83-16	15965-15969	each	_	
83-17	15970-15979	subject's	_	
83-18	15980-15983	MEG	_	
83-19	15984-15987	and	_	
83-20	15988-15998	anatomical	_	
83-21	15999-16002	MRI	_	
83-22	16002-16003	.	_	

#Text=During the 5-min resting-state scan, subjects were placed in the supine position with eyes closed.
84-1	16004-16010	During	_	
84-2	16011-16014	the	_	
84-3	16015-16016	5	_	
84-4	16016-16017	-	_	
84-5	16017-16020	min	_	
84-6	16021-16034	resting-state	_	
84-7	16035-16039	scan	_	
84-8	16039-16040	,	_	
84-9	16041-16049	subjects	_	
84-10	16050-16054	were	_	
84-11	16055-16061	placed	_	
84-12	16062-16064	in	_	
84-13	16065-16068	the	_	
84-14	16069-16075	supine	_	
84-15	16076-16084	position	_	
84-16	16085-16089	with	_	
84-17	16090-16094	eyes	_	
84-18	16095-16101	closed	_	
84-19	16101-16102	.	_	

#Text=Visual inspection of the real-time display showed no MEG correlates of sleep.
85-1	16103-16109	Visual	_	
85-2	16110-16120	inspection	_	
85-3	16121-16123	of	_	
85-4	16124-16127	the	_	
85-5	16128-16137	real-time	_	
85-6	16138-16145	display	_	
85-7	16146-16152	showed	_	
85-8	16153-16155	no	_	
85-9	16156-16159	MEG	_	
85-10	16160-16170	correlates	_	
85-11	16171-16173	of	_	
85-12	16174-16179	sleep	_	
85-13	16179-16180	.	_	

#Text=Subjects were also clearly responsive immediately before and after the scanning period as they all instantly opened their eyes upon instruction.
86-1	16181-16189	Subjects	_	
86-2	16190-16194	were	_	
86-3	16195-16199	also	_	
86-4	16200-16207	clearly	_	
86-5	16208-16218	responsive	_	
86-6	16219-16230	immediately	_	
86-7	16231-16237	before	_	
86-8	16238-16241	and	_	
86-9	16242-16247	after	_	
86-10	16248-16251	the	_	
86-11	16252-16260	scanning	_	
86-12	16261-16267	period	_	
86-13	16268-16270	as	_	
86-14	16271-16275	they	_	
86-15	16276-16279	all	_	
86-16	16280-16289	instantly	_	
86-17	16290-16296	opened	_	
86-18	16297-16302	their	_	
86-19	16303-16307	eyes	_	
86-20	16308-16312	upon	_	
86-21	16313-16324	instruction	_	
86-22	16324-16325	.	_	

#Text=MEG preprocessing
#Text=MEG data were analyzed using Brainstorm.
87-1	16326-16329	MEG	_	
87-2	16330-16343	preprocessing	_	
87-3	16344-16347	MEG	_	
87-4	16348-16352	data	_	
87-5	16353-16357	were	_	
87-6	16358-16366	analyzed	_	
87-7	16367-16372	using	_	
87-8	16373-16383	Brainstorm	_	
87-9	16383-16384	.	_	

#Text=Preprocessing of the raw data included removal of line noise data using a notch filter (60, 120, 180, 240, 300 Hz) and high-pass filtering at 0.3 Hz.
88-1	16385-16398	Preprocessing	_	
88-2	16399-16401	of	_	
88-3	16402-16405	the	_	
88-4	16406-16409	raw	_	
88-5	16410-16414	data	_	
88-6	16415-16423	included	_	
88-7	16424-16431	removal	_	
88-8	16432-16434	of	_	
88-9	16435-16439	line	_	
88-10	16440-16445	noise	_	
88-11	16446-16450	data	_	
88-12	16451-16456	using	_	
88-13	16457-16458	a	_	
88-14	16459-16464	notch	_	
88-15	16465-16471	filter	_	
88-16	16472-16473	(	_	
88-17	16473-16475	60	_	
88-18	16475-16476	,	_	
88-19	16477-16480	120	_	
88-20	16480-16481	,	_	
88-21	16482-16485	180	_	
88-22	16485-16486	,	_	
88-23	16487-16490	240	_	
88-24	16490-16491	,	_	
88-25	16492-16495	300	_	
88-26	16495-16496	 	_	
88-27	16496-16498	Hz	_	
88-28	16498-16499	)	_	
88-29	16500-16503	and	_	
88-30	16504-16513	high-pass	_	
88-31	16514-16523	filtering	_	
88-32	16524-16526	at	_	
88-33	16527-16530	0.3	_	
88-34	16530-16531	 	_	
88-35	16531-16533	Hz	_	
88-36	16533-16534	.	_	

#Text=Cardiac and motion artifact was removed from the signal using an independent component analysis where the signal was decomposed into 20 independent components using JADE (joint approximate diagonalization of eigenmatrices).
89-1	16535-16542	Cardiac	_	
89-2	16543-16546	and	_	
89-3	16547-16553	motion	_	
89-4	16554-16562	artifact	_	
89-5	16563-16566	was	_	
89-6	16567-16574	removed	_	
89-7	16575-16579	from	_	
89-8	16580-16583	the	_	
89-9	16584-16590	signal	_	
89-10	16591-16596	using	_	
89-11	16597-16599	an	_	
89-12	16600-16611	independent	_	
89-13	16612-16621	component	_	
89-14	16622-16630	analysis	_	
89-15	16631-16636	where	_	
89-16	16637-16640	the	_	
89-17	16641-16647	signal	_	
89-18	16648-16651	was	_	
89-19	16652-16662	decomposed	_	
89-20	16663-16667	into	_	
89-21	16668-16670	20	_	
89-22	16671-16682	independent	_	
89-23	16683-16693	components	_	
89-24	16694-16699	using	_	
89-25	16700-16704	JADE	_	
89-26	16705-16706	(	_	
89-27	16706-16711	joint	_	
89-28	16712-16723	approximate	_	
89-29	16724-16739	diagonalization	_	
89-30	16740-16742	of	_	
89-31	16743-16756	eigenmatrices	_	
89-32	16756-16757	)	_	
89-33	16757-16758	.	_	

#Text=Additional artifacts were removed using a signal-space projection method.
90-1	16759-16769	Additional	_	
90-2	16770-16779	artifacts	_	
90-3	16780-16784	were	_	
90-4	16785-16792	removed	_	
90-5	16793-16798	using	_	
90-6	16799-16800	a	_	
90-7	16801-16813	signal-space	_	
90-8	16814-16824	projection	_	
90-9	16825-16831	method	_	
90-10	16831-16832	.	_	

#Text=Resting-state MEG data was then registered to individual subject high resolution structural MRI scans.
91-1	16833-16846	Resting-state	_	
91-2	16847-16850	MEG	_	
91-3	16851-16855	data	_	
91-4	16856-16859	was	_	
91-5	16860-16864	then	_	
91-6	16865-16875	registered	_	
91-7	16876-16878	to	_	
91-8	16879-16889	individual	_	
91-9	16890-16897	subject	_	
91-10	16898-16902	high	_	
91-11	16903-16913	resolution	_	
91-12	16914-16924	structural	_	
91-13	16925-16928	MRI	_	
91-14	16929-16934	scans	_	
91-15	16934-16935	.	_	

#Text=Prior to MEG-MRI registration, cortical surfaces and subcortical structures from each structural MRI were extracted using the FreeSurfer image analysis suite (http://surfer.nmr.mgh.harvard.edu/) and subsequently inspected using FreeSurfer's QA Tools.
92-1	16936-16941	Prior	_	
92-2	16942-16944	to	_	
92-3	16945-16952	MEG-MRI	_	
92-4	16953-16965	registration	_	
92-5	16965-16966	,	_	
92-6	16967-16975	cortical	_	
92-7	16976-16984	surfaces	_	
92-8	16985-16988	and	_	
92-9	16989-17000	subcortical	_	
92-10	17001-17011	structures	_	
92-11	17012-17016	from	_	
92-12	17017-17021	each	_	
92-13	17022-17032	structural	_	
92-14	17033-17036	MRI	_	
92-15	17037-17041	were	_	
92-16	17042-17051	extracted	_	
92-17	17052-17057	using	_	
92-18	17058-17061	the	_	
92-19	17062-17072	FreeSurfer	_	
92-20	17073-17078	image	_	
92-21	17079-17087	analysis	_	
92-22	17088-17093	suite	_	
92-23	17094-17095	(	_	
92-24	17095-17099	http	_	
92-25	17099-17100	:	_	
92-26	17100-17101	/	_	
92-27	17101-17102	/	_	
92-28	17102-17128	surfer.nmr.mgh.harvard.edu	_	
92-29	17128-17129	/	_	
92-30	17129-17130	)	_	
92-31	17131-17134	and	_	
92-32	17135-17147	subsequently	_	
92-33	17148-17157	inspected	_	
92-34	17158-17163	using	_	
92-35	17164-17176	FreeSurfer's	_	
92-36	17177-17179	QA	_	
92-37	17180-17185	Tools	_	
92-38	17185-17186	.	_	

#Text=Data identified as unsatisfactory during quality assurance were manually corrected and reprocessed.
93-1	17187-17191	Data	_	
93-2	17192-17202	identified	_	
93-3	17203-17205	as	_	
93-4	17206-17220	unsatisfactory	_	
93-5	17221-17227	during	_	
93-6	17228-17235	quality	_	
93-7	17236-17245	assurance	_	
93-8	17246-17250	were	_	
93-9	17251-17259	manually	_	
93-10	17260-17269	corrected	_	
93-11	17270-17273	and	_	
93-12	17274-17285	reprocessed	_	
93-13	17285-17286	.	_	

#Text=A pseudo-individual anatomy for each subject missing structural MRI scans (n = 5) was created by warping the default ICBM 152 template anatomy in Brainstorm to the digitized head points.
94-1	17287-17288	A	_	
94-2	17289-17306	pseudo-individual	_	
94-3	17307-17314	anatomy	_	
94-4	17315-17318	for	_	
94-5	17319-17323	each	_	
94-6	17324-17331	subject	_	
94-7	17332-17339	missing	_	
94-8	17340-17350	structural	_	
94-9	17351-17354	MRI	_	
94-10	17355-17360	scans	_	
94-11	17361-17362	(	_	
94-12	17362-17363	n	_	
94-13	17363-17364	 	_	
94-14	17364-17365	=	_	
94-15	17365-17366	 	_	
94-16	17366-17367	5	_	
94-17	17367-17368	)	_	
94-18	17369-17372	was	_	
94-19	17373-17380	created	_	
94-20	17381-17383	by	_	
94-21	17384-17391	warping	_	
94-22	17392-17395	the	_	
94-23	17396-17403	default	_	
94-24	17404-17408	ICBM	_	
94-25	17409-17412	152	_	
94-26	17413-17421	template	_	
94-27	17422-17429	anatomy	_	
94-28	17430-17432	in	_	
94-29	17433-17443	Brainstorm	_	
94-30	17444-17446	to	_	
94-31	17447-17450	the	_	
94-32	17451-17460	digitized	_	
94-33	17461-17465	head	_	
94-34	17466-17472	points	_	
94-35	17472-17473	.	_	

#Text=A 15,000-vertex cortical surface source model was used for head modeling.
95-1	17474-17475	A	_	
95-2	17476-17482	15,000	_	
95-3	17482-17483	-	_	
95-4	17483-17489	vertex	_	
95-5	17490-17498	cortical	_	
95-6	17499-17506	surface	_	
95-7	17507-17513	source	_	
95-8	17514-17519	model	_	
95-9	17520-17523	was	_	
95-10	17524-17528	used	_	
95-11	17529-17532	for	_	
95-12	17533-17537	head	_	
95-13	17538-17546	modeling	_	
95-14	17546-17547	.	_	

#Text=Forward volume head modeling of the magnetic field was defined using an overlapping-sphere method where voxels were placed on a 5 mm3 grid of the brain.
96-1	17548-17555	Forward	_	
96-2	17556-17562	volume	_	
96-3	17563-17567	head	_	
96-4	17568-17576	modeling	_	
96-5	17577-17579	of	_	
96-6	17580-17583	the	_	
96-7	17584-17592	magnetic	_	
96-8	17593-17598	field	_	
96-9	17599-17602	was	_	
96-10	17603-17610	defined	_	
96-11	17611-17616	using	_	
96-12	17617-17619	an	_	
96-13	17620-17638	overlapping-sphere	_	
96-14	17639-17645	method	_	
96-15	17646-17651	where	_	
96-16	17652-17658	voxels	_	
96-17	17659-17663	were	_	
96-18	17664-17670	placed	_	
96-19	17671-17673	on	_	
96-20	17674-17675	a	_	
96-21	17676-17677	5	_	
96-22	17677-17678	 	_	
96-23	17678-17681	mm3	_	
96-24	17682-17686	grid	_	
96-25	17687-17689	of	_	
96-26	17690-17693	the	_	
96-27	17694-17699	brain	_	
96-28	17699-17700	.	_	

#Text=Inverse source modeling was performed using a linearly-constrained minimum variance (LCMV) beamformer.
97-1	17701-17708	Inverse	_	
97-2	17709-17715	source	_	
97-3	17716-17724	modeling	_	
97-4	17725-17728	was	_	
97-5	17729-17738	performed	_	
97-6	17739-17744	using	_	
97-7	17745-17746	a	_	
97-8	17747-17767	linearly-constrained	_	
97-9	17768-17775	minimum	_	
97-10	17776-17784	variance	_	
97-11	17785-17786	(	_	
97-12	17786-17790	LCMV	_	
97-13	17790-17791	)	_	
97-14	17792-17802	beamformer	_	
97-15	17802-17803	.	_	

#Text=Beamformer projection was performed using an unconstrained dipole orientation for each subject separately.
98-1	17804-17814	Beamformer	_	
98-2	17815-17825	projection	_	
98-3	17826-17829	was	_	
98-4	17830-17839	performed	_	
98-5	17840-17845	using	_	
98-6	17846-17848	an	_	
98-7	17849-17862	unconstrained	_	
98-8	17863-17869	dipole	_	
98-9	17870-17881	orientation	_	
98-10	17882-17885	for	_	
98-11	17886-17890	each	_	
98-12	17891-17898	subject	_	
98-13	17899-17909	separately	_	
98-14	17909-17910	.	_	

#Text=Data covariance matrices generated for each subject were regularized using a median eigenvalue approach where the tail of the eigenvalues spectrum is flattened to the median value.
99-1	17911-17915	Data	_	
99-2	17916-17926	covariance	_	
99-3	17927-17935	matrices	_	
99-4	17936-17945	generated	_	
99-5	17946-17949	for	_	
99-6	17950-17954	each	_	
99-7	17955-17962	subject	_	
99-8	17963-17967	were	_	
99-9	17968-17979	regularized	_	
99-10	17980-17985	using	_	
99-11	17986-17987	a	_	
99-12	17988-17994	median	_	
99-13	17995-18005	eigenvalue	_	
99-14	18006-18014	approach	_	
99-15	18015-18020	where	_	
99-16	18021-18024	the	_	
99-17	18025-18029	tail	_	
99-18	18030-18032	of	_	
99-19	18033-18036	the	_	
99-20	18037-18048	eigenvalues	_	
99-21	18049-18057	spectrum	_	
99-22	18058-18060	is	_	
99-23	18061-18070	flattened	_	
99-24	18071-18073	to	_	
99-25	18074-18077	the	_	
99-26	18078-18084	median	_	
99-27	18085-18090	value	_	
99-28	18090-18091	.	_	

#Text=MEG Hilbert envelope computation
#Text=The Hilbert transform was applied to the resting-state time courses in which the signals were first filtered into delta (1–4 Hz), theta (4–8 Hz), alpha (8–13 Hz), beta (13–30 Hz), and gamma (30–50 Hz) frequency bands using a band-pass filter followed by application of the Hilbert transform.
100-1	18092-18095	MEG	_	
100-2	18096-18103	Hilbert	_	
100-3	18104-18112	envelope	_	
100-4	18113-18124	computation	_	
100-5	18125-18128	The	_	
100-6	18129-18136	Hilbert	_	
100-7	18137-18146	transform	_	
100-8	18147-18150	was	_	
100-9	18151-18158	applied	_	
100-10	18159-18161	to	_	
100-11	18162-18165	the	_	
100-12	18166-18179	resting-state	_	
100-13	18180-18184	time	_	
100-14	18185-18192	courses	_	
100-15	18193-18195	in	_	
100-16	18196-18201	which	_	
100-17	18202-18205	the	_	
100-18	18206-18213	signals	_	
100-19	18214-18218	were	_	
100-20	18219-18224	first	_	
100-21	18225-18233	filtered	_	
100-22	18234-18238	into	_	
100-23	18239-18244	delta	_	
100-24	18245-18246	(	_	
100-25	18246-18247	1	_	
100-26	18247-18248	–	_	
100-27	18248-18249	4	_	
100-28	18249-18250	 	_	
100-29	18250-18252	Hz	_	
100-30	18252-18253	)	_	
100-31	18253-18254	,	_	
100-32	18255-18260	theta	_	
100-33	18261-18262	(	_	
100-34	18262-18263	4	_	
100-35	18263-18264	–	_	
100-36	18264-18265	8	_	
100-37	18265-18266	 	_	
100-38	18266-18268	Hz	_	
100-39	18268-18269	)	_	
100-40	18269-18270	,	_	
100-41	18271-18276	alpha	_	
100-42	18277-18278	(	_	
100-43	18278-18279	8	_	
100-44	18279-18280	–	_	
100-45	18280-18282	13	_	
100-46	18282-18283	 	_	
100-47	18283-18285	Hz	_	
100-48	18285-18286	)	_	
100-49	18286-18287	,	_	
100-50	18288-18292	beta	_	
100-51	18293-18294	(	_	
100-52	18294-18296	13	_	
100-53	18296-18297	–	_	
100-54	18297-18299	30	_	
100-55	18299-18300	 	_	
100-56	18300-18302	Hz	_	
100-57	18302-18303	)	_	
100-58	18303-18304	,	_	
100-59	18305-18308	and	_	
100-60	18309-18314	gamma	_	
100-61	18315-18316	(	_	
100-62	18316-18318	30	_	
100-63	18318-18319	–	_	
100-64	18319-18321	50	_	
100-65	18321-18322	 	_	
100-66	18322-18324	Hz	_	
100-67	18324-18325	)	_	
100-68	18326-18335	frequency	_	
100-69	18336-18341	bands	_	
100-70	18342-18347	using	_	
100-71	18348-18349	a	_	
100-72	18350-18359	band-pass	_	
100-73	18360-18366	filter	_	
100-74	18367-18375	followed	_	
100-75	18376-18378	by	_	
100-76	18379-18390	application	_	
100-77	18391-18393	of	_	
100-78	18394-18397	the	_	
100-79	18398-18405	Hilbert	_	
100-80	18406-18415	transform	_	
100-81	18415-18416	.	_	

#Text=The absolute value of the transformed signals was subsequently computed in order to provide a measure of the envelope of the signal.
101-1	18417-18420	The	_	
101-2	18421-18429	absolute	_	
101-3	18430-18435	value	_	
101-4	18436-18438	of	_	
101-5	18439-18442	the	_	
101-6	18443-18454	transformed	_	
101-7	18455-18462	signals	_	
101-8	18463-18466	was	_	
101-9	18467-18479	subsequently	_	
101-10	18480-18488	computed	_	
101-11	18489-18491	in	_	
101-12	18492-18497	order	_	
101-13	18498-18500	to	_	
101-14	18501-18508	provide	_	
101-15	18509-18510	a	_	
101-16	18511-18518	measure	_	
101-17	18519-18521	of	_	
101-18	18522-18525	the	_	
101-19	18526-18534	envelope	_	
101-20	18535-18537	of	_	
101-21	18538-18541	the	_	
101-22	18542-18548	signal	_	
101-23	18548-18549	.	_	

#Text=The Hilbert envelope values were then standardized using a 1/frequency compensation where values at each frequency bin were multiplied by the frequency value.
102-1	18550-18553	The	_	
102-2	18554-18561	Hilbert	_	
102-3	18562-18570	envelope	_	
102-4	18571-18577	values	_	
102-5	18578-18582	were	_	
102-6	18583-18587	then	_	
102-7	18588-18600	standardized	_	
102-8	18601-18606	using	_	
102-9	18607-18608	a	_	
102-10	18609-18610	1	_	
102-11	18610-18611	/	_	
102-12	18611-18620	frequency	_	
102-13	18621-18633	compensation	_	
102-14	18634-18639	where	_	
102-15	18640-18646	values	_	
102-16	18647-18649	at	_	
102-17	18650-18654	each	_	
102-18	18655-18664	frequency	_	
102-19	18665-18668	bin	_	
102-20	18669-18673	were	_	
102-21	18674-18684	multiplied	_	
102-22	18685-18687	by	_	
102-23	18688-18691	the	_	
102-24	18692-18701	frequency	_	
102-25	18702-18707	value	_	
102-26	18707-18708	.	_	

#Text=Following spectrum normalization, the Hilbert envelope was downsampled to 1 Hz in accordance with previous studies.
103-1	18709-18718	Following	_	
103-2	18719-18727	spectrum	_	
103-3	18728-18741	normalization	_	
103-4	18741-18742	,	_	
103-5	18743-18746	the	_	
103-6	18747-18754	Hilbert	_	
103-7	18755-18763	envelope	_	
103-8	18764-18767	was	_	
103-9	18768-18779	downsampled	_	
103-10	18780-18782	to	_	
103-11	18783-18784	1	_	
103-12	18784-18785	 	_	
103-13	18785-18787	Hz	_	
103-14	18788-18790	in	_	
103-15	18791-18801	accordance	_	
103-16	18802-18806	with	_	
103-17	18807-18815	previous	_	
103-18	18816-18823	studies	_	
103-19	18823-18824	.	_	

#Text=Therefore, scans consisted of 301 volumes for each frequency band.
104-1	18825-18834	Therefore	_	
104-2	18834-18835	,	_	
104-3	18836-18841	scans	_	
104-4	18842-18851	consisted	_	
104-5	18852-18854	of	_	
104-6	18855-18858	301	_	
104-7	18859-18866	volumes	_	
104-8	18867-18870	for	_	
104-9	18871-18875	each	_	
104-10	18876-18885	frequency	_	
104-11	18886-18890	band	_	
104-12	18890-18891	.	_	

#Text=In order to enable comparison between subjects and groups, downsampled source envelope data for each subject were spatially interpolated from the individual subject head model to the MNI ICBM 152 default MRI template in Brainstorm and spatially smoothed (5 mm FWHM).
105-1	18892-18894	In	_	
105-2	18895-18900	order	_	
105-3	18901-18903	to	_	
105-4	18904-18910	enable	_	
105-5	18911-18921	comparison	_	
105-6	18922-18929	between	_	
105-7	18930-18938	subjects	_	
105-8	18939-18942	and	_	
105-9	18943-18949	groups	_	
105-10	18949-18950	,	_	
105-11	18951-18962	downsampled	_	
105-12	18963-18969	source	_	
105-13	18970-18978	envelope	_	
105-14	18979-18983	data	_	
105-15	18984-18987	for	_	
105-16	18988-18992	each	_	
105-17	18993-19000	subject	_	
105-18	19001-19005	were	_	
105-19	19006-19015	spatially	_	
105-20	19016-19028	interpolated	_	
105-21	19029-19033	from	_	
105-22	19034-19037	the	_	
105-23	19038-19048	individual	_	
105-24	19049-19056	subject	_	
105-25	19057-19061	head	_	
105-26	19062-19067	model	_	
105-27	19068-19070	to	_	
105-28	19071-19074	the	_	
105-29	19075-19078	MNI	_	
105-30	19079-19083	ICBM	_	
105-31	19084-19087	152	_	
105-32	19088-19095	default	_	
105-33	19096-19099	MRI	_	
105-34	19100-19108	template	_	
105-35	19109-19111	in	_	
105-36	19112-19122	Brainstorm	_	
105-37	19123-19126	and	_	
105-38	19127-19136	spatially	_	
105-39	19137-19145	smoothed	_	
105-40	19146-19147	(	_	
105-41	19147-19148	5	_	
105-42	19148-19149	 	_	
105-43	19149-19151	mm	_	
105-44	19152-19156	FWHM	_	
105-45	19156-19157	)	_	
105-46	19157-19158	.	_	

#Text=MEG Group independent component analysis
#Text=Group-level spatial ICA was performed on the MEG data in the GIFT Toolbox where each frequency band – delta (1–4 Hz), theta (4–8 Hz), alpha (8–13 Hz), beta (13–30 Hz), and gamma (30–50 Hz) – was input as a different session for each individual.
106-1	19159-19162	MEG	_	
106-2	19163-19168	Group	_	
106-3	19169-19180	independent	_	
106-4	19181-19190	component	_	
106-5	19191-19199	analysis	_	
106-6	19200-19211	Group-level	_	
106-7	19212-19219	spatial	_	
106-8	19220-19223	ICA	_	
106-9	19224-19227	was	_	
106-10	19228-19237	performed	_	
106-11	19238-19240	on	_	
106-12	19241-19244	the	_	
106-13	19245-19248	MEG	_	
106-14	19249-19253	data	_	
106-15	19254-19256	in	_	
106-16	19257-19260	the	_	
106-17	19261-19265	GIFT	_	
106-18	19266-19273	Toolbox	_	
106-19	19274-19279	where	_	
106-20	19280-19284	each	_	
106-21	19285-19294	frequency	_	
106-22	19295-19299	band	_	
106-23	19300-19301	–	_	
106-24	19302-19307	delta	_	
106-25	19308-19309	(	_	
106-26	19309-19310	1	_	
106-27	19310-19311	–	_	
106-28	19311-19312	4	_	
106-29	19312-19313	 	_	
106-30	19313-19315	Hz	_	
106-31	19315-19316	)	_	
106-32	19316-19317	,	_	
106-33	19318-19323	theta	_	
106-34	19324-19325	(	_	
106-35	19325-19326	4	_	
106-36	19326-19327	–	_	
106-37	19327-19328	8	_	
106-38	19328-19329	 	_	
106-39	19329-19331	Hz	_	
106-40	19331-19332	)	_	
106-41	19332-19333	,	_	
106-42	19334-19339	alpha	_	
106-43	19340-19341	(	_	
106-44	19341-19342	8	_	
106-45	19342-19343	–	_	
106-46	19343-19345	13	_	
106-47	19345-19346	 	_	
106-48	19346-19348	Hz	_	
106-49	19348-19349	)	_	
106-50	19349-19350	,	_	
106-51	19351-19355	beta	_	
106-52	19356-19357	(	_	
106-53	19357-19359	13	_	
106-54	19359-19360	–	_	
106-55	19360-19362	30	_	
106-56	19362-19363	 	_	
106-57	19363-19365	Hz	_	
106-58	19365-19366	)	_	
106-59	19366-19367	,	_	
106-60	19368-19371	and	_	
106-61	19372-19377	gamma	_	
106-62	19378-19379	(	_	
106-63	19379-19381	30	_	
106-64	19381-19382	–	_	
106-65	19382-19384	50	_	
106-66	19384-19385	 	_	
106-67	19385-19387	Hz	_	
106-68	19387-19388	)	_	
106-69	19389-19390	–	_	
106-70	19391-19394	was	_	
106-71	19395-19400	input	_	
106-72	19401-19403	as	_	
106-73	19404-19405	a	_	
106-74	19406-19415	different	_	
106-75	19416-19423	session	_	
106-76	19424-19427	for	_	
106-77	19428-19432	each	_	
106-78	19433-19443	individual	_	
106-79	19443-19444	.	_	

#Text=Similar to fMRI group ICA analysis, MEG data were first reduced to 75 principal components using a subject-specific data reduction PCA and then reduced to 50 principal components via group data reduction.
107-1	19445-19452	Similar	_	
107-2	19453-19455	to	_	
107-3	19456-19460	fMRI	_	
107-4	19461-19466	group	_	
107-5	19467-19470	ICA	_	
107-6	19471-19479	analysis	_	
107-7	19479-19480	,	_	
107-8	19481-19484	MEG	_	
107-9	19485-19489	data	_	
107-10	19490-19494	were	_	
107-11	19495-19500	first	_	
107-12	19501-19508	reduced	_	
107-13	19509-19511	to	_	
107-14	19512-19514	75	_	
107-15	19515-19524	principal	_	
107-16	19525-19535	components	_	
107-17	19536-19541	using	_	
107-18	19542-19543	a	_	
107-19	19544-19560	subject-specific	_	
107-20	19561-19565	data	_	
107-21	19566-19575	reduction	_	
107-22	19576-19579	PCA	_	
107-23	19580-19583	and	_	
107-24	19584-19588	then	_	
107-25	19589-19596	reduced	_	
107-26	19597-19599	to	_	
107-27	19600-19602	50	_	
107-28	19603-19612	principal	_	
107-29	19613-19623	components	_	
107-30	19624-19627	via	_	
107-31	19628-19633	group	_	
107-32	19634-19638	data	_	
107-33	19639-19648	reduction	_	
107-34	19648-19649	.	_	

#Text=PCA was carried out using the expectation maximization algorithm.
108-1	19650-19653	PCA	_	
108-2	19654-19657	was	_	
108-3	19658-19665	carried	_	
108-4	19666-19669	out	_	
108-5	19670-19675	using	_	
108-6	19676-19679	the	_	
108-7	19680-19691	expectation	_	
108-8	19692-19704	maximization	_	
108-9	19705-19714	algorithm	_	
108-10	19714-19715	.	_	

#Text=The infomax algorithm was then utilized for group-level spatial ICA to generate 50 spatially independent components (ICs) (See Supplementary Fig. 1 for estimation of the number of ICs using minimum description length criteria).
109-1	19716-19719	The	_	
109-2	19720-19727	infomax	_	
109-3	19728-19737	algorithm	_	
109-4	19738-19741	was	_	
109-5	19742-19746	then	_	
109-6	19747-19755	utilized	_	
109-7	19756-19759	for	_	
109-8	19760-19771	group-level	_	
109-9	19772-19779	spatial	_	
109-10	19780-19783	ICA	_	
109-11	19784-19786	to	_	
109-12	19787-19795	generate	_	
109-13	19796-19798	50	_	
109-14	19799-19808	spatially	_	
109-15	19809-19820	independent	_	
109-16	19821-19831	components	_	
109-17	19832-19833	(	_	
109-18	19833-19836	ICs	_	
109-19	19836-19837	)	_	
109-20	19838-19839	(	_	
109-21	19839-19842	See	_	
109-22	19843-19856	Supplementary	_	
109-23	19857-19860	Fig	_	
109-24	19860-19861	.	_	
109-25	19862-19863	1	_	
109-26	19864-19867	for	_	
109-27	19868-19878	estimation	_	
109-28	19879-19881	of	_	
109-29	19882-19885	the	_	
109-30	19886-19892	number	_	
109-31	19893-19895	of	_	
109-32	19896-19899	ICs	_	
109-33	19900-19905	using	_	
109-34	19906-19913	minimum	_	
109-35	19914-19925	description	_	
109-36	19926-19932	length	_	
109-37	19933-19941	criteria	_	
109-38	19941-19942	)	_	
109-39	19942-19943	.	_	

#Text=Component stability/quality was measured by repeating the infomax ICA algorithm 20 times in ICASSO.
110-1	19944-19953	Component	_	
110-2	19954-19963	stability	_	
110-3	19963-19964	/	_	
110-4	19964-19971	quality	_	
110-5	19972-19975	was	_	
110-6	19976-19984	measured	_	
110-7	19985-19987	by	_	
110-8	19988-19997	repeating	_	
110-9	19998-20001	the	_	
110-10	20002-20009	infomax	_	
110-11	20010-20013	ICA	_	
110-12	20014-20023	algorithm	_	
110-13	20024-20026	20	_	
110-14	20027-20032	times	_	
110-15	20033-20035	in	_	
110-16	20036-20042	ICASSO	_	
110-17	20042-20043	.	_	

#Text=Subject-specific spatial maps and time courses were estimated using GICA back-reconstruction.
111-1	20044-20060	Subject-specific	_	
111-2	20061-20068	spatial	_	
111-3	20069-20073	maps	_	
111-4	20074-20077	and	_	
111-5	20078-20082	time	_	
111-6	20083-20090	courses	_	
111-7	20091-20095	were	_	
111-8	20096-20105	estimated	_	
111-9	20106-20111	using	_	
111-10	20112-20116	GICA	_	
111-11	20117-20136	back-reconstruction	_	
111-12	20136-20137	.	_	

#Text=MEG component identification
#Text=MEG ICs were classified as RSNs, rather than artifacts, following the same method described in the previous section: fMRI Component Identification.
112-1	20138-20141	MEG	_	
112-2	20142-20151	component	_	
112-3	20152-20166	identification	_	
112-4	20167-20170	MEG	_	
112-5	20171-20174	ICs	_	
112-6	20175-20179	were	_	
112-7	20180-20190	classified	_	
112-8	20191-20193	as	_	
112-9	20194-20198	RSNs	_	
112-10	20198-20199	,	_	
112-11	20200-20206	rather	_	
112-12	20207-20211	than	_	
112-13	20212-20221	artifacts	_	
112-14	20221-20222	,	_	
112-15	20223-20232	following	_	
112-16	20233-20236	the	_	
112-17	20237-20241	same	_	
112-18	20242-20248	method	_	
112-19	20249-20258	described	_	
112-20	20259-20261	in	_	
112-21	20262-20265	the	_	
112-22	20266-20274	previous	_	
112-23	20275-20282	section	_	
112-24	20282-20283	:	_	
112-25	20284-20288	fMRI	_	
112-26	20289-20298	Component	_	
112-27	20299-20313	Identification	_	
112-28	20313-20314	.	_	

#Text=Of the 50 components extracted, 33 were identified as RSNs (Fig. 1).
113-1	20315-20317	Of	_	
113-2	20318-20321	the	_	
113-3	20322-20324	50	_	
113-4	20325-20335	components	_	
113-5	20336-20345	extracted	_	
113-6	20345-20346	,	_	
113-7	20347-20349	33	_	
113-8	20350-20354	were	_	
113-9	20355-20365	identified	_	
113-10	20366-20368	as	_	
113-11	20369-20373	RSNs	_	
113-12	20374-20375	(	_	
113-13	20375-20378	Fig	_	
113-14	20378-20379	.	_	
113-15	20380-20381	1	_	
113-16	20381-20382	)	_	
113-17	20382-20383	.	_	

#Text=Functional connectivity analysis
#Text=Functional connectivity analysis
#Text=Functional connectivity analysis for fMRI and MEG was performed using the spatial maps and corresponding time courses extracted during the ICA analysis.
114-1	20384-20394	Functional	_	
114-2	20395-20407	connectivity	_	
114-3	20408-20416	analysis	_	
114-4	20417-20427	Functional	_	
114-5	20428-20440	connectivity	_	
114-6	20441-20449	analysis	_	
114-7	20450-20460	Functional	_	
114-8	20461-20473	connectivity	_	
114-9	20474-20482	analysis	_	
114-10	20483-20486	for	_	
114-11	20487-20491	fMRI	_	
114-12	20492-20495	and	_	
114-13	20496-20499	MEG	_	
114-14	20500-20503	was	_	
114-15	20504-20513	performed	_	
114-16	20514-20519	using	_	
114-17	20520-20523	the	_	
114-18	20524-20531	spatial	_	
114-19	20532-20536	maps	_	
114-20	20537-20540	and	_	
114-21	20541-20554	corresponding	_	
114-22	20555-20559	time	_	
114-23	20560-20567	courses	_	
114-24	20568-20577	extracted	_	
114-25	20578-20584	during	_	
114-26	20585-20588	the	_	
114-27	20589-20592	ICA	_	
114-28	20593-20601	analysis	_	
114-29	20601-20602	.	_	

#Text=For the fMRI data, framewise displacement was regressed from the subject-specific RSN time courses prior to connectivity analyses.
115-1	20603-20606	For	_	
115-2	20607-20610	the	_	
115-3	20611-20615	fMRI	_	
115-4	20616-20620	data	_	
115-5	20620-20621	,	_	
115-6	20622-20631	framewise	_	
115-7	20632-20644	displacement	_	
115-8	20645-20648	was	_	
115-9	20649-20658	regressed	_	
115-10	20659-20663	from	_	
115-11	20664-20667	the	_	
115-12	20668-20684	subject-specific	_	
115-13	20685-20688	RSN	_	
115-14	20689-20693	time	_	
115-15	20694-20701	courses	_	
115-16	20702-20707	prior	_	
115-17	20708-20710	to	_	
115-18	20711-20723	connectivity	_	
115-19	20724-20732	analyses	_	
115-20	20732-20733	.	_	

#Text=Framewise displacement was computed as the absolute frame-to-frame displacement of the brain from six realignment parameters using a radius of 50 mm to convert angle rotations to displacements.
116-1	20734-20743	Framewise	_	
116-2	20744-20756	displacement	_	
116-3	20757-20760	was	_	
116-4	20761-20769	computed	_	
116-5	20770-20772	as	_	
116-6	20773-20776	the	_	
116-7	20777-20785	absolute	_	
116-8	20786-20800	frame-to-frame	_	
116-9	20801-20813	displacement	_	
116-10	20814-20816	of	_	
116-11	20817-20820	the	_	
116-12	20821-20826	brain	_	
116-13	20827-20831	from	_	
116-14	20832-20835	six	_	
116-15	20836-20847	realignment	_	
116-16	20848-20858	parameters	_	
116-17	20859-20864	using	_	
116-18	20865-20866	a	_	
116-19	20867-20873	radius	_	
116-20	20874-20876	of	_	
116-21	20877-20879	50	_	
116-22	20879-20880	 	_	
116-23	20880-20882	mm	_	
116-24	20883-20885	to	_	
116-25	20886-20893	convert	_	
116-26	20894-20899	angle	_	
116-27	20900-20909	rotations	_	
116-28	20910-20912	to	_	
116-29	20913-20926	displacements	_	
116-30	20926-20927	.	_	

#Text=Therefore, individual displacement values for each volume of the time course (i.e., 120 frame-to-frame displacement values) resulted.
117-1	20928-20937	Therefore	_	
117-2	20937-20938	,	_	
117-3	20939-20949	individual	_	
117-4	20950-20962	displacement	_	
117-5	20963-20969	values	_	
117-6	20970-20973	for	_	
117-7	20974-20978	each	_	
117-8	20979-20985	volume	_	
117-9	20986-20988	of	_	
117-10	20989-20992	the	_	
117-11	20993-20997	time	_	
117-12	20998-21004	course	_	
117-13	21005-21006	(	_	
117-14	21006-21009	i.e	_	
117-15	21009-21010	.	_	
117-16	21010-21011	,	_	
117-17	21012-21015	120	_	
117-18	21016-21030	frame-to-frame	_	
117-19	21031-21043	displacement	_	
117-20	21044-21050	values	_	
117-21	21050-21051	)	_	
117-22	21052-21060	resulted	_	
117-23	21060-21061	.	_	

#Text=Framewise displacement was regressed from the subject-specific RSN time courses prior to functional connectivity analysis.
118-1	21062-21071	Framewise	_	
118-2	21072-21084	displacement	_	
118-3	21085-21088	was	_	
118-4	21089-21098	regressed	_	
118-5	21099-21103	from	_	
118-6	21104-21107	the	_	
118-7	21108-21124	subject-specific	_	
118-8	21125-21128	RSN	_	
118-9	21129-21133	time	_	
118-10	21134-21141	courses	_	
118-11	21142-21147	prior	_	
118-12	21148-21150	to	_	
118-13	21151-21161	functional	_	
118-14	21162-21174	connectivity	_	
118-15	21175-21183	analysis	_	
118-16	21183-21184	.	_	

#Text=It is important to note that mean framewise displacement did not differ between groups [HC: 0.19±0.09 mm (range: 0.07–0.44 mm); SZ: 0.21±0.14 mm (range: 0.04–0.47 mm); t = −0.78, p = .44].
119-1	21185-21187	It	_	
119-2	21188-21190	is	_	
119-3	21191-21200	important	_	
119-4	21201-21203	to	_	
119-5	21204-21208	note	_	
119-6	21209-21213	that	_	
119-7	21214-21218	mean	_	
119-8	21219-21228	framewise	_	
119-9	21229-21241	displacement	_	
119-10	21242-21245	did	_	
119-11	21246-21249	not	_	
119-12	21250-21256	differ	_	
119-13	21257-21264	between	_	
119-14	21265-21271	groups	_	
119-15	21272-21273	[	_	
119-16	21273-21275	HC	_	
119-17	21275-21276	:	_	
119-18	21277-21281	0.19	_	
119-19	21281-21282	±	_	
119-20	21282-21286	0.09	_	
119-21	21286-21287	 	_	
119-22	21287-21289	mm	_	
119-23	21290-21291	(	_	
119-24	21291-21296	range	_	
119-25	21296-21297	:	_	
119-26	21298-21302	0.07	_	
119-27	21302-21303	–	_	
119-28	21303-21307	0.44	_	
119-29	21307-21308	 	_	
119-30	21308-21310	mm	_	
119-31	21310-21311	)	_	
119-32	21311-21312	;	_	
119-33	21313-21315	SZ	_	
119-34	21315-21316	:	_	
119-35	21317-21321	0.21	_	
119-36	21321-21322	±	_	
119-37	21322-21326	0.14	_	
119-38	21326-21327	 	_	
119-39	21327-21329	mm	_	
119-40	21330-21331	(	_	
119-41	21331-21336	range	_	
119-42	21336-21337	:	_	
119-43	21338-21342	0.04	_	
119-44	21342-21343	–	_	
119-45	21343-21347	0.47	_	
119-46	21347-21348	 	_	
119-47	21348-21350	mm	_	
119-48	21350-21351	)	_	
119-49	21351-21352	;	_	
119-50	21353-21354	t	_	
119-51	21354-21355	 	_	
119-52	21355-21356	=	_	
119-53	21356-21357	 	_	
119-54	21357-21358	−	_	
119-55	21358-21362	0.78	_	
119-56	21362-21363	,	_	
119-57	21364-21365	p	_	
119-58	21365-21366	 	_	
119-59	21366-21367	=	_	
119-60	21367-21368	 	_	
119-61	21368-21371	.44	_	
119-62	21371-21372	]	_	
119-63	21372-21373	.	_	

#Text=No participants exceeded mean framewise displacement of 0.5 mm.
120-1	21374-21376	No	_	
120-2	21377-21389	participants	_	
120-3	21390-21398	exceeded	_	
120-4	21399-21403	mean	_	
120-5	21404-21413	framewise	_	
120-6	21414-21426	displacement	_	
120-7	21427-21429	of	_	
120-8	21430-21433	0.5	_	
120-9	21433-21434	 	_	
120-10	21434-21436	mm	_	
120-11	21436-21437	.	_	

#Text=The number of head motion outliers (defined as FD >0.5 mm) did not differ between groups (HC: 5.67±6.51%, SZ: 6.79+/− 7.49%, t = −0.51 p = .62).
121-1	21438-21441	The	_	
121-2	21442-21448	number	_	
121-3	21449-21451	of	_	
121-4	21452-21456	head	_	
121-5	21457-21463	motion	_	
121-6	21464-21472	outliers	_	
121-7	21473-21474	(	_	
121-8	21474-21481	defined	_	
121-9	21482-21484	as	_	
121-10	21485-21487	FD	_	
121-11	21488-21489	>	_	
121-12	21489-21492	0.5	_	
121-13	21492-21493	 	_	
121-14	21493-21495	mm	_	
121-15	21495-21496	)	_	
121-16	21497-21500	did	_	
121-17	21501-21504	not	_	
121-18	21505-21511	differ	_	
121-19	21512-21519	between	_	
121-20	21520-21526	groups	_	
121-21	21527-21528	(	_	
121-22	21528-21530	HC	_	
121-23	21530-21531	:	_	
121-24	21532-21536	5.67	_	
121-25	21536-21537	±	_	
121-26	21537-21542	6.51%	_	
121-27	21542-21543	,	_	
121-28	21544-21546	SZ	_	
121-29	21546-21547	:	_	
121-30	21548-21552	6.79	_	
121-31	21552-21553	+	_	
121-32	21553-21554	/	_	
121-33	21554-21555	−	_	
121-34	21556-21561	7.49%	_	
121-35	21561-21562	,	_	
121-36	21563-21564	t	_	
121-37	21564-21565	 	_	
121-38	21565-21566	=	_	
121-39	21566-21567	 	_	
121-40	21567-21568	−	_	
121-41	21568-21572	0.51	_	
121-42	21573-21574	p	_	
121-43	21574-21575	 	_	
121-44	21575-21576	=	_	
121-45	21576-21577	 	_	
121-46	21577-21580	.62	_	
121-47	21580-21581	)	_	
121-48	21581-21582	.	_	

#Text=Subject-specific fMRI and MEG RSN time courses were detrended and despiked using 3dDespike (http://afni.nimh.nih.gov/afni) and then filtered with a fifth-order Butterworth low-pass filter (0.15 Hz cutoff) prior to connectivity computation.
122-1	21583-21599	Subject-specific	_	
122-2	21600-21604	fMRI	_	
122-3	21605-21608	and	_	
122-4	21609-21612	MEG	_	
122-5	21613-21616	RSN	_	
122-6	21617-21621	time	_	
122-7	21622-21629	courses	_	
122-8	21630-21634	were	_	
122-9	21635-21644	detrended	_	
122-10	21645-21648	and	_	
122-11	21649-21657	despiked	_	
122-12	21658-21663	using	_	
122-13	21664-21673	3dDespike	_	
122-14	21674-21675	(	_	
122-15	21675-21679	http	_	
122-16	21679-21680	:	_	
122-17	21680-21681	/	_	
122-18	21681-21682	/	_	
122-19	21682-21699	afni.nimh.nih.gov	_	
122-20	21699-21700	/	_	
122-21	21700-21704	afni	_	
122-22	21704-21705	)	_	
122-23	21706-21709	and	_	
122-24	21710-21714	then	_	
122-25	21715-21723	filtered	_	
122-26	21724-21728	with	_	
122-27	21729-21730	a	_	
122-28	21731-21742	fifth-order	_	
122-29	21743-21754	Butterworth	_	
122-30	21755-21763	low-pass	_	
122-31	21764-21770	filter	_	
122-32	21771-21772	(	_	
122-33	21772-21776	0.15	_	
122-34	21776-21777	 	_	
122-35	21777-21779	Hz	_	
122-36	21780-21786	cutoff	_	
122-37	21786-21787	)	_	
122-38	21788-21793	prior	_	
122-39	21794-21796	to	_	
122-40	21797-21809	connectivity	_	
122-41	21810-21821	computation	_	
122-42	21821-21822	.	_	

#Text=Functional connectivity was calculated as the pairwise Pearson correlation between RSN time courses, resulting in individual correlation matrices for each subject's fMRI data and MEG frequency bands.
123-1	21823-21833	Functional	_	
123-2	21834-21846	connectivity	_	
123-3	21847-21850	was	_	
123-4	21851-21861	calculated	_	
123-5	21862-21864	as	_	
123-6	21865-21868	the	_	
123-7	21869-21877	pairwise	_	
123-8	21878-21885	Pearson	_	
123-9	21886-21897	correlation	_	
123-10	21898-21905	between	_	
123-11	21906-21909	RSN	_	
123-12	21910-21914	time	_	
123-13	21915-21922	courses	_	
123-14	21922-21923	,	_	
123-15	21924-21933	resulting	_	
123-16	21934-21936	in	_	
123-17	21937-21947	individual	_	
123-18	21948-21959	correlation	_	
123-19	21960-21968	matrices	_	
123-20	21969-21972	for	_	
123-21	21973-21977	each	_	
123-22	21978-21987	subject's	_	
123-23	21988-21992	fMRI	_	
123-24	21993-21997	data	_	
123-25	21998-22001	and	_	
123-26	22002-22005	MEG	_	
123-27	22006-22015	frequency	_	
123-28	22016-22021	bands	_	
123-29	22021-22022	.	_	

#Text=Time courses were extracted from the independent components obtained by ICA.
124-1	22023-22027	Time	_	
124-2	22028-22035	courses	_	
124-3	22036-22040	were	_	
124-4	22041-22050	extracted	_	
124-5	22051-22055	from	_	
124-6	22056-22059	the	_	
124-7	22060-22071	independent	_	
124-8	22072-22082	components	_	
124-9	22083-22091	obtained	_	
124-10	22092-22094	by	_	
124-11	22095-22098	ICA	_	
124-12	22098-22099	.	_	

#Text=Correlations were based on the average time course across voxels within each independent component.
125-1	22100-22112	Correlations	_	
125-2	22113-22117	were	_	
125-3	22118-22123	based	_	
125-4	22124-22126	on	_	
125-5	22127-22130	the	_	
125-6	22131-22138	average	_	
125-7	22139-22143	time	_	
125-8	22144-22150	course	_	
125-9	22151-22157	across	_	
125-10	22158-22164	voxels	_	
125-11	22165-22171	within	_	
125-12	22172-22176	each	_	
125-13	22177-22188	independent	_	
125-14	22189-22198	component	_	
125-15	22198-22199	.	_	

#Text=Individual correlation matrices were averaged across subjects in each group in order to generate group-level connectivity matrices.
126-1	22200-22210	Individual	_	
126-2	22211-22222	correlation	_	
126-3	22223-22231	matrices	_	
126-4	22232-22236	were	_	
126-5	22237-22245	averaged	_	
126-6	22246-22252	across	_	
126-7	22253-22261	subjects	_	
126-8	22262-22264	in	_	
126-9	22265-22269	each	_	
126-10	22270-22275	group	_	
126-11	22276-22278	in	_	
126-12	22279-22284	order	_	
126-13	22285-22287	to	_	
126-14	22288-22296	generate	_	
126-15	22297-22308	group-level	_	
126-16	22309-22321	connectivity	_	
126-17	22322-22330	matrices	_	
126-18	22330-22331	.	_	

#Text=Within- and between-group differences in functional connectivity were evaluated on subject-level correlation matrices via paired and two-sample univariate t-tests, respectively.
127-1	22332-22338	Within	_	
127-2	22338-22339	-	_	
127-3	22340-22343	and	_	
127-4	22344-22357	between-group	_	
127-5	22358-22369	differences	_	
127-6	22370-22372	in	_	
127-7	22373-22383	functional	_	
127-8	22384-22396	connectivity	_	
127-9	22397-22401	were	_	
127-10	22402-22411	evaluated	_	
127-11	22412-22414	on	_	
127-12	22415-22428	subject-level	_	
127-13	22429-22440	correlation	_	
127-14	22441-22449	matrices	_	
127-15	22450-22453	via	_	
127-16	22454-22460	paired	_	
127-17	22461-22464	and	_	
127-18	22465-22475	two-sample	_	
127-19	22476-22486	univariate	_	
127-20	22487-22494	t-tests	_	
127-21	22494-22495	,	_	
127-22	22496-22508	respectively	_	
127-23	22508-22509	.	_	

#Text=In exploratory post hoc analyses, the relationship between functional connectivity and symptom scores including, BPRS, SAPS, and SANS was explored using Spearman correlations in order to examine the potential impact of symptoms on functional connectivity.
128-1	22510-22512	In	_	
128-2	22513-22524	exploratory	_	
128-3	22525-22529	post	_	
128-4	22530-22533	hoc	_	
128-5	22534-22542	analyses	_	
128-6	22542-22543	,	_	
128-7	22544-22547	the	_	
128-8	22548-22560	relationship	_	
128-9	22561-22568	between	_	
128-10	22569-22579	functional	_	
128-11	22580-22592	connectivity	_	
128-12	22593-22596	and	_	
128-13	22597-22604	symptom	_	
128-14	22605-22611	scores	_	
128-15	22612-22621	including	_	
128-16	22621-22622	,	_	
128-17	22623-22627	BPRS	_	
128-18	22627-22628	,	_	
128-19	22629-22633	SAPS	_	
128-20	22633-22634	,	_	
128-21	22635-22638	and	_	
128-22	22639-22643	SANS	_	
128-23	22644-22647	was	_	
128-24	22648-22656	explored	_	
128-25	22657-22662	using	_	
128-26	22663-22671	Spearman	_	
128-27	22672-22684	correlations	_	
128-28	22685-22687	in	_	
128-29	22688-22693	order	_	
128-30	22694-22696	to	_	
128-31	22697-22704	examine	_	
128-32	22705-22708	the	_	
128-33	22709-22718	potential	_	
128-34	22719-22725	impact	_	
128-35	22726-22728	of	_	
128-36	22729-22737	symptoms	_	
128-37	22738-22740	on	_	
128-38	22741-22751	functional	_	
128-39	22752-22764	connectivity	_	
128-40	22764-22765	.	_	

#Text=Results
#Text=Demographics
#Text=Demographics and clinical assessments for MEG and fMRI connectivitya.
129-1	22766-22773	Results	_	
129-2	22774-22786	Demographics	_	
129-3	22787-22799	Demographics	_	
129-4	22800-22803	and	_	
129-5	22804-22812	clinical	_	
129-6	22813-22824	assessments	_	
129-7	22825-22828	for	_	
129-8	22829-22832	MEG	_	
129-9	22833-22836	and	_	
129-10	22837-22841	fMRI	_	
129-11	22842-22855	connectivitya	_	
129-12	22855-22856	.	_	

#Text=Table 1\t \t
#Text=\tHC (n = 24)\tSZ (n = 21)b\tt/χ2\tp-value\t \tAge (years)\t24.13 ± 5.02\t23.52 ± 4.64\t0.415\t0.680\t \tGender (male/female)\t17/7\t15/6\t0.002\t0.965\t \tParental SESc\t3.46 ± 3.32\t4.25 ± 4.38\t6.272\t0.617\t \tEducationd\t3.08 ± 0.58\t2.85 ± 0.59\t1.747\t0.418\t \tSmoking (packs per day)\t0.01 ± 0.06\t0.07 ± 0.15\t−1.607\t0.121\t \tDuration of Illness (months)e\t–\t18.58 ± 26.68\t–\t–\t \t  \t \tBPRSf (n = 19)\t \tTotal score\t–\t32.26 ± 9.82\t\t\t \tPositive symptom subscale\t–\t5.05 ± 2.95\t\t\t \tNegative symptom subscale\t–\t5.74 ± 2.21\t\t\t \t  \t \tSANSg (n = 17)\t \tTotal composite scoreh\t–\t21.56 ± 17.81\t\t\t \tGlobal summary score\t–\t6.47 ± 4.96\t\t\t \t  \t \tSAPSi (n = 17)\t \tTotal composite score\t–\t7.12 ± 11.77\t\t\t \tGlobal summary score\t–\t2.47 ± 3.48\t\t\t \t  \t \tRBANSj\t \tTotal index\t93.43 ± 8.66\t74.35 ± 15.31\t4.579\t<0.001\t \tImmediate memory\t99.67 ± 12.11\t79.65 ± 14.81\t4.587\t<0.001\t \tVisuospatial\t86.24 ± 14.98\t79.94 ± 17.15\t1.208\t0.235\t \tLanguage\t103.71 ± 10.72\t82.82 ± 11.17\t5.862\t<0.001\t \tAttention\t96.14 ± 13.54\t76.47 ± 20.66\t3.532\t0.001\t \tDelayed Memory\t92.05 ± 8.27\t79.88 ± 19.60\t2.393\t0.026\t \t
#Text=Abbreviations: HC, healthy control; SZ, schizophrenia; SES, socioeconomic status; Y, yes; N, no; BPRS, Brief Psychiatric Rating Scale; SANS, Scale for the Assessment of Negative Symptoms; SAPS, Scale for the Assessment of Positive Symptoms; RBANS, Repeated Battery for the Assessment of Neuropsychological Status.
130-1	22857-22862	Table	_	
130-2	22863-22864	1	_	
130-3	22869-22871	HC	_	
130-4	22872-22873	(	_	
130-5	22873-22874	n	_	
130-6	22874-22875	 	_	
130-7	22875-22876	=	_	
130-8	22876-22877	 	_	
130-9	22877-22879	24	_	
130-10	22879-22880	)	_	
130-11	22881-22883	SZ	_	
130-12	22884-22885	(	_	
130-13	22885-22886	n	_	
130-14	22886-22887	 	_	
130-15	22887-22888	=	_	
130-16	22888-22889	 	_	
130-17	22889-22891	21	_	
130-18	22891-22892	)	_	
130-19	22892-22893	b	_	
130-20	22894-22895	t	_	
130-21	22895-22896	/	_	
130-22	22896-22898	χ2	_	
130-23	22899-22906	p-value	_	
130-24	22909-22912	Age	_	
130-25	22913-22914	(	_	
130-26	22914-22919	years	_	
130-27	22919-22920	)	_	
130-28	22921-22926	24.13	_	
130-29	22926-22927	 	_	
130-30	22927-22928	±	_	
130-31	22928-22929	 	_	
130-32	22929-22933	5.02	_	
130-33	22934-22939	23.52	_	
130-34	22939-22940	 	_	
130-35	22940-22941	±	_	
130-36	22941-22942	 	_	
130-37	22942-22946	4.64	_	
130-38	22947-22952	0.415	_	
130-39	22953-22958	0.680	_	
130-40	22961-22967	Gender	_	
130-41	22968-22969	(	_	
130-42	22969-22973	male	_	
130-43	22973-22974	/	_	
130-44	22974-22980	female	_	
130-45	22980-22981	)	_	
130-46	22982-22984	17	_	
130-47	22984-22985	/	_	
130-48	22985-22986	7	_	
130-49	22987-22989	15	_	
130-50	22989-22990	/	_	
130-51	22990-22991	6	_	
130-52	22992-22997	0.002	_	
130-53	22998-23003	0.965	_	
130-54	23006-23014	Parental	_	
130-55	23015-23019	SESc	_	
130-56	23020-23024	3.46	_	
130-57	23024-23025	 	_	
130-58	23025-23026	±	_	
130-59	23026-23027	 	_	
130-60	23027-23031	3.32	_	
130-61	23032-23036	4.25	_	
130-62	23036-23037	 	_	
130-63	23037-23038	±	_	
130-64	23038-23039	 	_	
130-65	23039-23043	4.38	_	
130-66	23044-23049	6.272	_	
130-67	23050-23055	0.617	_	
130-68	23058-23068	Educationd	_	
130-69	23069-23073	3.08	_	
130-70	23073-23074	 	_	
130-71	23074-23075	±	_	
130-72	23075-23076	 	_	
130-73	23076-23080	0.58	_	
130-74	23081-23085	2.85	_	
130-75	23085-23086	 	_	
130-76	23086-23087	±	_	
130-77	23087-23088	 	_	
130-78	23088-23092	0.59	_	
130-79	23093-23098	1.747	_	
130-80	23099-23104	0.418	_	
130-81	23107-23114	Smoking	_	
130-82	23115-23116	(	_	
130-83	23116-23121	packs	_	
130-84	23122-23125	per	_	
130-85	23126-23129	day	_	
130-86	23129-23130	)	_	
130-87	23131-23135	0.01	_	
130-88	23135-23136	 	_	
130-89	23136-23137	±	_	
130-90	23137-23138	 	_	
130-91	23138-23142	0.06	_	
130-92	23143-23147	0.07	_	
130-93	23147-23148	 	_	
130-94	23148-23149	±	_	
130-95	23149-23150	 	_	
130-96	23150-23154	0.15	_	
130-97	23155-23156	−	_	
130-98	23156-23161	1.607	_	
130-99	23162-23167	0.121	_	
130-100	23170-23178	Duration	_	
130-101	23179-23181	of	_	
130-102	23182-23189	Illness	_	
130-103	23190-23191	(	_	
130-104	23191-23197	months	_	
130-105	23197-23198	)	_	
130-106	23198-23199	e	_	
130-107	23200-23201	–	_	
130-108	23202-23207	18.58	_	
130-109	23207-23208	 	_	
130-110	23208-23209	±	_	
130-111	23209-23210	 	_	
130-112	23210-23215	26.68	_	
130-113	23216-23217	–	_	
130-114	23218-23219	–	_	
130-115	23227-23232	BPRSf	_	
130-116	23233-23234	(	_	
130-117	23234-23235	n	_	
130-118	23235-23236	 	_	
130-119	23236-23237	=	_	
130-120	23237-23238	 	_	
130-121	23238-23240	19	_	
130-122	23240-23241	)	_	
130-123	23244-23249	Total	_	
130-124	23250-23255	score	_	
130-125	23256-23257	–	_	
130-126	23258-23263	32.26	_	
130-127	23263-23264	 	_	
130-128	23264-23265	±	_	
130-129	23265-23266	 	_	
130-130	23266-23270	9.82	_	
130-131	23275-23283	Positive	_	
130-132	23284-23291	symptom	_	
130-133	23292-23300	subscale	_	
130-134	23301-23302	–	_	
130-135	23303-23307	5.05	_	
130-136	23307-23308	 	_	
130-137	23308-23309	±	_	
130-138	23309-23310	 	_	
130-139	23310-23314	2.95	_	
130-140	23319-23327	Negative	_	
130-141	23328-23335	symptom	_	
130-142	23336-23344	subscale	_	
130-143	23345-23346	–	_	
130-144	23347-23351	5.74	_	
130-145	23351-23352	 	_	
130-146	23352-23353	±	_	
130-147	23353-23354	 	_	
130-148	23354-23358	2.21	_	
130-149	23368-23373	SANSg	_	
130-150	23374-23375	(	_	
130-151	23375-23376	n	_	
130-152	23376-23377	 	_	
130-153	23377-23378	=	_	
130-154	23378-23379	 	_	
130-155	23379-23381	17	_	
130-156	23381-23382	)	_	
130-157	23385-23390	Total	_	
130-158	23391-23400	composite	_	
130-159	23401-23407	scoreh	_	
130-160	23408-23409	–	_	
130-161	23410-23415	21.56	_	
130-162	23415-23416	 	_	
130-163	23416-23417	±	_	
130-164	23417-23418	 	_	
130-165	23418-23423	17.81	_	
130-166	23428-23434	Global	_	
130-167	23435-23442	summary	_	
130-168	23443-23448	score	_	
130-169	23449-23450	–	_	
130-170	23451-23455	6.47	_	
130-171	23455-23456	 	_	
130-172	23456-23457	±	_	
130-173	23457-23458	 	_	
130-174	23458-23462	4.96	_	
130-175	23472-23477	SAPSi	_	
130-176	23478-23479	(	_	
130-177	23479-23480	n	_	
130-178	23480-23481	 	_	
130-179	23481-23482	=	_	
130-180	23482-23483	 	_	
130-181	23483-23485	17	_	
130-182	23485-23486	)	_	
130-183	23489-23494	Total	_	
130-184	23495-23504	composite	_	
130-185	23505-23510	score	_	
130-186	23511-23512	–	_	
130-187	23513-23517	7.12	_	
130-188	23517-23518	 	_	
130-189	23518-23519	±	_	
130-190	23519-23520	 	_	
130-191	23520-23525	11.77	_	
130-192	23530-23536	Global	_	
130-193	23537-23544	summary	_	
130-194	23545-23550	score	_	
130-195	23551-23552	–	_	
130-196	23553-23557	2.47	_	
130-197	23557-23558	 	_	
130-198	23558-23559	±	_	
130-199	23559-23560	 	_	
130-200	23560-23564	3.48	_	
130-201	23574-23580	RBANSj	_	
130-202	23583-23588	Total	_	
130-203	23589-23594	index	_	
130-204	23595-23600	93.43	_	
130-205	23600-23601	 	_	
130-206	23601-23602	±	_	
130-207	23602-23603	 	_	
130-208	23603-23607	8.66	_	
130-209	23608-23613	74.35	_	
130-210	23613-23614	 	_	
130-211	23614-23615	±	_	
130-212	23615-23616	 	_	
130-213	23616-23621	15.31	_	
130-214	23622-23627	4.579	_	
130-215	23628-23629	<	_	
130-216	23629-23634	0.001	_	
130-217	23637-23646	Immediate	_	
130-218	23647-23653	memory	_	
130-219	23654-23659	99.67	_	
130-220	23659-23660	 	_	
130-221	23660-23661	±	_	
130-222	23661-23662	 	_	
130-223	23662-23667	12.11	_	
130-224	23668-23673	79.65	_	
130-225	23673-23674	 	_	
130-226	23674-23675	±	_	
130-227	23675-23676	 	_	
130-228	23676-23681	14.81	_	
130-229	23682-23687	4.587	_	
130-230	23688-23689	<	_	
130-231	23689-23694	0.001	_	
130-232	23697-23709	Visuospatial	_	
130-233	23710-23715	86.24	_	
130-234	23715-23716	 	_	
130-235	23716-23717	±	_	
130-236	23717-23718	 	_	
130-237	23718-23723	14.98	_	
130-238	23724-23729	79.94	_	
130-239	23729-23730	 	_	
130-240	23730-23731	±	_	
130-241	23731-23732	 	_	
130-242	23732-23737	17.15	_	
130-243	23738-23743	1.208	_	
130-244	23744-23749	0.235	_	
130-245	23752-23760	Language	_	
130-246	23761-23767	103.71	_	
130-247	23767-23768	 	_	
130-248	23768-23769	±	_	
130-249	23769-23770	 	_	
130-250	23770-23775	10.72	_	
130-251	23776-23781	82.82	_	
130-252	23781-23782	 	_	
130-253	23782-23783	±	_	
130-254	23783-23784	 	_	
130-255	23784-23789	11.17	_	
130-256	23790-23795	5.862	_	
130-257	23796-23797	<	_	
130-258	23797-23802	0.001	_	
130-259	23805-23814	Attention	_	
130-260	23815-23820	96.14	_	
130-261	23820-23821	 	_	
130-262	23821-23822	±	_	
130-263	23822-23823	 	_	
130-264	23823-23828	13.54	_	
130-265	23829-23834	76.47	_	
130-266	23834-23835	 	_	
130-267	23835-23836	±	_	
130-268	23836-23837	 	_	
130-269	23837-23842	20.66	_	
130-270	23843-23848	3.532	_	
130-271	23849-23854	0.001	_	
130-272	23857-23864	Delayed	_	
130-273	23865-23871	Memory	_	
130-274	23872-23877	92.05	_	
130-275	23877-23878	 	_	
130-276	23878-23879	±	_	
130-277	23879-23880	 	_	
130-278	23880-23884	8.27	_	
130-279	23885-23890	79.88	_	
130-280	23890-23891	 	_	
130-281	23891-23892	±	_	
130-282	23892-23893	 	_	
130-283	23893-23898	19.60	_	
130-284	23899-23904	2.393	_	
130-285	23905-23910	0.026	_	
130-286	23914-23927	Abbreviations	_	
130-287	23927-23928	:	_	
130-288	23929-23931	HC	_	
130-289	23931-23932	,	_	
130-290	23933-23940	healthy	_	
130-291	23941-23948	control	_	
130-292	23948-23949	;	_	
130-293	23950-23952	SZ	_	
130-294	23952-23953	,	_	
130-295	23954-23967	schizophrenia	_	
130-296	23967-23968	;	_	
130-297	23969-23972	SES	_	
130-298	23972-23973	,	_	
130-299	23974-23987	socioeconomic	_	
130-300	23988-23994	status	_	
130-301	23994-23995	;	_	
130-302	23996-23997	Y	_	
130-303	23997-23998	,	_	
130-304	23999-24002	yes	_	
130-305	24002-24003	;	_	
130-306	24004-24005	N	_	
130-307	24005-24006	,	_	
130-308	24007-24009	no	_	
130-309	24009-24010	;	_	
130-310	24011-24015	BPRS	_	
130-311	24015-24016	,	_	
130-312	24017-24022	Brief	_	
130-313	24023-24034	Psychiatric	_	
130-314	24035-24041	Rating	_	
130-315	24042-24047	Scale	_	
130-316	24047-24048	;	_	
130-317	24049-24053	SANS	_	
130-318	24053-24054	,	_	
130-319	24055-24060	Scale	_	
130-320	24061-24064	for	_	
130-321	24065-24068	the	_	
130-322	24069-24079	Assessment	_	
130-323	24080-24082	of	_	
130-324	24083-24091	Negative	_	
130-325	24092-24100	Symptoms	_	
130-326	24100-24101	;	_	
130-327	24102-24106	SAPS	_	
130-328	24106-24107	,	_	
130-329	24108-24113	Scale	_	
130-330	24114-24117	for	_	
130-331	24118-24121	the	_	
130-332	24122-24132	Assessment	_	
130-333	24133-24135	of	_	
130-334	24136-24144	Positive	_	
130-335	24145-24153	Symptoms	_	
130-336	24153-24154	;	_	
130-337	24155-24160	RBANS	_	
130-338	24160-24161	,	_	
130-339	24162-24170	Repeated	_	
130-340	24171-24178	Battery	_	
130-341	24179-24182	for	_	
130-342	24183-24186	the	_	
130-343	24187-24197	Assessment	_	
130-344	24198-24200	of	_	
130-345	24201-24219	Neuropsychological	_	
130-346	24220-24226	Status	_	
130-347	24226-24227	.	_	

#Text=Mean ± SD unless otherwise indicated.
131-1	24228-24232	Mean	_	
131-2	24232-24233	 	_	
131-3	24233-24234	±	_	
131-4	24234-24235	 	_	
131-5	24235-24237	SD	_	
131-6	24238-24244	unless	_	
131-7	24245-24254	otherwise	_	
131-8	24255-24264	indicated	_	
131-9	24264-24265	.	_	

#Text=SZ values for SES, education, and smoking (packs per day) calculated with n = 20 due to data missing for one patient.
132-1	24266-24268	SZ	_	
132-2	24269-24275	values	_	
132-3	24276-24279	for	_	
132-4	24280-24283	SES	_	
132-5	24283-24284	,	_	
132-6	24285-24294	education	_	
132-7	24294-24295	,	_	
132-8	24296-24299	and	_	
132-9	24300-24307	smoking	_	
132-10	24308-24309	(	_	
132-11	24309-24314	packs	_	
132-12	24315-24318	per	_	
132-13	24319-24322	day	_	
132-14	24322-24323	)	_	
132-15	24324-24334	calculated	_	
132-16	24335-24339	with	_	
132-17	24340-24341	n	_	
132-18	24341-24342	 	_	
132-19	24342-24343	=	_	
132-20	24343-24344	 	_	
132-21	24344-24346	20	_	
132-22	24347-24350	due	_	
132-23	24351-24353	to	_	
132-24	24354-24358	data	_	
132-25	24359-24366	missing	_	
132-26	24367-24370	for	_	
132-27	24371-24374	one	_	
132-28	24375-24382	patient	_	
132-29	24382-24383	.	_	

#Text=SES ranks reported from Diagnostic Interview for Genetic Studies scale (1–18); high rank (lower numerical value) corresponds to high socioeconomic status.
133-1	24384-24387	SES	_	
133-2	24388-24393	ranks	_	
133-3	24394-24402	reported	_	
133-4	24403-24407	from	_	
133-5	24408-24418	Diagnostic	_	
133-6	24419-24428	Interview	_	
133-7	24429-24432	for	_	
133-8	24433-24440	Genetic	_	
133-9	24441-24448	Studies	_	
133-10	24449-24454	scale	_	
133-11	24455-24456	(	_	
133-12	24456-24457	1	_	
133-13	24457-24458	–	_	
133-14	24458-24460	18	_	
133-15	24460-24461	)	_	
133-16	24461-24462	;	_	
133-17	24463-24467	high	_	
133-18	24468-24472	rank	_	
133-19	24473-24474	(	_	
133-20	24474-24479	lower	_	
133-21	24480-24489	numerical	_	
133-22	24490-24495	value	_	
133-23	24495-24496	)	_	
133-24	24497-24508	corresponds	_	
133-25	24509-24511	to	_	
133-26	24512-24516	high	_	
133-27	24517-24530	socioeconomic	_	
133-28	24531-24537	status	_	
133-29	24537-24538	.	_	

#Text=Years of education reported from Diagnostic Interview for Genetic Studies scale.
134-1	24539-24544	Years	_	
134-2	24545-24547	of	_	
134-3	24548-24557	education	_	
134-4	24558-24566	reported	_	
134-5	24567-24571	from	_	
134-6	24572-24582	Diagnostic	_	
134-7	24583-24592	Interview	_	
134-8	24593-24596	for	_	
134-9	24597-24604	Genetic	_	
134-10	24605-24612	Studies	_	
134-11	24613-24618	scale	_	
134-12	24618-24619	.	_	

#Text=Duration of illness (months) calculated with n = 19 due to missing data for 2 patients.
135-1	24620-24628	Duration	_	
135-2	24629-24631	of	_	
135-3	24632-24639	illness	_	
135-4	24640-24641	(	_	
135-5	24641-24647	months	_	
135-6	24647-24648	)	_	
135-7	24649-24659	calculated	_	
135-8	24660-24664	with	_	
135-9	24665-24666	n	_	
135-10	24666-24667	 	_	
135-11	24667-24668	=	_	
135-12	24668-24669	 	_	
135-13	24669-24671	19	_	
135-14	24672-24675	due	_	
135-15	24676-24678	to	_	
135-16	24679-24686	missing	_	
135-17	24687-24691	data	_	
135-18	24692-24695	for	_	
135-19	24696-24697	2	_	
135-20	24698-24706	patients	_	
135-21	24706-24707	.	_	

#Text=BPRS reported on 1–7 scale; positive (conceptual disorganization, hallucinatory behavior, and unusual thought content); negative (emotional withdrawal, motor retardation, and blunted affect).
136-1	24708-24712	BPRS	_	
136-2	24713-24721	reported	_	
136-3	24722-24724	on	_	
136-4	24725-24726	1	_	
136-5	24726-24727	–	_	
136-6	24727-24728	7	_	
136-7	24729-24734	scale	_	
136-8	24734-24735	;	_	
136-9	24736-24744	positive	_	
136-10	24745-24746	(	_	
136-11	24746-24756	conceptual	_	
136-12	24757-24772	disorganization	_	
136-13	24772-24773	,	_	
136-14	24774-24787	hallucinatory	_	
136-15	24788-24796	behavior	_	
136-16	24796-24797	,	_	
136-17	24798-24801	and	_	
136-18	24802-24809	unusual	_	
136-19	24810-24817	thought	_	
136-20	24818-24825	content	_	
136-21	24825-24826	)	_	
136-22	24826-24827	;	_	
136-23	24828-24836	negative	_	
136-24	24837-24838	(	_	
136-25	24838-24847	emotional	_	
136-26	24848-24858	withdrawal	_	
136-27	24858-24859	,	_	
136-28	24860-24865	motor	_	
136-29	24866-24877	retardation	_	
136-30	24877-24878	,	_	
136-31	24879-24882	and	_	
136-32	24883-24890	blunted	_	
136-33	24891-24897	affect	_	
136-34	24897-24898	)	_	
136-35	24898-24899	.	_	

#Text=SANS includes five subscales: affective flattening or blunting, alogia, avolition-apathy, anhedonia-asociality, and attention.
137-1	24900-24904	SANS	_	
137-2	24905-24913	includes	_	
137-3	24914-24918	five	_	
137-4	24919-24928	subscales	_	
137-5	24928-24929	:	_	
137-6	24930-24939	affective	_	
137-7	24940-24950	flattening	_	
137-8	24951-24953	or	_	
137-9	24954-24962	blunting	_	
137-10	24962-24963	,	_	
137-11	24964-24970	alogia	_	
137-12	24970-24971	,	_	
137-13	24972-24988	avolition-apathy	_	
137-14	24988-24989	,	_	
137-15	24990-25010	anhedonia-asociality	_	
137-16	25010-25011	,	_	
137-17	25012-25015	and	_	
137-18	25016-25025	attention	_	
137-19	25025-25026	.	_	

#Text=SANS average total composite score calculated with data from 16 SZ due to missing data from one SZ.
138-1	25027-25031	SANS	_	
138-2	25032-25039	average	_	
138-3	25040-25045	total	_	
138-4	25046-25055	composite	_	
138-5	25056-25061	score	_	
138-6	25062-25072	calculated	_	
138-7	25073-25077	with	_	
138-8	25078-25082	data	_	
138-9	25083-25087	from	_	
138-10	25088-25090	16	_	
138-11	25091-25093	SZ	_	
138-12	25094-25097	due	_	
138-13	25098-25100	to	_	
138-14	25101-25108	missing	_	
138-15	25109-25113	data	_	
138-16	25114-25118	from	_	
138-17	25119-25122	one	_	
138-18	25123-25125	SZ	_	
138-19	25125-25126	.	_	

#Text=SAPS includes four subscales: hallucinations, delusions, bizarre behavior, and positive formal thought disorder.
139-1	25127-25131	SAPS	_	
139-2	25132-25140	includes	_	
139-3	25141-25145	four	_	
139-4	25146-25155	subscales	_	
139-5	25155-25156	:	_	
139-6	25157-25171	hallucinations	_	
139-7	25171-25172	,	_	
139-8	25173-25182	delusions	_	
139-9	25182-25183	,	_	
139-10	25184-25191	bizarre	_	
139-11	25192-25200	behavior	_	
139-12	25200-25201	,	_	
139-13	25202-25205	and	_	
139-14	25206-25214	positive	_	
139-15	25215-25221	formal	_	
139-16	25222-25229	thought	_	
139-17	25230-25238	disorder	_	
139-18	25238-25239	.	_	

#Text=RBANS data missing from 3 HC (n = 21) and 3 SZ (n = 17).
140-1	25240-25245	RBANS	_	
140-2	25246-25250	data	_	
140-3	25251-25258	missing	_	
140-4	25259-25263	from	_	
140-5	25264-25265	3	_	
140-6	25266-25268	HC	_	
140-7	25269-25270	(	_	
140-8	25270-25271	n	_	
140-9	25271-25272	 	_	
140-10	25272-25273	=	_	
140-11	25273-25274	 	_	
140-12	25274-25276	21	_	
140-13	25276-25277	)	_	
140-14	25278-25281	and	_	
140-15	25282-25283	3	_	
140-16	25284-25286	SZ	_	
140-17	25287-25288	(	_	
140-18	25288-25289	n	_	
140-19	25289-25290	 	_	
140-20	25290-25291	=	_	
140-21	25291-25292	 	_	
140-22	25292-25294	17	_	
140-23	25294-25295	)	_	
140-24	25295-25296	.	_	

#Text=No significant differences in age, gender, parental SES, years of education, and smoking status (packs per day) were exhibited between patients and controls (Table 1).
141-1	25297-25299	No	_	
141-2	25300-25311	significant	_	
141-3	25312-25323	differences	_	
141-4	25324-25326	in	_	
141-5	25327-25330	age	_	
141-6	25330-25331	,	_	
141-7	25332-25338	gender	_	
141-8	25338-25339	,	_	
141-9	25340-25348	parental	_	
141-10	25349-25352	SES	_	
141-11	25352-25353	,	_	
141-12	25354-25359	years	_	
141-13	25360-25362	of	_	
141-14	25363-25372	education	_	
141-15	25372-25373	,	_	
141-16	25374-25377	and	_	
141-17	25378-25385	smoking	_	
141-18	25386-25392	status	_	
141-19	25393-25394	(	_	
141-20	25394-25399	packs	_	
141-21	25400-25403	per	_	
141-22	25404-25407	day	_	
141-23	25407-25408	)	_	
141-24	25409-25413	were	_	
141-25	25414-25423	exhibited	_	
141-26	25424-25431	between	_	
141-27	25432-25440	patients	_	
141-28	25441-25444	and	_	
141-29	25445-25453	controls	_	
141-30	25454-25455	(	_	
141-31	25455-25460	Table	_	
141-32	25461-25462	1	_	
141-33	25462-25463	)	_	
141-34	25463-25464	.	_	

#Text=Of the patients enrolled in the study, most were treated with risperidone, one was unmedicated, two were treated with aripiprazole, one with clozapine, and one with a combination of ziprasidone and clozapine.
142-1	25465-25467	Of	_	
142-2	25468-25471	the	_	
142-3	25472-25480	patients	_	
142-4	25481-25489	enrolled	_	
142-5	25490-25492	in	_	
142-6	25493-25496	the	_	
142-7	25497-25502	study	_	
142-8	25502-25503	,	_	
142-9	25504-25508	most	_	
142-10	25509-25513	were	_	
142-11	25514-25521	treated	_	
142-12	25522-25526	with	_	
142-13	25527-25538	risperidone	_	
142-14	25538-25539	,	_	
142-15	25540-25543	one	_	
142-16	25544-25547	was	_	
142-17	25548-25559	unmedicated	_	
142-18	25559-25560	,	_	
142-19	25561-25564	two	_	
142-20	25565-25569	were	_	
142-21	25570-25577	treated	_	
142-22	25578-25582	with	_	
142-23	25583-25595	aripiprazole	_	
142-24	25595-25596	,	_	
142-25	25597-25600	one	_	
142-26	25601-25605	with	_	
142-27	25606-25615	clozapine	_	
142-28	25615-25616	,	_	
142-29	25617-25620	and	_	
142-30	25621-25624	one	_	
142-31	25625-25629	with	_	
142-32	25630-25631	a	_	
142-33	25632-25643	combination	_	
142-34	25644-25646	of	_	
142-35	25647-25658	ziprasidone	_	
142-36	25659-25662	and	_	
142-37	25663-25672	clozapine	_	
142-38	25672-25673	.	_	

#Text=As illustrated in Table 1, patients demonstrated significantly lower immediate memory, language, attention, delayed memory, and total RBANS scores in comparison to controls.
143-1	25674-25676	As	_	
143-2	25677-25688	illustrated	_	
143-3	25689-25691	in	_	
143-4	25692-25697	Table	_	
143-5	25698-25699	1	_	
143-6	25699-25700	,	_	
143-7	25701-25709	patients	_	
143-8	25710-25722	demonstrated	_	
143-9	25723-25736	significantly	_	
143-10	25737-25742	lower	_	
143-11	25743-25752	immediate	_	
143-12	25753-25759	memory	_	
143-13	25759-25760	,	_	
143-14	25761-25769	language	_	
143-15	25769-25770	,	_	
143-16	25771-25780	attention	_	
143-17	25780-25781	,	_	
143-18	25782-25789	delayed	_	
143-19	25790-25796	memory	_	
143-20	25796-25797	,	_	
143-21	25798-25801	and	_	
143-22	25802-25807	total	_	
143-23	25808-25813	RBANS	_	
143-24	25814-25820	scores	_	
143-25	25821-25823	in	_	
143-26	25824-25834	comparison	_	
143-27	25835-25837	to	_	
143-28	25838-25846	controls	_	
143-29	25846-25847	.	_	

#Text=Patient symptoms scores can also be found in Table 1.
144-1	25848-25855	Patient	_	
144-2	25856-25864	symptoms	_	
144-3	25865-25871	scores	_	
144-4	25872-25875	can	_	
144-5	25876-25880	also	_	
144-6	25881-25883	be	_	
144-7	25884-25889	found	_	
144-8	25890-25892	in	_	
144-9	25893-25898	Table	_	
144-10	25899-25900	1	_	
144-11	25900-25901	.	_	

#Text=No significant differences in mean framewise displacement (t = −0.78, p = .44) between controls and patients were found.
145-1	25902-25904	No	_	
145-2	25905-25916	significant	_	
145-3	25917-25928	differences	_	
145-4	25929-25931	in	_	
145-5	25932-25936	mean	_	
145-6	25937-25946	framewise	_	
145-7	25947-25959	displacement	_	
145-8	25960-25961	(	_	
145-9	25961-25962	t	_	
145-10	25962-25963	 	_	
145-11	25963-25964	=	_	
145-12	25964-25965	 	_	
145-13	25965-25966	−	_	
145-14	25966-25970	0.78	_	
145-15	25970-25971	,	_	
145-16	25972-25973	p	_	
145-17	25973-25974	 	_	
145-18	25974-25975	=	_	
145-19	25975-25976	 	_	
145-20	25976-25979	.44	_	
145-21	25979-25980	)	_	
145-22	25981-25988	between	_	
145-23	25989-25997	controls	_	
145-24	25998-26001	and	_	
145-25	26002-26010	patients	_	
145-26	26011-26015	were	_	
145-27	26016-26021	found	_	
145-28	26021-26022	.	_	

#Text=Independent components
#Text=fMRI
#Text=Of the 50 extracted ICs, 30 were identified as RSNs as opposed to artifacts based on the criteria described in the methods (Fig. 1).
146-1	26023-26034	Independent	_	
146-2	26035-26045	components	_	
146-3	26046-26050	fMRI	_	
146-4	26051-26053	Of	_	
146-5	26054-26057	the	_	
146-6	26058-26060	50	_	
146-7	26061-26070	extracted	_	
146-8	26071-26074	ICs	_	
146-9	26074-26075	,	_	
146-10	26076-26078	30	_	
146-11	26079-26083	were	_	
146-12	26084-26094	identified	_	
146-13	26095-26097	as	_	
146-14	26098-26102	RSNs	_	
146-15	26103-26105	as	_	
146-16	26106-26113	opposed	_	
146-17	26114-26116	to	_	
146-18	26117-26126	artifacts	_	
146-19	26127-26132	based	_	
146-20	26133-26135	on	_	
146-21	26136-26139	the	_	
146-22	26140-26148	criteria	_	
146-23	26149-26158	described	_	
146-24	26159-26161	in	_	
146-25	26162-26165	the	_	
146-26	26166-26173	methods	_	
146-27	26174-26175	(	_	
146-28	26175-26178	Fig	_	
146-29	26178-26179	.	_	
146-30	26180-26181	1	_	
146-31	26181-26182	)	_	
146-32	26182-26183	.	_	

#Text=Identified RSNs were organized into six different networks including subcortical (1 RSN), auditory (1 RSN), sensorimotor (7 RSNs), visual (5 RSNs), task positive (9 RSNs), and default-mode (7 RSNs) networks (Fig. 1; Supplementary Table 1).
147-1	26184-26194	Identified	_	
147-2	26195-26199	RSNs	_	
147-3	26200-26204	were	_	
147-4	26205-26214	organized	_	
147-5	26215-26219	into	_	
147-6	26220-26223	six	_	
147-7	26224-26233	different	_	
147-8	26234-26242	networks	_	
147-9	26243-26252	including	_	
147-10	26253-26264	subcortical	_	
147-11	26265-26266	(	_	
147-12	26266-26267	1	_	
147-13	26268-26271	RSN	_	
147-14	26271-26272	)	_	
147-15	26272-26273	,	_	
147-16	26274-26282	auditory	_	
147-17	26283-26284	(	_	
147-18	26284-26285	1	_	
147-19	26286-26289	RSN	_	
147-20	26289-26290	)	_	
147-21	26290-26291	,	_	
147-22	26292-26304	sensorimotor	_	
147-23	26305-26306	(	_	
147-24	26306-26307	7	_	
147-25	26308-26312	RSNs	_	
147-26	26312-26313	)	_	
147-27	26313-26314	,	_	
147-28	26315-26321	visual	_	
147-29	26322-26323	(	_	
147-30	26323-26324	5	_	
147-31	26325-26329	RSNs	_	
147-32	26329-26330	)	_	
147-33	26330-26331	,	_	
147-34	26332-26336	task	_	
147-35	26337-26345	positive	_	
147-36	26346-26347	(	_	
147-37	26347-26348	9	_	
147-38	26349-26353	RSNs	_	
147-39	26353-26354	)	_	
147-40	26354-26355	,	_	
147-41	26356-26359	and	_	
147-42	26360-26372	default-mode	_	
147-43	26373-26374	(	_	
147-44	26374-26375	7	_	
147-45	26376-26380	RSNs	_	
147-46	26380-26381	)	_	
147-47	26382-26390	networks	_	
147-48	26391-26392	(	_	
147-49	26392-26395	Fig	_	
147-50	26395-26396	.	_	
147-51	26397-26398	1	_	
147-52	26398-26399	;	_	
147-53	26400-26413	Supplementary	_	
147-54	26414-26419	Table	_	
147-55	26420-26421	1	_	
147-56	26421-26422	)	_	
147-57	26422-26423	.	_	

#Text=MEG
#Text=Of the 50 extracted MEG ICs, 33 were identified as RSNs (Fig. 1) and organized into auditory (3 RSNs), sensorimotor (10 RSNs), visual (6 RSNs), task positive (9 RSNs), and default-mode (5 RSNs) networks (Fig. 1; Supplementary Table 2).
#Text=fMRI functional connectivity
#Text=Resting-state fMRI and MEG functional connectivity.
148-1	26424-26427	MEG	_	
148-2	26428-26430	Of	_	
148-3	26431-26434	the	_	
148-4	26435-26437	50	_	
148-5	26438-26447	extracted	_	
148-6	26448-26451	MEG	_	
148-7	26452-26455	ICs	_	
148-8	26455-26456	,	_	
148-9	26457-26459	33	_	
148-10	26460-26464	were	_	
148-11	26465-26475	identified	_	
148-12	26476-26478	as	_	
148-13	26479-26483	RSNs	_	
148-14	26484-26485	(	_	
148-15	26485-26488	Fig	_	
148-16	26488-26489	.	_	
148-17	26490-26491	1	_	
148-18	26491-26492	)	_	
148-19	26493-26496	and	_	
148-20	26497-26506	organized	_	
148-21	26507-26511	into	_	
148-22	26512-26520	auditory	_	
148-23	26521-26522	(	_	
148-24	26522-26523	3	_	
148-25	26524-26528	RSNs	_	
148-26	26528-26529	)	_	
148-27	26529-26530	,	_	
148-28	26531-26543	sensorimotor	_	
148-29	26544-26545	(	_	
148-30	26545-26547	10	_	
148-31	26548-26552	RSNs	_	
148-32	26552-26553	)	_	
148-33	26553-26554	,	_	
148-34	26555-26561	visual	_	
148-35	26562-26563	(	_	
148-36	26563-26564	6	_	
148-37	26565-26569	RSNs	_	
148-38	26569-26570	)	_	
148-39	26570-26571	,	_	
148-40	26572-26576	task	_	
148-41	26577-26585	positive	_	
148-42	26586-26587	(	_	
148-43	26587-26588	9	_	
148-44	26589-26593	RSNs	_	
148-45	26593-26594	)	_	
148-46	26594-26595	,	_	
148-47	26596-26599	and	_	
148-48	26600-26612	default-mode	_	
148-49	26613-26614	(	_	
148-50	26614-26615	5	_	
148-51	26616-26620	RSNs	_	
148-52	26620-26621	)	_	
148-53	26622-26630	networks	_	
148-54	26631-26632	(	_	
148-55	26632-26635	Fig	_	
148-56	26635-26636	.	_	
148-57	26637-26638	1	_	
148-58	26638-26639	;	_	
148-59	26640-26653	Supplementary	_	
148-60	26654-26659	Table	_	
148-61	26660-26661	2	_	
148-62	26661-26662	)	_	
148-63	26662-26663	.	_	
148-64	26664-26668	fMRI	_	
148-65	26669-26679	functional	_	
148-66	26680-26692	connectivity	_	
148-67	26693-26706	Resting-state	_	
148-68	26707-26711	fMRI	_	
148-69	26712-26715	and	_	
148-70	26716-26719	MEG	_	
148-71	26720-26730	functional	_	
148-72	26731-26743	connectivity	_	
148-73	26743-26744	.	_	

#Text=Functional connectivity for resting-state fMRI (top) and MEG averaged across frequency bands (bottom).
149-1	26745-26755	Functional	_	
149-2	26756-26768	connectivity	_	
149-3	26769-26772	for	_	
149-4	26773-26786	resting-state	_	
149-5	26787-26791	fMRI	_	
149-6	26792-26793	(	_	
149-7	26793-26796	top	_	
149-8	26796-26797	)	_	
149-9	26798-26801	and	_	
149-10	26802-26805	MEG	_	
149-11	26806-26814	averaged	_	
149-12	26815-26821	across	_	
149-13	26822-26831	frequency	_	
149-14	26832-26837	bands	_	
149-15	26838-26839	(	_	
149-16	26839-26845	bottom	_	
149-17	26845-26846	)	_	
149-18	26846-26847	.	_	

#Text=Connectivity for controls (left column), first-episode patients (middle column), and the significant difference between groups (right column) are shown.
150-1	26848-26860	Connectivity	_	
150-2	26861-26864	for	_	
150-3	26865-26873	controls	_	
150-4	26874-26875	(	_	
150-5	26875-26879	left	_	
150-6	26880-26886	column	_	
150-7	26886-26887	)	_	
150-8	26887-26888	,	_	
150-9	26889-26902	first-episode	_	
150-10	26903-26911	patients	_	
150-11	26912-26913	(	_	
150-12	26913-26919	middle	_	
150-13	26920-26926	column	_	
150-14	26926-26927	)	_	
150-15	26927-26928	,	_	
150-16	26929-26932	and	_	
150-17	26933-26936	the	_	
150-18	26937-26948	significant	_	
150-19	26949-26959	difference	_	
150-20	26960-26967	between	_	
150-21	26968-26974	groups	_	
150-22	26975-26976	(	_	
150-23	26976-26981	right	_	
150-24	26982-26988	column	_	
150-25	26988-26989	)	_	
150-26	26990-26993	are	_	
150-27	26994-26999	shown	_	
150-28	26999-27000	.	_	

#Text=FDR-corrected significant differences (pFDR < 0.05) are indicated with • and uncorrected significant differences (puncorrected < 0.05) are indicated with *.
151-1	27001-27014	FDR-corrected	_	
151-2	27015-27026	significant	_	
151-3	27027-27038	differences	_	
151-4	27039-27040	(	_	
151-5	27040-27044	pFDR	_	
151-6	27044-27045	 	_	
151-7	27045-27046	<	_	
151-8	27046-27047	 	_	
151-9	27047-27051	0.05	_	
151-10	27051-27052	)	_	
151-11	27053-27056	are	_	
151-12	27057-27066	indicated	_	
151-13	27067-27071	with	_	
151-14	27072-27073	•	_	
151-15	27074-27077	and	_	
151-16	27078-27089	uncorrected	_	
151-17	27090-27101	significant	_	
151-18	27102-27113	differences	_	
151-19	27114-27115	(	_	
151-20	27115-27127	puncorrected	_	
151-21	27127-27128	 	_	
151-22	27128-27129	<	_	
151-23	27129-27130	 	_	
151-24	27130-27134	0.05	_	
151-25	27134-27135	)	_	
151-26	27136-27139	are	_	
151-27	27140-27149	indicated	_	
151-28	27150-27154	with	_	
151-29	27155-27156	*	_	
151-30	27156-27157	.	_	

#Text=Fig. 2
#Text=fMRI connectogram and symptom correlations.
152-1	27158-27161	Fig	_	
152-2	27161-27162	.	_	
152-3	27163-27164	2	_	
152-4	27165-27169	fMRI	_	
152-5	27170-27182	connectogram	_	
152-6	27183-27186	and	_	
152-7	27187-27194	symptom	_	
152-8	27195-27207	correlations	_	
152-9	27207-27208	.	_	

#Text=(A) fMRI connectogram depicting significant (pFDR < 0.05) connectivity differences between patients and controls.
153-1	27209-27210	(	_	
153-2	27210-27211	A	_	
153-3	27211-27212	)	_	
153-4	27213-27217	fMRI	_	
153-5	27218-27230	connectogram	_	
153-6	27231-27240	depicting	_	
153-7	27241-27252	significant	_	
153-8	27253-27254	(	_	
153-9	27254-27258	pFDR	_	
153-10	27258-27259	 	_	
153-11	27259-27260	<	_	
153-12	27260-27261	 	_	
153-13	27261-27265	0.05	_	
153-14	27265-27266	)	_	
153-15	27267-27279	connectivity	_	
153-16	27280-27291	differences	_	
153-17	27292-27299	between	_	
153-18	27300-27308	patients	_	
153-19	27309-27312	and	_	
153-20	27313-27321	controls	_	
153-21	27321-27322	.	_	

#Text=Warm colors represent decreased and cool colors represent increased connectivity in patients.
154-1	27323-27327	Warm	_	
154-2	27328-27334	colors	_	
154-3	27335-27344	represent	_	
154-4	27345-27354	decreased	_	
154-5	27355-27358	and	_	
154-6	27359-27363	cool	_	
154-7	27364-27370	colors	_	
154-8	27371-27380	represent	_	
154-9	27381-27390	increased	_	
154-10	27391-27403	connectivity	_	
154-11	27404-27406	in	_	
154-12	27407-27415	patients	_	
154-13	27415-27416	.	_	

#Text=(B) Correlation between significant subcortical-auditory connectivity values and patients BPRS positive scores.
155-1	27417-27418	(	_	
155-2	27418-27419	B	_	
155-3	27419-27420	)	_	
155-4	27421-27432	Correlation	_	
155-5	27433-27440	between	_	
155-6	27441-27452	significant	_	
155-7	27453-27473	subcortical-auditory	_	
155-8	27474-27486	connectivity	_	
155-9	27487-27493	values	_	
155-10	27494-27497	and	_	
155-11	27498-27506	patients	_	
155-12	27507-27511	BPRS	_	
155-13	27512-27520	positive	_	
155-14	27521-27527	scores	_	
155-15	27527-27528	.	_	

#Text=Fig. 3
#Text=Mean functional connectivity for controls and patients are illustrated in the top row of Fig. 2.
156-1	27529-27532	Fig	_	
156-2	27532-27533	.	_	
156-3	27534-27535	3	_	
156-4	27536-27540	Mean	_	
156-5	27541-27551	functional	_	
156-6	27552-27564	connectivity	_	
156-7	27565-27568	for	_	
156-8	27569-27577	controls	_	
156-9	27578-27581	and	_	
156-10	27582-27590	patients	_	
156-11	27591-27594	are	_	
156-12	27595-27606	illustrated	_	
156-13	27607-27609	in	_	
156-14	27610-27613	the	_	
156-15	27614-27617	top	_	
156-16	27618-27621	row	_	
156-17	27622-27624	of	_	
156-18	27625-27628	Fig	_	
156-19	27628-27629	.	_	
156-20	27630-27631	2	_	
156-21	27631-27632	.	_	

#Text=Patients demonstrated significantly higher connectivity (p < .001) between subcortical (IC 49) and auditory (IC 18) RSNs compared to controls (Fig. 2, Fig. 3).
157-1	27633-27641	Patients	_	
157-2	27642-27654	demonstrated	_	
157-3	27655-27668	significantly	_	
157-4	27669-27675	higher	_	
157-5	27676-27688	connectivity	_	
157-6	27689-27690	(	_	
157-7	27690-27691	p	_	
157-8	27691-27692	 	_	
157-9	27692-27693	<	_	
157-10	27693-27694	 	_	
157-11	27694-27698	.001	_	
157-12	27698-27699	)	_	
157-13	27700-27707	between	_	
157-14	27708-27719	subcortical	_	
157-15	27720-27721	(	_	
157-16	27721-27723	IC	_	
157-17	27724-27726	49	_	
157-18	27726-27727	)	_	
157-19	27728-27731	and	_	
157-20	27732-27740	auditory	_	
157-21	27741-27742	(	_	
157-22	27742-27744	IC	_	
157-23	27745-27747	18	_	
157-24	27747-27748	)	_	
157-25	27749-27753	RSNs	_	
157-26	27754-27762	compared	_	
157-27	27763-27765	to	_	
157-28	27766-27774	controls	_	
157-29	27775-27776	(	_	
157-30	27776-27779	Fig	_	
157-31	27779-27780	.	_	
157-32	27781-27782	2	_	
157-33	27782-27783	,	_	
157-34	27784-27787	Fig	_	
157-35	27787-27788	.	_	
157-36	27789-27790	3	_	
157-37	27790-27791	)	_	
157-38	27791-27792	.	_	

#Text=However, patients also exhibited significantly lower (p < .001) connectivity between two sensorimotor RSNs (i.e., IC1 and IC2) when compared to controls (Fig. 2, Fig. 3).
158-1	27793-27800	However	_	
158-2	27800-27801	,	_	
158-3	27802-27810	patients	_	
158-4	27811-27815	also	_	
158-5	27816-27825	exhibited	_	
158-6	27826-27839	significantly	_	
158-7	27840-27845	lower	_	
158-8	27846-27847	(	_	
158-9	27847-27848	p	_	
158-10	27848-27849	 	_	
158-11	27849-27850	<	_	
158-12	27850-27851	 	_	
158-13	27851-27855	.001	_	
158-14	27855-27856	)	_	
158-15	27857-27869	connectivity	_	
158-16	27870-27877	between	_	
158-17	27878-27881	two	_	
158-18	27882-27894	sensorimotor	_	
158-19	27895-27899	RSNs	_	
158-20	27900-27901	(	_	
158-21	27901-27904	i.e	_	
158-22	27904-27905	.	_	
158-23	27905-27906	,	_	
158-24	27907-27910	IC1	_	
158-25	27911-27914	and	_	
158-26	27915-27918	IC2	_	
158-27	27918-27919	)	_	
158-28	27920-27924	when	_	
158-29	27925-27933	compared	_	
158-30	27934-27936	to	_	
158-31	27937-27945	controls	_	
158-32	27946-27947	(	_	
158-33	27947-27950	Fig	_	
158-34	27950-27951	.	_	
158-35	27952-27953	2	_	
158-36	27953-27954	,	_	
158-37	27955-27958	Fig	_	
158-38	27958-27959	.	_	
158-39	27960-27961	3	_	
158-40	27961-27962	)	_	
158-41	27962-27963	.	_	

#Text=Connectivity results are corrected for multiple comparisons using the false discovery rate (FDR) and reported at pFDR < 0.05.
159-1	27964-27976	Connectivity	_	
159-2	27977-27984	results	_	
159-3	27985-27988	are	_	
159-4	27989-27998	corrected	_	
159-5	27999-28002	for	_	
159-6	28003-28011	multiple	_	
159-7	28012-28023	comparisons	_	
159-8	28024-28029	using	_	
159-9	28030-28033	the	_	
159-10	28034-28039	false	_	
159-11	28040-28049	discovery	_	
159-12	28050-28054	rate	_	
159-13	28055-28056	(	_	
159-14	28056-28059	FDR	_	
159-15	28059-28060	)	_	
159-16	28061-28064	and	_	
159-17	28065-28073	reported	_	
159-18	28074-28076	at	_	
159-19	28077-28081	pFDR	_	
159-20	28081-28082	 	_	
159-21	28082-28083	<	_	
159-22	28083-28084	 	_	
159-23	28084-28088	0.05	_	
159-24	28088-28089	.	_	

#Text=Exploratory post hoc analyses revealed a significant relationship (rho = 0.59; p = .013, confidence interval: 0.1175 to 0.8533), using Spearman correlations over 1000 bootstrap, between patient BPRS positive symptom score and functional connectivity between subcortical and auditory RSNs (Fig. 3).
160-1	28090-28101	Exploratory	_	
160-2	28102-28106	post	_	
160-3	28107-28110	hoc	_	
160-4	28111-28119	analyses	_	
160-5	28120-28128	revealed	_	
160-6	28129-28130	a	_	
160-7	28131-28142	significant	_	
160-8	28143-28155	relationship	_	
160-9	28156-28157	(	_	
160-10	28157-28160	rho	_	
160-11	28160-28161	 	_	
160-12	28161-28162	=	_	
160-13	28162-28163	 	_	
160-14	28163-28167	0.59	_	
160-15	28167-28168	;	_	
160-16	28169-28170	p	_	
160-17	28170-28171	 	_	
160-18	28171-28172	=	_	
160-19	28172-28173	 	_	
160-20	28173-28177	.013	_	
160-21	28177-28178	,	_	
160-22	28179-28189	confidence	_	
160-23	28190-28198	interval	_	
160-24	28198-28199	:	_	
160-25	28200-28206	0.1175	_	
160-26	28207-28209	to	_	
160-27	28210-28216	0.8533	_	
160-28	28216-28217	)	_	
160-29	28217-28218	,	_	
160-30	28219-28224	using	_	
160-31	28225-28233	Spearman	_	
160-32	28234-28246	correlations	_	
160-33	28247-28251	over	_	
160-34	28252-28256	1000	_	
160-35	28257-28266	bootstrap	_	
160-36	28266-28267	,	_	
160-37	28268-28275	between	_	
160-38	28276-28283	patient	_	
160-39	28284-28288	BPRS	_	
160-40	28289-28297	positive	_	
160-41	28298-28305	symptom	_	
160-42	28306-28311	score	_	
160-43	28312-28315	and	_	
160-44	28316-28326	functional	_	
160-45	28327-28339	connectivity	_	
160-46	28340-28347	between	_	
160-47	28348-28359	subcortical	_	
160-48	28360-28363	and	_	
160-49	28364-28372	auditory	_	
160-50	28373-28377	RSNs	_	
160-51	28378-28379	(	_	
160-52	28379-28382	Fig	_	
160-53	28382-28383	.	_	
160-54	28384-28385	3	_	
160-55	28385-28386	)	_	
160-56	28386-28387	.	_	

#Text=This indicates that as BPRS positive symptoms increase, connectivity between subcortical and auditory networks in patients also increases.
161-1	28388-28392	This	_	
161-2	28393-28402	indicates	_	
161-3	28403-28407	that	_	
161-4	28408-28410	as	_	
161-5	28411-28415	BPRS	_	
161-6	28416-28424	positive	_	
161-7	28425-28433	symptoms	_	
161-8	28434-28442	increase	_	
161-9	28442-28443	,	_	
161-10	28444-28456	connectivity	_	
161-11	28457-28464	between	_	
161-12	28465-28476	subcortical	_	
161-13	28477-28480	and	_	
161-14	28481-28489	auditory	_	
161-15	28490-28498	networks	_	
161-16	28499-28501	in	_	
161-17	28502-28510	patients	_	
161-18	28511-28515	also	_	
161-19	28516-28525	increases	_	
161-20	28525-28526	.	_	

#Text=However, given the number of correlations conducted, including with the BPRS negative subscale, the SAPS and SANS total scores (all p > .05), this correlation would not survive multiple comparison correction.
162-1	28527-28534	However	_	
162-2	28534-28535	,	_	
162-3	28536-28541	given	_	
162-4	28542-28545	the	_	
162-5	28546-28552	number	_	
162-6	28553-28555	of	_	
162-7	28556-28568	correlations	_	
162-8	28569-28578	conducted	_	
162-9	28578-28579	,	_	
162-10	28580-28589	including	_	
162-11	28590-28594	with	_	
162-12	28595-28598	the	_	
162-13	28599-28603	BPRS	_	
162-14	28604-28612	negative	_	
162-15	28613-28621	subscale	_	
162-16	28621-28622	,	_	
162-17	28623-28626	the	_	
162-18	28627-28631	SAPS	_	
162-19	28632-28635	and	_	
162-20	28636-28640	SANS	_	
162-21	28641-28646	total	_	
162-22	28647-28653	scores	_	
162-23	28654-28655	(	_	
162-24	28655-28658	all	_	
162-25	28659-28660	p	_	
162-26	28660-28661	 	_	
162-27	28661-28662	>	_	
162-28	28662-28663	 	_	
162-29	28663-28666	.05	_	
162-30	28666-28667	)	_	
162-31	28667-28668	,	_	
162-32	28669-28673	this	_	
162-33	28674-28685	correlation	_	
162-34	28686-28691	would	_	
162-35	28692-28695	not	_	
162-36	28696-28703	survive	_	
162-37	28704-28712	multiple	_	
162-38	28713-28723	comparison	_	
162-39	28724-28734	correction	_	
162-40	28734-28735	.	_	

#Text=MEG functional connectivity
#Text=Mean functional connectivity for the average of all frequency bands is shown for controls and patients in the bottom row of Fig. 2.
163-1	28736-28739	MEG	_	
163-2	28740-28750	functional	_	
163-3	28751-28763	connectivity	_	
163-4	28764-28768	Mean	_	
163-5	28769-28779	functional	_	
163-6	28780-28792	connectivity	_	
163-7	28793-28796	for	_	
163-8	28797-28800	the	_	
163-9	28801-28808	average	_	
163-10	28809-28811	of	_	
163-11	28812-28815	all	_	
163-12	28816-28825	frequency	_	
163-13	28826-28831	bands	_	
163-14	28832-28834	is	_	
163-15	28835-28840	shown	_	
163-16	28841-28844	for	_	
163-17	28845-28853	controls	_	
163-18	28854-28857	and	_	
163-19	28858-28866	patients	_	
163-20	28867-28869	in	_	
163-21	28870-28873	the	_	
163-22	28874-28880	bottom	_	
163-23	28881-28884	row	_	
163-24	28885-28887	of	_	
163-25	28888-28891	Fig	_	
163-26	28891-28892	.	_	
163-27	28893-28894	2	_	
163-28	28894-28895	.	_	

#Text=In the delta frequency band, patients demonstrated significantly lower connectivity (p < .001) between sensorimotor (IC 5) and task positive (IC 34) RSNs (Fig. 4, Fig. 5).
164-1	28896-28898	In	_	
164-2	28899-28902	the	_	
164-3	28903-28908	delta	_	
164-4	28909-28918	frequency	_	
164-5	28919-28923	band	_	
164-6	28923-28924	,	_	
164-7	28925-28933	patients	_	
164-8	28934-28946	demonstrated	_	
164-9	28947-28960	significantly	_	
164-10	28961-28966	lower	_	
164-11	28967-28979	connectivity	_	
164-12	28980-28981	(	_	
164-13	28981-28982	p	_	
164-14	28982-28983	 	_	
164-15	28983-28984	<	_	
164-16	28984-28985	 	_	
164-17	28985-28989	.001	_	
164-18	28989-28990	)	_	
164-19	28991-28998	between	_	
164-20	28999-29011	sensorimotor	_	
164-21	29012-29013	(	_	
164-22	29013-29015	IC	_	
164-23	29016-29017	5	_	
164-24	29017-29018	)	_	
164-25	29019-29022	and	_	
164-26	29023-29027	task	_	
164-27	29028-29036	positive	_	
164-28	29037-29038	(	_	
164-29	29038-29040	IC	_	
164-30	29041-29043	34	_	
164-31	29043-29044	)	_	
164-32	29045-29049	RSNs	_	
164-33	29050-29051	(	_	
164-34	29051-29054	Fig	_	
164-35	29054-29055	.	_	
164-36	29056-29057	4	_	
164-37	29057-29058	,	_	
164-38	29059-29062	Fig	_	
164-39	29062-29063	.	_	
164-40	29064-29065	5	_	
164-41	29065-29066	)	_	
164-42	29066-29067	.	_	

#Text=Patients also exhibited significantly lower connectivity (p < .001) between sensorimotor (IC 25) and task positive (IC 34) RSNs in the delta band (Fig. 4, Fig. 5).
165-1	29068-29076	Patients	_	
165-2	29077-29081	also	_	
165-3	29082-29091	exhibited	_	
165-4	29092-29105	significantly	_	
165-5	29106-29111	lower	_	
165-6	29112-29124	connectivity	_	
165-7	29125-29126	(	_	
165-8	29126-29127	p	_	
165-9	29127-29128	 	_	
165-10	29128-29129	<	_	
165-11	29129-29130	 	_	
165-12	29130-29134	.001	_	
165-13	29134-29135	)	_	
165-14	29136-29143	between	_	
165-15	29144-29156	sensorimotor	_	
165-16	29157-29158	(	_	
165-17	29158-29160	IC	_	
165-18	29161-29163	25	_	
165-19	29163-29164	)	_	
165-20	29165-29168	and	_	
165-21	29169-29173	task	_	
165-22	29174-29182	positive	_	
165-23	29183-29184	(	_	
165-24	29184-29186	IC	_	
165-25	29187-29189	34	_	
165-26	29189-29190	)	_	
165-27	29191-29195	RSNs	_	
165-28	29196-29198	in	_	
165-29	29199-29202	the	_	
165-30	29203-29208	delta	_	
165-31	29209-29213	band	_	
165-32	29214-29215	(	_	
165-33	29215-29218	Fig	_	
165-34	29218-29219	.	_	
165-35	29220-29221	4	_	
165-36	29221-29222	,	_	
165-37	29223-29226	Fig	_	
165-38	29226-29227	.	_	
165-39	29228-29229	5	_	
165-40	29229-29230	)	_	
165-41	29230-29231	.	_	

#Text=Connectivity results are corrected for multiple comparisons and reported at pFDR < 0.05.
166-1	29232-29244	Connectivity	_	
166-2	29245-29252	results	_	
166-3	29253-29256	are	_	
166-4	29257-29266	corrected	_	
166-5	29267-29270	for	_	
166-6	29271-29279	multiple	_	
166-7	29280-29291	comparisons	_	
166-8	29292-29295	and	_	
166-9	29296-29304	reported	_	
166-10	29305-29307	at	_	
166-11	29308-29312	pFDR	_	
166-12	29312-29313	 	_	
166-13	29313-29314	<	_	
166-14	29314-29315	 	_	
166-15	29315-29319	0.05	_	
166-16	29319-29320	.	_	

#Text=No other significant group differences corrected for multiple comparisons were exhibited in the remaining frequency bands.
167-1	29321-29323	No	_	
167-2	29324-29329	other	_	
167-3	29330-29341	significant	_	
167-4	29342-29347	group	_	
167-5	29348-29359	differences	_	
167-6	29360-29369	corrected	_	
167-7	29370-29373	for	_	
167-8	29374-29382	multiple	_	
167-9	29383-29394	comparisons	_	
167-10	29395-29399	were	_	
167-11	29400-29409	exhibited	_	
167-12	29410-29412	in	_	
167-13	29413-29416	the	_	
167-14	29417-29426	remaining	_	
167-15	29427-29436	frequency	_	
167-16	29437-29442	bands	_	
167-17	29442-29443	.	_	

#Text=Frequency band-specific functional connectivity for each group and group differences (puncorrected < 0.05) are illustrated in Supplementary Fig. 2, Supplementary Fig. 3, Supplementary Fig. 4, Supplementary Fig. 5.
168-1	29444-29453	Frequency	_	
168-2	29454-29467	band-specific	_	
168-3	29468-29478	functional	_	
168-4	29479-29491	connectivity	_	
168-5	29492-29495	for	_	
168-6	29496-29500	each	_	
168-7	29501-29506	group	_	
168-8	29507-29510	and	_	
168-9	29511-29516	group	_	
168-10	29517-29528	differences	_	
168-11	29529-29530	(	_	
168-12	29530-29542	puncorrected	_	
168-13	29542-29543	 	_	
168-14	29543-29544	<	_	
168-15	29544-29545	 	_	
168-16	29545-29549	0.05	_	
168-17	29549-29550	)	_	
168-18	29551-29554	are	_	
168-19	29555-29566	illustrated	_	
168-20	29567-29569	in	_	
168-21	29570-29583	Supplementary	_	
168-22	29584-29587	Fig	_	
168-23	29587-29588	.	_	
168-24	29589-29590	2	_	
168-25	29590-29591	,	_	
168-26	29592-29605	Supplementary	_	
168-27	29606-29609	Fig	_	
168-28	29609-29610	.	_	
168-29	29611-29612	3	_	
168-30	29612-29613	,	_	
168-31	29614-29627	Supplementary	_	
168-32	29628-29631	Fig	_	
168-33	29631-29632	.	_	
168-34	29633-29634	4	_	
168-35	29634-29635	,	_	
168-36	29636-29649	Supplementary	_	
168-37	29650-29653	Fig	_	
168-38	29653-29654	.	_	
168-39	29655-29656	5	_	
168-40	29656-29657	.	_	

#Text=Resting-state delta frequency band MEG functional connectivity.
169-1	29658-29671	Resting-state	_	
169-2	29672-29677	delta	_	
169-3	29678-29687	frequency	_	
169-4	29688-29692	band	_	
169-5	29693-29696	MEG	_	
169-6	29697-29707	functional	_	
169-7	29708-29720	connectivity	_	
169-8	29720-29721	.	_	

#Text=Functional connectivity for resting-state MEG delta band.
170-1	29722-29732	Functional	_	
170-2	29733-29745	connectivity	_	
170-3	29746-29749	for	_	
170-4	29750-29763	resting-state	_	
170-5	29764-29767	MEG	_	
170-6	29768-29773	delta	_	
170-7	29774-29778	band	_	
170-8	29778-29779	.	_	

#Text=Connectivity for controls (left column), first-episode patients (middle column), and the significant difference between groups (right column) are shown.
171-1	29780-29792	Connectivity	_	
171-2	29793-29796	for	_	
171-3	29797-29805	controls	_	
171-4	29806-29807	(	_	
171-5	29807-29811	left	_	
171-6	29812-29818	column	_	
171-7	29818-29819	)	_	
171-8	29819-29820	,	_	
171-9	29821-29834	first-episode	_	
171-10	29835-29843	patients	_	
171-11	29844-29845	(	_	
171-12	29845-29851	middle	_	
171-13	29852-29858	column	_	
171-14	29858-29859	)	_	
171-15	29859-29860	,	_	
171-16	29861-29864	and	_	
171-17	29865-29868	the	_	
171-18	29869-29880	significant	_	
171-19	29881-29891	difference	_	
171-20	29892-29899	between	_	
171-21	29900-29906	groups	_	
171-22	29907-29908	(	_	
171-23	29908-29913	right	_	
171-24	29914-29920	column	_	
171-25	29920-29921	)	_	
171-26	29922-29925	are	_	
171-27	29926-29931	shown	_	
171-28	29931-29932	.	_	

#Text=FDR-corrected significant differences (pFDR < 0.05) are indicated with • and uncorrected significant differences (puncorrected < 0.05) are indicated with *.
172-1	29933-29946	FDR-corrected	_	
172-2	29947-29958	significant	_	
172-3	29959-29970	differences	_	
172-4	29971-29972	(	_	
172-5	29972-29976	pFDR	_	
172-6	29976-29977	 	_	
172-7	29977-29978	<	_	
172-8	29978-29979	 	_	
172-9	29979-29983	0.05	_	
172-10	29983-29984	)	_	
172-11	29985-29988	are	_	
172-12	29989-29998	indicated	_	
172-13	29999-30003	with	_	
172-14	30004-30005	•	_	
172-15	30006-30009	and	_	
172-16	30010-30021	uncorrected	_	
172-17	30022-30033	significant	_	
172-18	30034-30045	differences	_	
172-19	30046-30047	(	_	
172-20	30047-30059	puncorrected	_	
172-21	30059-30060	 	_	
172-22	30060-30061	<	_	
172-23	30061-30062	 	_	
172-24	30062-30066	0.05	_	
172-25	30066-30067	)	_	
172-26	30068-30071	are	_	
172-27	30072-30081	indicated	_	
172-28	30082-30086	with	_	
172-29	30087-30088	*	_	
172-30	30088-30089	.	_	

#Text=Fig. 4
#Text=MEG delta frequency band connectogram.
173-1	30090-30093	Fig	_	
173-2	30093-30094	.	_	
173-3	30095-30096	4	_	
173-4	30097-30100	MEG	_	
173-5	30101-30106	delta	_	
173-6	30107-30116	frequency	_	
173-7	30117-30121	band	_	
173-8	30122-30134	connectogram	_	
173-9	30134-30135	.	_	

#Text=MEG delta band connectogram depicting significant (pFDR < 0.05) connectivity differences between patients and controls.
174-1	30136-30139	MEG	_	
174-2	30140-30145	delta	_	
174-3	30146-30150	band	_	
174-4	30151-30163	connectogram	_	
174-5	30164-30173	depicting	_	
174-6	30174-30185	significant	_	
174-7	30186-30187	(	_	
174-8	30187-30191	pFDR	_	
174-9	30191-30192	 	_	
174-10	30192-30193	<	_	
174-11	30193-30194	 	_	
174-12	30194-30198	0.05	_	
174-13	30198-30199	)	_	
174-14	30200-30212	connectivity	_	
174-15	30213-30224	differences	_	
174-16	30225-30232	between	_	
174-17	30233-30241	patients	_	
174-18	30242-30245	and	_	
174-19	30246-30254	controls	_	
174-20	30254-30255	.	_	

#Text=Warm colors represent decreased and cool colors represent increased connectivity in patients.
175-1	30256-30260	Warm	_	
175-2	30261-30267	colors	_	
175-3	30268-30277	represent	_	
175-4	30278-30287	decreased	_	
175-5	30288-30291	and	_	
175-6	30292-30296	cool	_	
175-7	30297-30303	colors	_	
175-8	30304-30313	represent	_	
175-9	30314-30323	increased	_	
175-10	30324-30336	connectivity	_	
175-11	30337-30339	in	_	
175-12	30340-30348	patients	_	
175-13	30348-30349	.	_	

#Text=Fig. 5
#Text=Exploratory post hoc analyses did not indicate a significant relationship between patient symptom scores (e.g., BPRS, SANS, SAPS) and significant functional connectivity in the delta frequency band.
176-1	30350-30353	Fig	_	
176-2	30353-30354	.	_	
176-3	30355-30356	5	_	
176-4	30357-30368	Exploratory	_	
176-5	30369-30373	post	_	
176-6	30374-30377	hoc	_	
176-7	30378-30386	analyses	_	
176-8	30387-30390	did	_	
176-9	30391-30394	not	_	
176-10	30395-30403	indicate	_	
176-11	30404-30405	a	_	
176-12	30406-30417	significant	_	
176-13	30418-30430	relationship	_	
176-14	30431-30438	between	_	
176-15	30439-30446	patient	_	
176-16	30447-30454	symptom	_	
176-17	30455-30461	scores	_	
176-18	30462-30463	(	_	
176-19	30463-30466	e.g	_	
176-20	30466-30467	.	_	
176-21	30467-30468	,	_	
176-22	30469-30473	BPRS	_	
176-23	30473-30474	,	_	
176-24	30475-30479	SANS	_	
176-25	30479-30480	,	_	
176-26	30481-30485	SAPS	_	
176-27	30485-30486	)	_	
176-28	30487-30490	and	_	
176-29	30491-30502	significant	_	
176-30	30503-30513	functional	_	
176-31	30514-30526	connectivity	_	
176-32	30527-30529	in	_	
176-33	30530-30533	the	_	
176-34	30534-30539	delta	_	
176-35	30540-30549	frequency	_	
176-36	30550-30554	band	_	
176-37	30554-30555	.	_	

#Text=Spatial maps
#Text=Spatial maps for each modality were evaluated as a one-sample t-test of subject-specific back-reconstructed spatial maps across groups (Fig. 1).
177-1	30556-30563	Spatial	_	
177-2	30564-30568	maps	_	
177-3	30569-30576	Spatial	_	
177-4	30577-30581	maps	_	
177-5	30582-30585	for	_	
177-6	30586-30590	each	_	
177-7	30591-30599	modality	_	
177-8	30600-30604	were	_	
177-9	30605-30614	evaluated	_	
177-10	30615-30617	as	_	
177-11	30618-30619	a	_	
177-12	30620-30630	one-sample	_	
177-13	30631-30637	t-test	_	
177-14	30638-30640	of	_	
177-15	30641-30657	subject-specific	_	
177-16	30658-30676	back-reconstructed	_	
177-17	30677-30684	spatial	_	
177-18	30685-30689	maps	_	
177-19	30690-30696	across	_	
177-20	30697-30703	groups	_	
177-21	30704-30705	(	_	
177-22	30705-30708	Fig	_	
177-23	30708-30709	.	_	
177-24	30710-30711	1	_	
177-25	30711-30712	)	_	
177-26	30712-30713	.	_	

#Text=In accordance with previous studies, spatial correlation of the rsfMRI and MEG group-level (rather than subject back-reconstructed) spatial map components was evaluated.
178-1	30714-30716	In	_	
178-2	30717-30727	accordance	_	
178-3	30728-30732	with	_	
178-4	30733-30741	previous	_	
178-5	30742-30749	studies	_	
178-6	30749-30750	,	_	
178-7	30751-30758	spatial	_	
178-8	30759-30770	correlation	_	
178-9	30771-30773	of	_	
178-10	30774-30777	the	_	
178-11	30778-30784	rsfMRI	_	
178-12	30785-30788	and	_	
178-13	30789-30792	MEG	_	
178-14	30793-30804	group-level	_	
178-15	30805-30806	(	_	
178-16	30806-30812	rather	_	
178-17	30813-30817	than	_	
178-18	30818-30825	subject	_	
178-19	30826-30844	back-reconstructed	_	
178-20	30844-30845	)	_	
178-21	30846-30853	spatial	_	
178-22	30854-30857	map	_	
178-23	30858-30868	components	_	
178-24	30869-30872	was	_	
178-25	30873-30882	evaluated	_	
178-26	30882-30883	.	_	

#Text=Spatial correlations between modality components and >0.50 were exhibited in sensorimotor, visual, and default-mode networks and illustrated in Supplementary Fig. 6, Supplementary Fig. 7, Supplementary Fig. 8.
179-1	30884-30891	Spatial	_	
179-2	30892-30904	correlations	_	
179-3	30905-30912	between	_	
179-4	30913-30921	modality	_	
179-5	30922-30932	components	_	
179-6	30933-30936	and	_	
179-7	30937-30938	>	_	
179-8	30938-30942	0.50	_	
179-9	30943-30947	were	_	
179-10	30948-30957	exhibited	_	
179-11	30958-30960	in	_	
179-12	30961-30973	sensorimotor	_	
179-13	30973-30974	,	_	
179-14	30975-30981	visual	_	
179-15	30981-30982	,	_	
179-16	30983-30986	and	_	
179-17	30987-30999	default-mode	_	
179-18	31000-31008	networks	_	
179-19	31009-31012	and	_	
179-20	31013-31024	illustrated	_	
179-21	31025-31027	in	_	
179-22	31028-31041	Supplementary	_	
179-23	31042-31045	Fig	_	
179-24	31045-31046	.	_	
179-25	31047-31048	6	_	
179-26	31048-31049	,	_	
179-27	31050-31063	Supplementary	_	
179-28	31064-31067	Fig	_	
179-29	31067-31068	.	_	
179-30	31069-31070	7	_	
179-31	31070-31071	,	_	
179-32	31072-31085	Supplementary	_	
179-33	31086-31089	Fig	_	
179-34	31089-31090	.	_	
179-35	31091-31092	8	_	
179-36	31092-31093	.	_	

#Text=Discussion
#Text=To our knowledge this is the first study examining resting-state functional connectivity in first-episode patients with schizophrenia using both 7 T fMRI and MEG.
180-1	31094-31104	Discussion	_	
180-2	31105-31107	To	_	
180-3	31108-31111	our	_	
180-4	31112-31121	knowledge	_	
180-5	31122-31126	this	_	
180-6	31127-31129	is	_	
180-7	31130-31133	the	_	
180-8	31134-31139	first	_	
180-9	31140-31145	study	_	
180-10	31146-31155	examining	_	
180-11	31156-31169	resting-state	_	
180-12	31170-31180	functional	_	
180-13	31181-31193	connectivity	_	
180-14	31194-31196	in	_	
180-15	31197-31210	first-episode	_	
180-16	31211-31219	patients	_	
180-17	31220-31224	with	_	
180-18	31225-31238	schizophrenia	_	
180-19	31239-31244	using	_	
180-20	31245-31249	both	_	
180-21	31250-31251	7	_	
180-22	31251-31252	 	_	
180-23	31252-31253	T	_	
180-24	31254-31258	fMRI	_	
180-25	31259-31262	and	_	
180-26	31263-31266	MEG	_	
180-27	31266-31267	.	_	

#Text=We describe fMRI connectivity alterations in subcortical, auditory, and sensorimotor networks and MEG connectivity alterations in sensorimotor and task positive networks in patients.
181-1	31268-31270	We	_	
181-2	31271-31279	describe	_	
181-3	31280-31284	fMRI	_	
181-4	31285-31297	connectivity	_	
181-5	31298-31309	alterations	_	
181-6	31310-31312	in	_	
181-7	31313-31324	subcortical	_	
181-8	31324-31325	,	_	
181-9	31326-31334	auditory	_	
181-10	31334-31335	,	_	
181-11	31336-31339	and	_	
181-12	31340-31352	sensorimotor	_	
181-13	31353-31361	networks	_	
181-14	31362-31365	and	_	
181-15	31366-31369	MEG	_	
181-16	31370-31382	connectivity	_	
181-17	31383-31394	alterations	_	
181-18	31395-31397	in	_	
181-19	31398-31410	sensorimotor	_	
181-20	31411-31414	and	_	
181-21	31415-31419	task	_	
181-22	31420-31428	positive	_	
181-23	31429-31437	networks	_	
181-24	31438-31440	in	_	
181-25	31441-31449	patients	_	
181-26	31449-31450	.	_	

#Text=As hypothesized, group differences in MEG functional connectivity were identified in a low frequency band.
182-1	31451-31453	As	_	
182-2	31454-31466	hypothesized	_	
182-3	31466-31467	,	_	
182-4	31468-31473	group	_	
182-5	31474-31485	differences	_	
182-6	31486-31488	in	_	
182-7	31489-31492	MEG	_	
182-8	31493-31503	functional	_	
182-9	31504-31516	connectivity	_	
182-10	31517-31521	were	_	
182-11	31522-31532	identified	_	
182-12	31533-31535	in	_	
182-13	31536-31537	a	_	
182-14	31538-31541	low	_	
182-15	31542-31551	frequency	_	
182-16	31552-31556	band	_	
182-17	31556-31557	.	_	

#Text=The identified connectivity alterations are all regions implicated in the disorder of schizophrenia and lend further support to the dysconnectivity hypothesis of schizophrenia.
183-1	31558-31561	The	_	
183-2	31562-31572	identified	_	
183-3	31573-31585	connectivity	_	
183-4	31586-31597	alterations	_	
183-5	31598-31601	are	_	
183-6	31602-31605	all	_	
183-7	31606-31613	regions	_	
183-8	31614-31624	implicated	_	
183-9	31625-31627	in	_	
183-10	31628-31631	the	_	
183-11	31632-31640	disorder	_	
183-12	31641-31643	of	_	
183-13	31644-31657	schizophrenia	_	
183-14	31658-31661	and	_	
183-15	31662-31666	lend	_	
183-16	31667-31674	further	_	
183-17	31675-31682	support	_	
183-18	31683-31685	to	_	
183-19	31686-31689	the	_	
183-20	31690-31705	dysconnectivity	_	
183-21	31706-31716	hypothesis	_	
183-22	31717-31719	of	_	
183-23	31720-31733	schizophrenia	_	
183-24	31733-31734	.	_	

#Text=Functional connectivity analysis of fMRI identified hyperconnectivity between the subcortical network (i.e., caudate) and auditory network (i.e., superior temporal gyrus) in first-episode patients (Fig. 2).
184-1	31735-31745	Functional	_	
184-2	31746-31758	connectivity	_	
184-3	31759-31767	analysis	_	
184-4	31768-31770	of	_	
184-5	31771-31775	fMRI	_	
184-6	31776-31786	identified	_	
184-7	31787-31804	hyperconnectivity	_	
184-8	31805-31812	between	_	
184-9	31813-31816	the	_	
184-10	31817-31828	subcortical	_	
184-11	31829-31836	network	_	
184-12	31837-31838	(	_	
184-13	31838-31841	i.e	_	
184-14	31841-31842	.	_	
184-15	31842-31843	,	_	
184-16	31844-31851	caudate	_	
184-17	31851-31852	)	_	
184-18	31853-31856	and	_	
184-19	31857-31865	auditory	_	
184-20	31866-31873	network	_	
184-21	31874-31875	(	_	
184-22	31875-31878	i.e	_	
184-23	31878-31879	.	_	
184-24	31879-31880	,	_	
184-25	31881-31889	superior	_	
184-26	31890-31898	temporal	_	
184-27	31899-31904	gyrus	_	
184-28	31904-31905	)	_	
184-29	31906-31908	in	_	
184-30	31909-31922	first-episode	_	
184-31	31923-31931	patients	_	
184-32	31932-31933	(	_	
184-33	31933-31936	Fig	_	
184-34	31936-31937	.	_	
184-35	31938-31939	2	_	
184-36	31939-31940	)	_	
184-37	31940-31941	.	_	

#Text=Exploratory post hoc exploration of this subcortical-auditory relationship indicates a significantly positive correlation (r = 0.59; p = .01) between connectivity strength and BPRS positive scores in patients (Fig. 4B).
185-1	31942-31953	Exploratory	_	
185-2	31954-31958	post	_	
185-3	31959-31962	hoc	_	
185-4	31963-31974	exploration	_	
185-5	31975-31977	of	_	
185-6	31978-31982	this	_	
185-7	31983-32003	subcortical-auditory	_	
185-8	32004-32016	relationship	_	
185-9	32017-32026	indicates	_	
185-10	32027-32028	a	_	
185-11	32029-32042	significantly	_	
185-12	32043-32051	positive	_	
185-13	32052-32063	correlation	_	
185-14	32064-32065	(	_	
185-15	32065-32066	r	_	
185-16	32066-32067	 	_	
185-17	32067-32068	=	_	
185-18	32068-32069	 	_	
185-19	32069-32073	0.59	_	
185-20	32073-32074	;	_	
185-21	32075-32076	p	_	
185-22	32076-32077	 	_	
185-23	32077-32078	=	_	
185-24	32078-32079	 	_	
185-25	32079-32082	.01	_	
185-26	32082-32083	)	_	
185-27	32084-32091	between	_	
185-28	32092-32104	connectivity	_	
185-29	32105-32113	strength	_	
185-30	32114-32117	and	_	
185-31	32118-32122	BPRS	_	
185-32	32123-32131	positive	_	
185-33	32132-32138	scores	_	
185-34	32139-32141	in	_	
185-35	32142-32150	patients	_	
185-36	32151-32152	(	_	
185-37	32152-32155	Fig	_	
185-38	32155-32156	.	_	
185-39	32157-32159	4B	_	
185-40	32159-32160	)	_	
185-41	32160-32161	.	_	

#Text=These findings may be indicative of the link both regions have been shown to exhibit with positive symptoms (e.g., hallucinations) in schizophrenia.
186-1	32162-32167	These	_	
186-2	32168-32176	findings	_	
186-3	32177-32180	may	_	
186-4	32181-32183	be	_	
186-5	32184-32194	indicative	_	
186-6	32195-32197	of	_	
186-7	32198-32201	the	_	
186-8	32202-32206	link	_	
186-9	32207-32211	both	_	
186-10	32212-32219	regions	_	
186-11	32220-32224	have	_	
186-12	32225-32229	been	_	
186-13	32230-32235	shown	_	
186-14	32236-32238	to	_	
186-15	32239-32246	exhibit	_	
186-16	32247-32251	with	_	
186-17	32252-32260	positive	_	
186-18	32261-32269	symptoms	_	
186-19	32270-32271	(	_	
186-20	32271-32274	e.g	_	
186-21	32274-32275	.	_	
186-22	32275-32276	,	_	
186-23	32277-32291	hallucinations	_	
186-24	32291-32292	)	_	
186-25	32293-32295	in	_	
186-26	32296-32309	schizophrenia	_	
186-27	32309-32310	.	_	

#Text=A relationship between hallucinations and structural and functional alterations in the superior temporal gyrus has been reported in a number of studies.
187-1	32311-32312	A	_	
187-2	32313-32325	relationship	_	
187-3	32326-32333	between	_	
187-4	32334-32348	hallucinations	_	
187-5	32349-32352	and	_	
187-6	32353-32363	structural	_	
187-7	32364-32367	and	_	
187-8	32368-32378	functional	_	
187-9	32379-32390	alterations	_	
187-10	32391-32393	in	_	
187-11	32394-32397	the	_	
187-12	32398-32406	superior	_	
187-13	32407-32415	temporal	_	
187-14	32416-32421	gyrus	_	
187-15	32422-32425	has	_	
187-16	32426-32430	been	_	
187-17	32431-32439	reported	_	
187-18	32440-32442	in	_	
187-19	32443-32444	a	_	
187-20	32445-32451	number	_	
187-21	32452-32454	of	_	
187-22	32455-32462	studies	_	
187-23	32462-32463	.	_	

#Text=In addition, these results are also indicative of the importance of the caudate in schizophrenia and its role in treatment response as it is highly innervated by dopaminergic neurons.
188-1	32464-32466	In	_	
188-2	32467-32475	addition	_	
188-3	32475-32476	,	_	
188-4	32477-32482	these	_	
188-5	32483-32490	results	_	
188-6	32491-32494	are	_	
188-7	32495-32499	also	_	
188-8	32500-32510	indicative	_	
188-9	32511-32513	of	_	
188-10	32514-32517	the	_	
188-11	32518-32528	importance	_	
188-12	32529-32531	of	_	
188-13	32532-32535	the	_	
188-14	32536-32543	caudate	_	
188-15	32544-32546	in	_	
188-16	32547-32560	schizophrenia	_	
188-17	32561-32564	and	_	
188-18	32565-32568	its	_	
188-19	32569-32573	role	_	
188-20	32574-32576	in	_	
188-21	32577-32586	treatment	_	
188-22	32587-32595	response	_	
188-23	32596-32598	as	_	
188-24	32599-32601	it	_	
188-25	32602-32604	is	_	
188-26	32605-32611	highly	_	
188-27	32612-32622	innervated	_	
188-28	32623-32625	by	_	
188-29	32626-32638	dopaminergic	_	
188-30	32639-32646	neurons	_	
188-31	32646-32647	.	_	

#Text=Future studies examining unmedicated first-episode patients would provide greater insight into the relationship between the caudate, temporal lobe, and positive symptoms.
189-1	32648-32654	Future	_	
189-2	32655-32662	studies	_	
189-3	32663-32672	examining	_	
189-4	32673-32684	unmedicated	_	
189-5	32685-32698	first-episode	_	
189-6	32699-32707	patients	_	
189-7	32708-32713	would	_	
189-8	32714-32721	provide	_	
189-9	32722-32729	greater	_	
189-10	32730-32737	insight	_	
189-11	32738-32742	into	_	
189-12	32743-32746	the	_	
189-13	32747-32759	relationship	_	
189-14	32760-32767	between	_	
189-15	32768-32771	the	_	
189-16	32772-32779	caudate	_	
189-17	32779-32780	,	_	
189-18	32781-32789	temporal	_	
189-19	32790-32794	lobe	_	
189-20	32794-32795	,	_	
189-21	32796-32799	and	_	
189-22	32800-32808	positive	_	
189-23	32809-32817	symptoms	_	
189-24	32817-32818	.	_	

#Text=Decreased fMRI functional connectivity between two sensorimotor network components was also demonstrated in patients (Fig. 2).
190-1	32819-32828	Decreased	_	
190-2	32829-32833	fMRI	_	
190-3	32834-32844	functional	_	
190-4	32845-32857	connectivity	_	
190-5	32858-32865	between	_	
190-6	32866-32869	two	_	
190-7	32870-32882	sensorimotor	_	
190-8	32883-32890	network	_	
190-9	32891-32901	components	_	
190-10	32902-32905	was	_	
190-11	32906-32910	also	_	
190-12	32911-32923	demonstrated	_	
190-13	32924-32926	in	_	
190-14	32927-32935	patients	_	
190-15	32936-32937	(	_	
190-16	32937-32940	Fig	_	
190-17	32940-32941	.	_	
190-18	32942-32943	2	_	
190-19	32943-32944	)	_	
190-20	32944-32945	.	_	

#Text=Specifically, this hypoconnectivity demonstrated in patients is exhibited between the sensorimotor network components comprised of the right precentral gyrus (IC 1) and left postcentral gyrus (IC2).
191-1	32946-32958	Specifically	_	
191-2	32958-32959	,	_	
191-3	32960-32964	this	_	
191-4	32965-32981	hypoconnectivity	_	
191-5	32982-32994	demonstrated	_	
191-6	32995-32997	in	_	
191-7	32998-33006	patients	_	
191-8	33007-33009	is	_	
191-9	33010-33019	exhibited	_	
191-10	33020-33027	between	_	
191-11	33028-33031	the	_	
191-12	33032-33044	sensorimotor	_	
191-13	33045-33052	network	_	
191-14	33053-33063	components	_	
191-15	33064-33073	comprised	_	
191-16	33074-33076	of	_	
191-17	33077-33080	the	_	
191-18	33081-33086	right	_	
191-19	33087-33097	precentral	_	
191-20	33098-33103	gyrus	_	
191-21	33104-33105	(	_	
191-22	33105-33107	IC	_	
191-23	33108-33109	1	_	
191-24	33109-33110	)	_	
191-25	33111-33114	and	_	
191-26	33115-33119	left	_	
191-27	33120-33131	postcentral	_	
191-28	33132-33137	gyrus	_	
191-29	33138-33139	(	_	
191-30	33139-33142	IC2	_	
191-31	33142-33143	)	_	
191-32	33143-33144	.	_	

#Text=Further examination of these sensorimotor components reveals they share interhemispheric homotopic or bilaterally symmetric regions as both IC1 and IC2 comprise regions of the precentral and postcentral gyrus.
192-1	33145-33152	Further	_	
192-2	33153-33164	examination	_	
192-3	33165-33167	of	_	
192-4	33168-33173	these	_	
192-5	33174-33186	sensorimotor	_	
192-6	33187-33197	components	_	
192-7	33198-33205	reveals	_	
192-8	33206-33210	they	_	
192-9	33211-33216	share	_	
192-10	33217-33233	interhemispheric	_	
192-11	33234-33243	homotopic	_	
192-12	33244-33246	or	_	
192-13	33247-33258	bilaterally	_	
192-14	33259-33268	symmetric	_	
192-15	33269-33276	regions	_	
192-16	33277-33279	as	_	
192-17	33280-33284	both	_	
192-18	33285-33288	IC1	_	
192-19	33289-33292	and	_	
192-20	33293-33296	IC2	_	
192-21	33297-33305	comprise	_	
192-22	33306-33313	regions	_	
192-23	33314-33316	of	_	
192-24	33317-33320	the	_	
192-25	33321-33331	precentral	_	
192-26	33332-33335	and	_	
192-27	33336-33347	postcentral	_	
192-28	33348-33353	gyrus	_	
192-29	33353-33354	.	_	

#Text=This altered sensorimotor connectivity is consistent with previous studies demonstrating decreased interhemispheric homotopic connectivity in first-episode patients with schizophrenia.
193-1	33355-33359	This	_	
193-2	33360-33367	altered	_	
193-3	33368-33380	sensorimotor	_	
193-4	33381-33393	connectivity	_	
193-5	33394-33396	is	_	
193-6	33397-33407	consistent	_	
193-7	33408-33412	with	_	
193-8	33413-33421	previous	_	
193-9	33422-33429	studies	_	
193-10	33430-33443	demonstrating	_	
193-11	33444-33453	decreased	_	
193-12	33454-33470	interhemispheric	_	
193-13	33471-33480	homotopic	_	
193-14	33481-33493	connectivity	_	
193-15	33494-33496	in	_	
193-16	33497-33510	first-episode	_	
193-17	33511-33519	patients	_	
193-18	33520-33524	with	_	
193-19	33525-33538	schizophrenia	_	
193-20	33538-33539	.	_	

#Text=Decreased connectivity between homotopic motor regions are thought to be related to cognitive dysfunction associated with motor function in schizophrenia.
194-1	33540-33549	Decreased	_	
194-2	33550-33562	connectivity	_	
194-3	33563-33570	between	_	
194-4	33571-33580	homotopic	_	
194-5	33581-33586	motor	_	
194-6	33587-33594	regions	_	
194-7	33595-33598	are	_	
194-8	33599-33606	thought	_	
194-9	33607-33609	to	_	
194-10	33610-33612	be	_	
194-11	33613-33620	related	_	
194-12	33621-33623	to	_	
194-13	33624-33633	cognitive	_	
194-14	33634-33645	dysfunction	_	
194-15	33646-33656	associated	_	
194-16	33657-33661	with	_	
194-17	33662-33667	motor	_	
194-18	33668-33676	function	_	
194-19	33677-33679	in	_	
194-20	33680-33693	schizophrenia	_	
194-21	33693-33694	.	_	

#Text=Moreover, decreased interhemispheric connectivity in the precentral gyrus has also been shown to be negatively related to positive and negative symptomatology.
195-1	33695-33703	Moreover	_	
195-2	33703-33704	,	_	
195-3	33705-33714	decreased	_	
195-4	33715-33731	interhemispheric	_	
195-5	33732-33744	connectivity	_	
195-6	33745-33747	in	_	
195-7	33748-33751	the	_	
195-8	33752-33762	precentral	_	
195-9	33763-33768	gyrus	_	
195-10	33769-33772	has	_	
195-11	33773-33777	also	_	
195-12	33778-33782	been	_	
195-13	33783-33788	shown	_	
195-14	33789-33791	to	_	
195-15	33792-33794	be	_	
195-16	33795-33805	negatively	_	
195-17	33806-33813	related	_	
195-18	33814-33816	to	_	
195-19	33817-33825	positive	_	
195-20	33826-33829	and	_	
195-21	33830-33838	negative	_	
195-22	33839-33853	symptomatology	_	
195-23	33853-33854	.	_	

#Text=Group differences in the MEG delta band indicated hypoconnectivity between sensorimotor and task positive network connections among patients.
196-1	33855-33860	Group	_	
196-2	33861-33872	differences	_	
196-3	33873-33875	in	_	
196-4	33876-33879	the	_	
196-5	33880-33883	MEG	_	
196-6	33884-33889	delta	_	
196-7	33890-33894	band	_	
196-8	33895-33904	indicated	_	
196-9	33905-33921	hypoconnectivity	_	
196-10	33922-33929	between	_	
196-11	33930-33942	sensorimotor	_	
196-12	33943-33946	and	_	
196-13	33947-33951	task	_	
196-14	33952-33960	positive	_	
196-15	33961-33968	network	_	
196-16	33969-33980	connections	_	
196-17	33981-33986	among	_	
196-18	33987-33995	patients	_	
196-19	33995-33996	.	_	

#Text=Specifically, the precuneus (IC 5) and superior parietal lobule (IC 25) connections with the insula (IC34) are altered in the delta frequency band in patients.
197-1	33997-34009	Specifically	_	
197-2	34009-34010	,	_	
197-3	34011-34014	the	_	
197-4	34015-34024	precuneus	_	
197-5	34025-34026	(	_	
197-6	34026-34028	IC	_	
197-7	34029-34030	5	_	
197-8	34030-34031	)	_	
197-9	34032-34035	and	_	
197-10	34036-34044	superior	_	
197-11	34045-34053	parietal	_	
197-12	34054-34060	lobule	_	
197-13	34061-34062	(	_	
197-14	34062-34064	IC	_	
197-15	34065-34067	25	_	
197-16	34067-34068	)	_	
197-17	34069-34080	connections	_	
197-18	34081-34085	with	_	
197-19	34086-34089	the	_	
197-20	34090-34096	insula	_	
197-21	34097-34098	(	_	
197-22	34098-34102	IC34	_	
197-23	34102-34103	)	_	
197-24	34104-34107	are	_	
197-25	34108-34115	altered	_	
197-26	34116-34118	in	_	
197-27	34119-34122	the	_	
197-28	34123-34128	delta	_	
197-29	34129-34138	frequency	_	
197-30	34139-34143	band	_	
197-31	34144-34146	in	_	
197-32	34147-34155	patients	_	
197-33	34155-34156	.	_	

#Text=Alterations in low frequency neural oscillations at rest have been implicated in previous studies in schizophrenia.
198-1	34157-34168	Alterations	_	
198-2	34169-34171	in	_	
198-3	34172-34175	low	_	
198-4	34176-34185	frequency	_	
198-5	34186-34192	neural	_	
198-6	34193-34205	oscillations	_	
198-7	34206-34208	at	_	
198-8	34209-34213	rest	_	
198-9	34214-34218	have	_	
198-10	34219-34223	been	_	
198-11	34224-34234	implicated	_	
198-12	34235-34237	in	_	
198-13	34238-34246	previous	_	
198-14	34247-34254	studies	_	
198-15	34255-34257	in	_	
198-16	34258-34271	schizophrenia	_	
198-17	34271-34272	.	_	

#Text=Supporting our results, previous studies have demonstrated altered delta band activity in frontal, temporal and parietal areas in schizophrenia.
199-1	34273-34283	Supporting	_	
199-2	34284-34287	our	_	
199-3	34288-34295	results	_	
199-4	34295-34296	,	_	
199-5	34297-34305	previous	_	
199-6	34306-34313	studies	_	
199-7	34314-34318	have	_	
199-8	34319-34331	demonstrated	_	
199-9	34332-34339	altered	_	
199-10	34340-34345	delta	_	
199-11	34346-34350	band	_	
199-12	34351-34359	activity	_	
199-13	34360-34362	in	_	
199-14	34363-34370	frontal	_	
199-15	34370-34371	,	_	
199-16	34372-34380	temporal	_	
199-17	34381-34384	and	_	
199-18	34385-34393	parietal	_	
199-19	34394-34399	areas	_	
199-20	34400-34402	in	_	
199-21	34403-34416	schizophrenia	_	
199-22	34416-34417	.	_	

#Text=In addition, our results are consistent with the literature indicating slow oscillations are more prone to travel longer distances and connect relatively distant regions of the brain.
200-1	34418-34420	In	_	
200-2	34421-34429	addition	_	
200-3	34429-34430	,	_	
200-4	34431-34434	our	_	
200-5	34435-34442	results	_	
200-6	34443-34446	are	_	
200-7	34447-34457	consistent	_	
200-8	34458-34462	with	_	
200-9	34463-34466	the	_	
200-10	34467-34477	literature	_	
200-11	34478-34488	indicating	_	
200-12	34489-34493	slow	_	
200-13	34494-34506	oscillations	_	
200-14	34507-34510	are	_	
200-15	34511-34515	more	_	
200-16	34516-34521	prone	_	
200-17	34522-34524	to	_	
200-18	34525-34531	travel	_	
200-19	34532-34538	longer	_	
200-20	34539-34548	distances	_	
200-21	34549-34552	and	_	
200-22	34553-34560	connect	_	
200-23	34561-34571	relatively	_	
200-24	34572-34579	distant	_	
200-25	34580-34587	regions	_	
200-26	34588-34590	of	_	
200-27	34591-34594	the	_	
200-28	34595-34600	brain	_	
200-29	34600-34601	.	_	

#Text=In fact, previous studies have suggested functional connectivity is affected by anatomical distance in schizophrenia.
201-1	34602-34604	In	_	
201-2	34605-34609	fact	_	
201-3	34609-34610	,	_	
201-4	34611-34619	previous	_	
201-5	34620-34627	studies	_	
201-6	34628-34632	have	_	
201-7	34633-34642	suggested	_	
201-8	34643-34653	functional	_	
201-9	34654-34666	connectivity	_	
201-10	34667-34669	is	_	
201-11	34670-34678	affected	_	
201-12	34679-34681	by	_	
201-13	34682-34692	anatomical	_	
201-14	34693-34701	distance	_	
201-15	34702-34704	in	_	
201-16	34705-34718	schizophrenia	_	
201-17	34718-34719	.	_	

#Text=Accordingly, our results indicate long range functional connections between the task positive and parietal sensorimotor networks are altered in schizophrenia.
202-1	34720-34731	Accordingly	_	
202-2	34731-34732	,	_	
202-3	34733-34736	our	_	
202-4	34737-34744	results	_	
202-5	34745-34753	indicate	_	
202-6	34754-34758	long	_	
202-7	34759-34764	range	_	
202-8	34765-34775	functional	_	
202-9	34776-34787	connections	_	
202-10	34788-34795	between	_	
202-11	34796-34799	the	_	
202-12	34800-34804	task	_	
202-13	34805-34813	positive	_	
202-14	34814-34817	and	_	
202-15	34818-34826	parietal	_	
202-16	34827-34839	sensorimotor	_	
202-17	34840-34848	networks	_	
202-18	34849-34852	are	_	
202-19	34853-34860	altered	_	
202-20	34861-34863	in	_	
202-21	34864-34877	schizophrenia	_	
202-22	34877-34878	.	_	

#Text=These results may be reflective of positive symptoms due to faulty sensory information processing characteristic of schizophrenia.
203-1	34879-34884	These	_	
203-2	34885-34892	results	_	
203-3	34893-34896	may	_	
203-4	34897-34899	be	_	
203-5	34900-34910	reflective	_	
203-6	34911-34913	of	_	
203-7	34914-34922	positive	_	
203-8	34923-34931	symptoms	_	
203-9	34932-34935	due	_	
203-10	34936-34938	to	_	
203-11	34939-34945	faulty	_	
203-12	34946-34953	sensory	_	
203-13	34954-34965	information	_	
203-14	34966-34976	processing	_	
203-15	34977-34991	characteristic	_	
203-16	34992-34994	of	_	
203-17	34995-35008	schizophrenia	_	
203-18	35008-35009	.	_	

#Text=Visual inspection of the patterns of group differences (puncorrected < 0.05) indicate patients tend to exhibit instances of hypoconnectivity across all networks with the exception of hyperconnectivity across subcortical network connections.
204-1	35010-35016	Visual	_	
204-2	35017-35027	inspection	_	
204-3	35028-35030	of	_	
204-4	35031-35034	the	_	
204-5	35035-35043	patterns	_	
204-6	35044-35046	of	_	
204-7	35047-35052	group	_	
204-8	35053-35064	differences	_	
204-9	35065-35066	(	_	
204-10	35066-35078	puncorrected	_	
204-11	35078-35079	 	_	
204-12	35079-35080	<	_	
204-13	35080-35081	 	_	
204-14	35081-35085	0.05	_	
204-15	35085-35086	)	_	
204-16	35087-35095	indicate	_	
204-17	35096-35104	patients	_	
204-18	35105-35109	tend	_	
204-19	35110-35112	to	_	
204-20	35113-35120	exhibit	_	
204-21	35121-35130	instances	_	
204-22	35131-35133	of	_	
204-23	35134-35150	hypoconnectivity	_	
204-24	35151-35157	across	_	
204-25	35158-35161	all	_	
204-26	35162-35170	networks	_	
204-27	35171-35175	with	_	
204-28	35176-35179	the	_	
204-29	35180-35189	exception	_	
204-30	35190-35192	of	_	
204-31	35193-35210	hyperconnectivity	_	
204-32	35211-35217	across	_	
204-33	35218-35229	subcortical	_	
204-34	35230-35237	network	_	
204-35	35238-35249	connections	_	
204-36	35249-35250	.	_	

#Text=However, patients generally demonstrated instances of hypoconnectivity within and between sensorimotor network connections in MEG in the overall mean and individual frequency bands.
205-1	35251-35258	However	_	
205-2	35258-35259	,	_	
205-3	35260-35268	patients	_	
205-4	35269-35278	generally	_	
205-5	35279-35291	demonstrated	_	
205-6	35292-35301	instances	_	
205-7	35302-35304	of	_	
205-8	35305-35321	hypoconnectivity	_	
205-9	35322-35328	within	_	
205-10	35329-35332	and	_	
205-11	35333-35340	between	_	
205-12	35341-35353	sensorimotor	_	
205-13	35354-35361	network	_	
205-14	35362-35373	connections	_	
205-15	35374-35376	in	_	
205-16	35377-35380	MEG	_	
205-17	35381-35383	in	_	
205-18	35384-35387	the	_	
205-19	35388-35395	overall	_	
205-20	35396-35400	mean	_	
205-21	35401-35404	and	_	
205-22	35405-35415	individual	_	
205-23	35416-35425	frequency	_	
205-24	35426-35431	bands	_	
205-25	35431-35432	.	_	

#Text=Although future studies would be necessary to determine if these differences survive multiple comparison correction in a larger sample size, altered sensorimotor connectivity has been reported in schizophrenia.
206-1	35433-35441	Although	_	
206-2	35442-35448	future	_	
206-3	35449-35456	studies	_	
206-4	35457-35462	would	_	
206-5	35463-35465	be	_	
206-6	35466-35475	necessary	_	
206-7	35476-35478	to	_	
206-8	35479-35488	determine	_	
206-9	35489-35491	if	_	
206-10	35492-35497	these	_	
206-11	35498-35509	differences	_	
206-12	35510-35517	survive	_	
206-13	35518-35526	multiple	_	
206-14	35527-35537	comparison	_	
206-15	35538-35548	correction	_	
206-16	35549-35551	in	_	
206-17	35552-35553	a	_	
206-18	35554-35560	larger	_	
206-19	35561-35567	sample	_	
206-20	35568-35572	size	_	
206-21	35572-35573	,	_	
206-22	35574-35581	altered	_	
206-23	35582-35594	sensorimotor	_	
206-24	35595-35607	connectivity	_	
206-25	35608-35611	has	_	
206-26	35612-35616	been	_	
206-27	35617-35625	reported	_	
206-28	35626-35628	in	_	
206-29	35629-35642	schizophrenia	_	
206-30	35642-35643	.	_	

#Text=Our results using group independent component analysis as well as functional connectivity measures of both resting-state fMRI and MEG indicate the importance of using these complementary imaging modalities to capture a more comprehensive picture of disorder-related abnormalities.
207-1	35644-35647	Our	_	
207-2	35648-35655	results	_	
207-3	35656-35661	using	_	
207-4	35662-35667	group	_	
207-5	35668-35679	independent	_	
207-6	35680-35689	component	_	
207-7	35690-35698	analysis	_	
207-8	35699-35701	as	_	
207-9	35702-35706	well	_	
207-10	35707-35709	as	_	
207-11	35710-35720	functional	_	
207-12	35721-35733	connectivity	_	
207-13	35734-35742	measures	_	
207-14	35743-35745	of	_	
207-15	35746-35750	both	_	
207-16	35751-35764	resting-state	_	
207-17	35765-35769	fMRI	_	
207-18	35770-35773	and	_	
207-19	35774-35777	MEG	_	
207-20	35778-35786	indicate	_	
207-21	35787-35790	the	_	
207-22	35791-35801	importance	_	
207-23	35802-35804	of	_	
207-24	35805-35810	using	_	
207-25	35811-35816	these	_	
207-26	35817-35830	complementary	_	
207-27	35831-35838	imaging	_	
207-28	35839-35849	modalities	_	
207-29	35850-35852	to	_	
207-30	35853-35860	capture	_	
207-31	35861-35862	a	_	
207-32	35863-35867	more	_	
207-33	35868-35881	comprehensive	_	
207-34	35882-35889	picture	_	
207-35	35890-35892	of	_	
207-36	35893-35909	disorder-related	_	
207-37	35910-35923	abnormalities	_	
207-38	35923-35924	.	_	

#Text=In particular, using both fMRI and MEG allows us to investigate both spatial and temporal characteristics of resting-state network functional connectivity that would have been missed by examining a single modality alone.
208-1	35925-35927	In	_	
208-2	35928-35938	particular	_	
208-3	35938-35939	,	_	
208-4	35940-35945	using	_	
208-5	35946-35950	both	_	
208-6	35951-35955	fMRI	_	
208-7	35956-35959	and	_	
208-8	35960-35963	MEG	_	
208-9	35964-35970	allows	_	
208-10	35971-35973	us	_	
208-11	35974-35976	to	_	
208-12	35977-35988	investigate	_	
208-13	35989-35993	both	_	
208-14	35994-36001	spatial	_	
208-15	36002-36005	and	_	
208-16	36006-36014	temporal	_	
208-17	36015-36030	characteristics	_	
208-18	36031-36033	of	_	
208-19	36034-36047	resting-state	_	
208-20	36048-36055	network	_	
208-21	36056-36066	functional	_	
208-22	36067-36079	connectivity	_	
208-23	36080-36084	that	_	
208-24	36085-36090	would	_	
208-25	36091-36095	have	_	
208-26	36096-36100	been	_	
208-27	36101-36107	missed	_	
208-28	36108-36110	by	_	
208-29	36111-36120	examining	_	
208-30	36121-36122	a	_	
208-31	36123-36129	single	_	
208-32	36130-36138	modality	_	
208-33	36139-36144	alone	_	
208-34	36144-36145	.	_	

#Text=In fact, a previous study of chronic schizophrenia patients indicated that the combination of fMRI and MEG functional connectivity data more accurately classifies patients than either modality alone.
209-1	36146-36148	In	_	
209-2	36149-36153	fact	_	
209-3	36153-36154	,	_	
209-4	36155-36156	a	_	
209-5	36157-36165	previous	_	
209-6	36166-36171	study	_	
209-7	36172-36174	of	_	
209-8	36175-36182	chronic	_	
209-9	36183-36196	schizophrenia	_	
209-10	36197-36205	patients	_	
209-11	36206-36215	indicated	_	
209-12	36216-36220	that	_	
209-13	36221-36224	the	_	
209-14	36225-36236	combination	_	
209-15	36237-36239	of	_	
209-16	36240-36244	fMRI	_	
209-17	36245-36248	and	_	
209-18	36249-36252	MEG	_	
209-19	36253-36263	functional	_	
209-20	36264-36276	connectivity	_	
209-21	36277-36281	data	_	
209-22	36282-36286	more	_	
209-23	36287-36297	accurately	_	
209-24	36298-36308	classifies	_	
209-25	36309-36317	patients	_	
209-26	36318-36322	than	_	
209-27	36323-36329	either	_	
209-28	36330-36338	modality	_	
209-29	36339-36344	alone	_	
209-30	36344-36345	.	_	

#Text=Furthermore, both modalities provide common and unique findings characterizing schizophrenia.
210-1	36346-36357	Furthermore	_	
210-2	36357-36358	,	_	
210-3	36359-36363	both	_	
210-4	36364-36374	modalities	_	
210-5	36375-36382	provide	_	
210-6	36383-36389	common	_	
210-7	36390-36393	and	_	
210-8	36394-36400	unique	_	
210-9	36401-36409	findings	_	
210-10	36410-36424	characterizing	_	
210-11	36425-36438	schizophrenia	_	
210-12	36438-36439	.	_	

#Text=As illustrated in Supplementary Fig. 6, Supplementary Fig. 7, Supplementary Fig. 8, similar and spatially overlapping RSNs were generated from separate group independent component analyses of fMRI and MEG further confirming the electrophysiological underpinnings of BOLD fMRI.
211-1	36440-36442	As	_	
211-2	36443-36454	illustrated	_	
211-3	36455-36457	in	_	
211-4	36458-36471	Supplementary	_	
211-5	36472-36475	Fig	_	
211-6	36475-36476	.	_	
211-7	36477-36478	6	_	
211-8	36478-36479	,	_	
211-9	36480-36493	Supplementary	_	
211-10	36494-36497	Fig	_	
211-11	36497-36498	.	_	
211-12	36499-36500	7	_	
211-13	36500-36501	,	_	
211-14	36502-36515	Supplementary	_	
211-15	36516-36519	Fig	_	
211-16	36519-36520	.	_	
211-17	36521-36522	8	_	
211-18	36522-36523	,	_	
211-19	36524-36531	similar	_	
211-20	36532-36535	and	_	
211-21	36536-36545	spatially	_	
211-22	36546-36557	overlapping	_	
211-23	36558-36562	RSNs	_	
211-24	36563-36567	were	_	
211-25	36568-36577	generated	_	
211-26	36578-36582	from	_	
211-27	36583-36591	separate	_	
211-28	36592-36597	group	_	
211-29	36598-36609	independent	_	
211-30	36610-36619	component	_	
211-31	36620-36628	analyses	_	
211-32	36629-36631	of	_	
211-33	36632-36636	fMRI	_	
211-34	36637-36640	and	_	
211-35	36641-36644	MEG	_	
211-36	36645-36652	further	_	
211-37	36653-36663	confirming	_	
211-38	36664-36667	the	_	
211-39	36668-36688	electrophysiological	_	
211-40	36689-36702	underpinnings	_	
211-41	36703-36705	of	_	
211-42	36706-36710	BOLD	_	
211-43	36711-36715	fMRI	_	
211-44	36715-36716	.	_	

#Text=While functional connectivity of fMRI and MEG both indicated connectivity alterations involving the sensorimotor networks (although the spatial overlap between fMRI and MEG sensorimotor networks alterations is not clear), unique findings of subcortical-auditory and delta band sensorimotor-task positive connectivity were exhibited in fMRI and MEG, respectively.
212-1	36717-36722	While	_	
212-2	36723-36733	functional	_	
212-3	36734-36746	connectivity	_	
212-4	36747-36749	of	_	
212-5	36750-36754	fMRI	_	
212-6	36755-36758	and	_	
212-7	36759-36762	MEG	_	
212-8	36763-36767	both	_	
212-9	36768-36777	indicated	_	
212-10	36778-36790	connectivity	_	
212-11	36791-36802	alterations	_	
212-12	36803-36812	involving	_	
212-13	36813-36816	the	_	
212-14	36817-36829	sensorimotor	_	
212-15	36830-36838	networks	_	
212-16	36839-36840	(	_	
212-17	36840-36848	although	_	
212-18	36849-36852	the	_	
212-19	36853-36860	spatial	_	
212-20	36861-36868	overlap	_	
212-21	36869-36876	between	_	
212-22	36877-36881	fMRI	_	
212-23	36882-36885	and	_	
212-24	36886-36889	MEG	_	
212-25	36890-36902	sensorimotor	_	
212-26	36903-36911	networks	_	
212-27	36912-36923	alterations	_	
212-28	36924-36926	is	_	
212-29	36927-36930	not	_	
212-30	36931-36936	clear	_	
212-31	36936-36937	)	_	
212-32	36937-36938	,	_	
212-33	36939-36945	unique	_	
212-34	36946-36954	findings	_	
212-35	36955-36957	of	_	
212-36	36958-36978	subcortical-auditory	_	
212-37	36979-36982	and	_	
212-38	36983-36988	delta	_	
212-39	36989-36993	band	_	
212-40	36994-37011	sensorimotor-task	_	
212-41	37012-37020	positive	_	
212-42	37021-37033	connectivity	_	
212-43	37034-37038	were	_	
212-44	37039-37048	exhibited	_	
212-45	37049-37051	in	_	
212-46	37052-37056	fMRI	_	
212-47	37057-37060	and	_	
212-48	37061-37064	MEG	_	
212-49	37064-37065	,	_	
212-50	37066-37078	respectively	_	
212-51	37078-37079	.	_	

#Text=When interpreting our findings, several strengths and limitations should be considered.
213-1	37080-37084	When	_	
213-2	37085-37097	interpreting	_	
213-3	37098-37101	our	_	
213-4	37102-37110	findings	_	
213-5	37110-37111	,	_	
213-6	37112-37119	several	_	
213-7	37120-37129	strengths	_	
213-8	37130-37133	and	_	
213-9	37134-37145	limitations	_	
213-10	37146-37152	should	_	
213-11	37153-37155	be	_	
213-12	37156-37166	considered	_	
213-13	37166-37167	.	_	

#Text=To minimize variance in the data, subjects were matched on factors including age, gender, parental SES, and smoking status.
214-1	37168-37170	To	_	
214-2	37171-37179	minimize	_	
214-3	37180-37188	variance	_	
214-4	37189-37191	in	_	
214-5	37192-37195	the	_	
214-6	37196-37200	data	_	
214-7	37200-37201	,	_	
214-8	37202-37210	subjects	_	
214-9	37211-37215	were	_	
214-10	37216-37223	matched	_	
214-11	37224-37226	on	_	
214-12	37227-37234	factors	_	
214-13	37235-37244	including	_	
214-14	37245-37248	age	_	
214-15	37248-37249	,	_	
214-16	37250-37256	gender	_	
214-17	37256-37257	,	_	
214-18	37258-37266	parental	_	
214-19	37267-37270	SES	_	
214-20	37270-37271	,	_	
214-21	37272-37275	and	_	
214-22	37276-37283	smoking	_	
214-23	37284-37290	status	_	
214-24	37290-37291	.	_	

#Text=As it has been shown that the early stages of schizophrenia are critical in determining the overall course and outcome of the disorder, a sample of medicated first-episode patients with schizophrenia were enrolled in the study.
215-1	37292-37294	As	_	
215-2	37295-37297	it	_	
215-3	37298-37301	has	_	
215-4	37302-37306	been	_	
215-5	37307-37312	shown	_	
215-6	37313-37317	that	_	
215-7	37318-37321	the	_	
215-8	37322-37327	early	_	
215-9	37328-37334	stages	_	
215-10	37335-37337	of	_	
215-11	37338-37351	schizophrenia	_	
215-12	37352-37355	are	_	
215-13	37356-37364	critical	_	
215-14	37365-37367	in	_	
215-15	37368-37379	determining	_	
215-16	37380-37383	the	_	
215-17	37384-37391	overall	_	
215-18	37392-37398	course	_	
215-19	37399-37402	and	_	
215-20	37403-37410	outcome	_	
215-21	37411-37413	of	_	
215-22	37414-37417	the	_	
215-23	37418-37426	disorder	_	
215-24	37426-37427	,	_	
215-25	37428-37429	a	_	
215-26	37430-37436	sample	_	
215-27	37437-37439	of	_	
215-28	37440-37449	medicated	_	
215-29	37450-37463	first-episode	_	
215-30	37464-37472	patients	_	
215-31	37473-37477	with	_	
215-32	37478-37491	schizophrenia	_	
215-33	37492-37496	were	_	
215-34	37497-37505	enrolled	_	
215-35	37506-37508	in	_	
215-36	37509-37512	the	_	
215-37	37513-37518	study	_	
215-38	37518-37519	.	_	

#Text=However, our sample size was limited and replication studies with larger sample size will be needed.
216-1	37520-37527	However	_	
216-2	37527-37528	,	_	
216-3	37529-37532	our	_	
216-4	37533-37539	sample	_	
216-5	37540-37544	size	_	
216-6	37545-37548	was	_	
216-7	37549-37556	limited	_	
216-8	37557-37560	and	_	
216-9	37561-37572	replication	_	
216-10	37573-37580	studies	_	
216-11	37581-37585	with	_	
216-12	37586-37592	larger	_	
216-13	37593-37599	sample	_	
216-14	37600-37604	size	_	
216-15	37605-37609	will	_	
216-16	37610-37612	be	_	
216-17	37613-37619	needed	_	
216-18	37619-37620	.	_	

#Text=Although patients were examined early in the course of the disorder and minimally treated, antipsychotic medication effects on brain function cannot be differentiated from intrinsic characteristics of the disorder.
217-1	37621-37629	Although	_	
217-2	37630-37638	patients	_	
217-3	37639-37643	were	_	
217-4	37644-37652	examined	_	
217-5	37653-37658	early	_	
217-6	37659-37661	in	_	
217-7	37662-37665	the	_	
217-8	37666-37672	course	_	
217-9	37673-37675	of	_	
217-10	37676-37679	the	_	
217-11	37680-37688	disorder	_	
217-12	37689-37692	and	_	
217-13	37693-37702	minimally	_	
217-14	37703-37710	treated	_	
217-15	37710-37711	,	_	
217-16	37712-37725	antipsychotic	_	
217-17	37726-37736	medication	_	
217-18	37737-37744	effects	_	
217-19	37745-37747	on	_	
217-20	37748-37753	brain	_	
217-21	37754-37762	function	_	
217-22	37763-37769	cannot	_	
217-23	37770-37772	be	_	
217-24	37773-37787	differentiated	_	
217-25	37788-37792	from	_	
217-26	37793-37802	intrinsic	_	
217-27	37803-37818	characteristics	_	
217-28	37819-37821	of	_	
217-29	37822-37825	the	_	
217-30	37826-37834	disorder	_	
217-31	37834-37835	.	_	

#Text=Patients in this study were receiving treatment with antipsychotic medication.
218-1	37836-37844	Patients	_	
218-2	37845-37847	in	_	
218-3	37848-37852	this	_	
218-4	37853-37858	study	_	
218-5	37859-37863	were	_	
218-6	37864-37873	receiving	_	
218-7	37874-37883	treatment	_	
218-8	37884-37888	with	_	
218-9	37889-37902	antipsychotic	_	
218-10	37903-37913	medication	_	
218-11	37913-37914	.	_	

#Text=Our previous fMRI studies have shown that these drugs can modify functional connectivity patterns.
219-1	37915-37918	Our	_	
219-2	37919-37927	previous	_	
219-3	37928-37932	fMRI	_	
219-4	37933-37940	studies	_	
219-5	37941-37945	have	_	
219-6	37946-37951	shown	_	
219-7	37952-37956	that	_	
219-8	37957-37962	these	_	
219-9	37963-37968	drugs	_	
219-10	37969-37972	can	_	
219-11	37973-37979	modify	_	
219-12	37980-37990	functional	_	
219-13	37991-38003	connectivity	_	
219-14	38004-38012	patterns	_	
219-15	38012-38013	.	_	

#Text=Further studies enrolling unmedicated or medication naïve patients are needed.
220-1	38014-38021	Further	_	
220-2	38022-38029	studies	_	
220-3	38030-38039	enrolling	_	
220-4	38040-38051	unmedicated	_	
220-5	38052-38054	or	_	
220-6	38055-38065	medication	_	
220-7	38066-38071	naïve	_	
220-8	38072-38080	patients	_	
220-9	38081-38084	are	_	
220-10	38085-38091	needed	_	
220-11	38091-38092	.	_	

#Text=While rigorous preprocessing steps were implemented on both the fMRI and MEG data, heart rate and breathing were not directly controlled for during data acquisition.
221-1	38093-38098	While	_	
221-2	38099-38107	rigorous	_	
221-3	38108-38121	preprocessing	_	
221-4	38122-38127	steps	_	
221-5	38128-38132	were	_	
221-6	38133-38144	implemented	_	
221-7	38145-38147	on	_	
221-8	38148-38152	both	_	
221-9	38153-38156	the	_	
221-10	38157-38161	fMRI	_	
221-11	38162-38165	and	_	
221-12	38166-38169	MEG	_	
221-13	38170-38174	data	_	
221-14	38174-38175	,	_	
221-15	38176-38181	heart	_	
221-16	38182-38186	rate	_	
221-17	38187-38190	and	_	
221-18	38191-38200	breathing	_	
221-19	38201-38205	were	_	
221-20	38206-38209	not	_	
221-21	38210-38218	directly	_	
221-22	38219-38229	controlled	_	
221-23	38230-38233	for	_	
221-24	38234-38240	during	_	
221-25	38241-38245	data	_	
221-26	38246-38257	acquisition	_	
221-27	38257-38258	.	_	

#Text=Although our preprocessing steps and ICA analysis attempted to control for these potential sources of noise, our results may still be impacted by artifacts due to motion or physiological processes.
222-1	38259-38267	Although	_	
222-2	38268-38271	our	_	
222-3	38272-38285	preprocessing	_	
222-4	38286-38291	steps	_	
222-5	38292-38295	and	_	
222-6	38296-38299	ICA	_	
222-7	38300-38308	analysis	_	
222-8	38309-38318	attempted	_	
222-9	38319-38321	to	_	
222-10	38322-38329	control	_	
222-11	38330-38333	for	_	
222-12	38334-38339	these	_	
222-13	38340-38349	potential	_	
222-14	38350-38357	sources	_	
222-15	38358-38360	of	_	
222-16	38361-38366	noise	_	
222-17	38366-38367	,	_	
222-18	38368-38371	our	_	
222-19	38372-38379	results	_	
222-20	38380-38383	may	_	
222-21	38384-38389	still	_	
222-22	38390-38392	be	_	
222-23	38393-38401	impacted	_	
222-24	38402-38404	by	_	
222-25	38405-38414	artifacts	_	
222-26	38415-38418	due	_	
222-27	38419-38421	to	_	
222-28	38422-38428	motion	_	
222-29	38429-38431	or	_	
222-30	38432-38445	physiological	_	
222-31	38446-38455	processes	_	
222-32	38455-38456	.	_	

#Text=Subjects self-reported that they did not fall asleep during the MEG scan, but it is still possible that some may have briefly fallen asleep and impacted our results.
223-1	38457-38465	Subjects	_	
223-2	38466-38479	self-reported	_	
223-3	38480-38484	that	_	
223-4	38485-38489	they	_	
223-5	38490-38493	did	_	
223-6	38494-38497	not	_	
223-7	38498-38502	fall	_	
223-8	38503-38509	asleep	_	
223-9	38510-38516	during	_	
223-10	38517-38520	the	_	
223-11	38521-38524	MEG	_	
223-12	38525-38529	scan	_	
223-13	38529-38530	,	_	
223-14	38531-38534	but	_	
223-15	38535-38537	it	_	
223-16	38538-38540	is	_	
223-17	38541-38546	still	_	
223-18	38547-38555	possible	_	
223-19	38556-38560	that	_	
223-20	38561-38565	some	_	
223-21	38566-38569	may	_	
223-22	38570-38574	have	_	
223-23	38575-38582	briefly	_	
223-24	38583-38589	fallen	_	
223-25	38590-38596	asleep	_	
223-26	38597-38600	and	_	
223-27	38601-38609	impacted	_	
223-28	38610-38613	our	_	
223-29	38614-38621	results	_	
223-30	38621-38622	.	_	

#Text=The number of significant functional connectivity group differences reported are much smaller than typically reported in the literature.
224-1	38623-38626	The	_	
224-2	38627-38633	number	_	
224-3	38634-38636	of	_	
224-4	38637-38648	significant	_	
224-5	38649-38659	functional	_	
224-6	38660-38672	connectivity	_	
224-7	38673-38678	group	_	
224-8	38679-38690	differences	_	
224-9	38691-38699	reported	_	
224-10	38700-38703	are	_	
224-11	38704-38708	much	_	
224-12	38709-38716	smaller	_	
224-13	38717-38721	than	_	
224-14	38722-38731	typically	_	
224-15	38732-38740	reported	_	
224-16	38741-38743	in	_	
224-17	38744-38747	the	_	
224-18	38748-38758	literature	_	
224-19	38758-38759	.	_	

#Text=We believe our findings may be impacted by the modest sample size.
225-1	38760-38762	We	_	
225-2	38763-38770	believe	_	
225-3	38771-38774	our	_	
225-4	38775-38783	findings	_	
225-5	38784-38787	may	_	
225-6	38788-38790	be	_	
225-7	38791-38799	impacted	_	
225-8	38800-38802	by	_	
225-9	38803-38806	the	_	
225-10	38807-38813	modest	_	
225-11	38814-38820	sample	_	
225-12	38821-38825	size	_	
225-13	38825-38826	.	_	

#Text=In addition, we examine functional connectivity for multiple regions independently comprising a network rather than using a single network template.
226-1	38827-38829	In	_	
226-2	38830-38838	addition	_	
226-3	38838-38839	,	_	
226-4	38840-38842	we	_	
226-5	38843-38850	examine	_	
226-6	38851-38861	functional	_	
226-7	38862-38874	connectivity	_	
226-8	38875-38878	for	_	
226-9	38879-38887	multiple	_	
226-10	38888-38895	regions	_	
226-11	38896-38909	independently	_	
226-12	38910-38920	comprising	_	
226-13	38921-38922	a	_	
226-14	38923-38930	network	_	
226-15	38931-38937	rather	_	
226-16	38938-38942	than	_	
226-17	38943-38948	using	_	
226-18	38949-38950	a	_	
226-19	38951-38957	single	_	
226-20	38958-38965	network	_	
226-21	38966-38974	template	_	
226-22	38974-38975	.	_	

#Text=Therefore, as multiple networks are examined in a functional connectivity analysis, our results may be impacted by the number of comparisons being made between functional networks (e.g., over 450 and 500 comparisons for fMRI and MEG, respectively).
227-1	38976-38985	Therefore	_	
227-2	38985-38986	,	_	
227-3	38987-38989	as	_	
227-4	38990-38998	multiple	_	
227-5	38999-39007	networks	_	
227-6	39008-39011	are	_	
227-7	39012-39020	examined	_	
227-8	39021-39023	in	_	
227-9	39024-39025	a	_	
227-10	39026-39036	functional	_	
227-11	39037-39049	connectivity	_	
227-12	39050-39058	analysis	_	
227-13	39058-39059	,	_	
227-14	39060-39063	our	_	
227-15	39064-39071	results	_	
227-16	39072-39075	may	_	
227-17	39076-39078	be	_	
227-18	39079-39087	impacted	_	
227-19	39088-39090	by	_	
227-20	39091-39094	the	_	
227-21	39095-39101	number	_	
227-22	39102-39104	of	_	
227-23	39105-39116	comparisons	_	
227-24	39117-39122	being	_	
227-25	39123-39127	made	_	
227-26	39128-39135	between	_	
227-27	39136-39146	functional	_	
227-28	39147-39155	networks	_	
227-29	39156-39157	(	_	
227-30	39157-39160	e.g	_	
227-31	39160-39161	.	_	
227-32	39161-39162	,	_	
227-33	39163-39167	over	_	
227-34	39168-39171	450	_	
227-35	39172-39175	and	_	
227-36	39176-39179	500	_	
227-37	39180-39191	comparisons	_	
227-38	39192-39195	for	_	
227-39	39196-39200	fMRI	_	
227-40	39201-39204	and	_	
227-41	39205-39208	MEG	_	
227-42	39208-39209	,	_	
227-43	39210-39222	respectively	_	
227-44	39222-39223	)	_	
227-45	39223-39224	.	_	

#Text=However, we believe that the compatibility of our results with the schizophrenia literature indicate the importance of our multiple comparison corrected and uncorrected functional connectivity findings.
228-1	39225-39232	However	_	
228-2	39232-39233	,	_	
228-3	39234-39236	we	_	
228-4	39237-39244	believe	_	
228-5	39245-39249	that	_	
228-6	39250-39253	the	_	
228-7	39254-39267	compatibility	_	
228-8	39268-39270	of	_	
228-9	39271-39274	our	_	
228-10	39275-39282	results	_	
228-11	39283-39287	with	_	
228-12	39288-39291	the	_	
228-13	39292-39305	schizophrenia	_	
228-14	39306-39316	literature	_	
228-15	39317-39325	indicate	_	
228-16	39326-39329	the	_	
228-17	39330-39340	importance	_	
228-18	39341-39343	of	_	
228-19	39344-39347	our	_	
228-20	39348-39356	multiple	_	
228-21	39357-39367	comparison	_	
228-22	39368-39377	corrected	_	
228-23	39378-39381	and	_	
228-24	39382-39393	uncorrected	_	
228-25	39394-39404	functional	_	
228-26	39405-39417	connectivity	_	
228-27	39418-39426	findings	_	
228-28	39426-39427	.	_	

#Text=Finally, as previous chronic schizophrenia studies have explored, future studies would benefit from utilizing classification analyses to quantitatively determine if examining functional connectivity using both fMRI and MEG provides better classification of first-episode patients with schizophrenia than using either modality alone.
229-1	39428-39435	Finally	_	
229-2	39435-39436	,	_	
229-3	39437-39439	as	_	
229-4	39440-39448	previous	_	
229-5	39449-39456	chronic	_	
229-6	39457-39470	schizophrenia	_	
229-7	39471-39478	studies	_	
229-8	39479-39483	have	_	
229-9	39484-39492	explored	_	
229-10	39492-39493	,	_	
229-11	39494-39500	future	_	
229-12	39501-39508	studies	_	
229-13	39509-39514	would	_	
229-14	39515-39522	benefit	_	
229-15	39523-39527	from	_	
229-16	39528-39537	utilizing	_	
229-17	39538-39552	classification	_	
229-18	39553-39561	analyses	_	
229-19	39562-39564	to	_	
229-20	39565-39579	quantitatively	_	
229-21	39580-39589	determine	_	
229-22	39590-39592	if	_	
229-23	39593-39602	examining	_	
229-24	39603-39613	functional	_	
229-25	39614-39626	connectivity	_	
229-26	39627-39632	using	_	
229-27	39633-39637	both	_	
229-28	39638-39642	fMRI	_	
229-29	39643-39646	and	_	
229-30	39647-39650	MEG	_	
229-31	39651-39659	provides	_	
229-32	39660-39666	better	_	
229-33	39667-39681	classification	_	
229-34	39682-39684	of	_	
229-35	39685-39698	first-episode	_	
229-36	39699-39707	patients	_	
229-37	39708-39712	with	_	
229-38	39713-39726	schizophrenia	_	
229-39	39727-39731	than	_	
229-40	39732-39737	using	_	
229-41	39738-39744	either	_	
229-42	39745-39753	modality	_	
229-43	39754-39759	alone	_	
229-44	39759-39760	.	_	

#Text=Conclusion
#Text=In conclusion, our results support the dysconnectivity hypothesis of schizophrenia as patients demonstrated altered connectivity between fMRI subcortical and auditory networks, as well as fMRI and MEG altered intra- and inter- sensorimotor connectivity in both fMRI and MEG.
230-1	39761-39771	Conclusion	_	
230-2	39772-39774	In	_	
230-3	39775-39785	conclusion	_	
230-4	39785-39786	,	_	
230-5	39787-39790	our	_	
230-6	39791-39798	results	_	
230-7	39799-39806	support	_	
230-8	39807-39810	the	_	
230-9	39811-39826	dysconnectivity	_	
230-10	39827-39837	hypothesis	_	
230-11	39838-39840	of	_	
230-12	39841-39854	schizophrenia	_	
230-13	39855-39857	as	_	
230-14	39858-39866	patients	_	
230-15	39867-39879	demonstrated	_	
230-16	39880-39887	altered	_	
230-17	39888-39900	connectivity	_	
230-18	39901-39908	between	_	
230-19	39909-39913	fMRI	_	
230-20	39914-39925	subcortical	_	
230-21	39926-39929	and	_	
230-22	39930-39938	auditory	_	
230-23	39939-39947	networks	_	
230-24	39947-39948	,	_	
230-25	39949-39951	as	_	
230-26	39952-39956	well	_	
230-27	39957-39959	as	_	
230-28	39960-39964	fMRI	_	
230-29	39965-39968	and	_	
230-30	39969-39972	MEG	_	
230-31	39973-39980	altered	_	
230-32	39981-39986	intra	_	
230-33	39986-39987	-	_	
230-34	39988-39991	and	_	
230-35	39992-39997	inter	_	
230-36	39997-39998	-	_	
230-37	39999-40011	sensorimotor	_	
230-38	40012-40024	connectivity	_	
230-39	40025-40027	in	_	
230-40	40028-40032	both	_	
230-41	40033-40037	fMRI	_	
230-42	40038-40041	and	_	
230-43	40042-40045	MEG	_	
230-44	40045-40046	.	_	

#Text=These findings illustrate the strength in combining complementary modalities like fMRI and MEG to examine resting-state brain function in schizophrenia.
231-1	40047-40052	These	_	
231-2	40053-40061	findings	_	
231-3	40062-40072	illustrate	_	
231-4	40073-40076	the	_	
231-5	40077-40085	strength	_	
231-6	40086-40088	in	_	
231-7	40089-40098	combining	_	
231-8	40099-40112	complementary	_	
231-9	40113-40123	modalities	_	
231-10	40124-40128	like	_	
231-11	40129-40133	fMRI	_	
231-12	40134-40137	and	_	
231-13	40138-40141	MEG	_	
231-14	40142-40144	to	_	
231-15	40145-40152	examine	_	
231-16	40153-40166	resting-state	_	
231-17	40167-40172	brain	_	
231-18	40173-40181	function	_	
231-19	40182-40184	in	_	
231-20	40185-40198	schizophrenia	_	
231-21	40198-40199	.	_	

#Text=More specifically, this study further highlights the importance of examining multimodal neuroimaging data when studying schizophrenia as critical information relating to different aspects of the brain (e.g., electrophysiological, hemodynamic, structural, etc.) may be missing in a single modality.
232-1	40200-40204	More	_	
232-2	40205-40217	specifically	_	
232-3	40217-40218	,	_	
232-4	40219-40223	this	_	
232-5	40224-40229	study	_	
232-6	40230-40237	further	_	
232-7	40238-40248	highlights	_	
232-8	40249-40252	the	_	
232-9	40253-40263	importance	_	
232-10	40264-40266	of	_	
232-11	40267-40276	examining	_	
232-12	40277-40287	multimodal	_	
232-13	40288-40300	neuroimaging	_	
232-14	40301-40305	data	_	
232-15	40306-40310	when	_	
232-16	40311-40319	studying	_	
232-17	40320-40333	schizophrenia	_	
232-18	40334-40336	as	_	
232-19	40337-40345	critical	_	
232-20	40346-40357	information	_	
232-21	40358-40366	relating	_	
232-22	40367-40369	to	_	
232-23	40370-40379	different	_	
232-24	40380-40387	aspects	_	
232-25	40388-40390	of	_	
232-26	40391-40394	the	_	
232-27	40395-40400	brain	_	
232-28	40401-40402	(	_	
232-29	40402-40405	e.g	_	
232-30	40405-40406	.	_	
232-31	40406-40407	,	_	
232-32	40408-40428	electrophysiological	_	
232-33	40428-40429	,	_	
232-34	40430-40441	hemodynamic	_	
232-35	40441-40442	,	_	
232-36	40443-40453	structural	_	
232-37	40453-40454	,	_	
232-38	40455-40458	etc	_	
232-39	40458-40459	.	_	
232-40	40459-40460	)	_	
232-41	40461-40464	may	_	
232-42	40465-40467	be	_	
232-43	40468-40475	missing	_	
232-44	40476-40478	in	_	
232-45	40479-40480	a	_	
232-46	40481-40487	single	_	
232-47	40488-40496	modality	_	
232-48	40496-40497	.	_	

#Text=Estimate of the number of independent components.
233-1	40498-40506	Estimate	_	
233-2	40507-40509	of	_	
233-3	40510-40513	the	_	
233-4	40514-40520	number	_	
233-5	40521-40523	of	_	
233-6	40524-40535	independent	_	
233-7	40536-40546	components	_	
233-8	40546-40547	.	_	

#Text=The mean number of independent components for fMRI (left) and MEG (right) was estimated to be 32 and 49 for all subjects, respectively, using minimum description length criteria.
234-1	40548-40551	The	_	
234-2	40552-40556	mean	_	
234-3	40557-40563	number	_	
234-4	40564-40566	of	_	
234-5	40567-40578	independent	_	
234-6	40579-40589	components	_	
234-7	40590-40593	for	_	
234-8	40594-40598	fMRI	_	
234-9	40599-40600	(	_	
234-10	40600-40604	left	_	
234-11	40604-40605	)	_	
234-12	40606-40609	and	_	
234-13	40610-40613	MEG	_	
234-14	40614-40615	(	_	
234-15	40615-40620	right	_	
234-16	40620-40621	)	_	
234-17	40622-40625	was	_	
234-18	40626-40635	estimated	_	
234-19	40636-40638	to	_	
234-20	40639-40641	be	_	
234-21	40642-40644	32	_	
234-22	40645-40648	and	_	
234-23	40649-40651	49	_	
234-24	40652-40655	for	_	
234-25	40656-40659	all	_	
234-26	40660-40668	subjects	_	
234-27	40668-40669	,	_	
234-28	40670-40682	respectively	_	
234-29	40682-40683	,	_	
234-30	40684-40689	using	_	
234-31	40690-40697	minimum	_	
234-32	40698-40709	description	_	
234-33	40710-40716	length	_	
234-34	40717-40725	criteria	_	
234-35	40725-40726	.	_	

#Text=For fMRI, the minimum and maximum number of components estimated using the minimum description length criteria was 17 and 55, respectively.
235-1	40727-40730	For	_	
235-2	40731-40735	fMRI	_	
235-3	40735-40736	,	_	
235-4	40737-40740	the	_	
235-5	40741-40748	minimum	_	
235-6	40749-40752	and	_	
235-7	40753-40760	maximum	_	
235-8	40761-40767	number	_	
235-9	40768-40770	of	_	
235-10	40771-40781	components	_	
235-11	40782-40791	estimated	_	
235-12	40792-40797	using	_	
235-13	40798-40801	the	_	
235-14	40802-40809	minimum	_	
235-15	40810-40821	description	_	
235-16	40822-40828	length	_	
235-17	40829-40837	criteria	_	
235-18	40838-40841	was	_	
235-19	40842-40844	17	_	
235-20	40845-40848	and	_	
235-21	40849-40851	55	_	
235-22	40851-40852	,	_	
235-23	40853-40865	respectively	_	
235-24	40865-40866	.	_	

#Text=For MEG, the minimum and maximum number of components estimated using the minimum description length criteria was 12 and 110, respectively.
236-1	40867-40870	For	_	
236-2	40871-40874	MEG	_	
236-3	40874-40875	,	_	
236-4	40876-40879	the	_	
236-5	40880-40887	minimum	_	
236-6	40888-40891	and	_	
236-7	40892-40899	maximum	_	
236-8	40900-40906	number	_	
236-9	40907-40909	of	_	
236-10	40910-40920	components	_	
236-11	40921-40930	estimated	_	
236-12	40931-40936	using	_	
236-13	40937-40940	the	_	
236-14	40941-40948	minimum	_	
236-15	40949-40960	description	_	
236-16	40961-40967	length	_	
236-17	40968-40976	criteria	_	
236-18	40977-40980	was	_	
236-19	40981-40983	12	_	
236-20	40984-40987	and	_	
236-21	40988-40991	110	_	
236-22	40991-40992	,	_	
236-23	40993-41005	respectively	_	
236-24	41005-41006	.	_	

#Text=Supplementary Fig. 1
#Text=Resting-state theta frequency band MEG functional connectivity.
237-1	41007-41020	Supplementary	_	
237-2	41021-41024	Fig	_	
237-3	41024-41025	.	_	
237-4	41026-41027	1	_	
237-5	41028-41041	Resting-state	_	
237-6	41042-41047	theta	_	
237-7	41048-41057	frequency	_	
237-8	41058-41062	band	_	
237-9	41063-41066	MEG	_	
237-10	41067-41077	functional	_	
237-11	41078-41090	connectivity	_	
237-12	41090-41091	.	_	

#Text=Functional connectivity for resting-state MEG theta band.
238-1	41092-41102	Functional	_	
238-2	41103-41115	connectivity	_	
238-3	41116-41119	for	_	
238-4	41120-41133	resting-state	_	
238-5	41134-41137	MEG	_	
238-6	41138-41143	theta	_	
238-7	41144-41148	band	_	
238-8	41148-41149	.	_	

#Text=Connectivity for controls (left column), first-episode patients (middle column), and the significant difference between groups (right column) are shown.
239-1	41150-41162	Connectivity	_	
239-2	41163-41166	for	_	
239-3	41167-41175	controls	_	
239-4	41176-41177	(	_	
239-5	41177-41181	left	_	
239-6	41182-41188	column	_	
239-7	41188-41189	)	_	
239-8	41189-41190	,	_	
239-9	41191-41204	first-episode	_	
239-10	41205-41213	patients	_	
239-11	41214-41215	(	_	
239-12	41215-41221	middle	_	
239-13	41222-41228	column	_	
239-14	41228-41229	)	_	
239-15	41229-41230	,	_	
239-16	41231-41234	and	_	
239-17	41235-41238	the	_	
239-18	41239-41250	significant	_	
239-19	41251-41261	difference	_	
239-20	41262-41269	between	_	
239-21	41270-41276	groups	_	
239-22	41277-41278	(	_	
239-23	41278-41283	right	_	
239-24	41284-41290	column	_	
239-25	41290-41291	)	_	
239-26	41292-41295	are	_	
239-27	41296-41301	shown	_	
239-28	41301-41302	.	_	

#Text=FDR-corrected significant differences (pFDR < 0.05) are indicated with • and uncorrected significant differences (puncorrected < 0.05) are indicated with *.
240-1	41303-41316	FDR-corrected	_	
240-2	41317-41328	significant	_	
240-3	41329-41340	differences	_	
240-4	41341-41342	(	_	
240-5	41342-41346	pFDR	_	
240-6	41346-41347	 	_	
240-7	41347-41348	<	_	
240-8	41348-41349	 	_	
240-9	41349-41353	0.05	_	
240-10	41353-41354	)	_	
240-11	41355-41358	are	_	
240-12	41359-41368	indicated	_	
240-13	41369-41373	with	_	
240-14	41374-41375	•	_	
240-15	41376-41379	and	_	
240-16	41380-41391	uncorrected	_	
240-17	41392-41403	significant	_	
240-18	41404-41415	differences	_	
240-19	41416-41417	(	_	
240-20	41417-41429	puncorrected	_	
240-21	41429-41430	 	_	
240-22	41430-41431	<	_	
240-23	41431-41432	 	_	
240-24	41432-41436	0.05	_	
240-25	41436-41437	)	_	
240-26	41438-41441	are	_	
240-27	41442-41451	indicated	_	
240-28	41452-41456	with	_	
240-29	41457-41458	*	_	
240-30	41458-41459	.	_	

#Text=Supplementary Fig. 2
#Text=Resting-state alpha frequency band MEG functional connectivity.
241-1	41460-41473	Supplementary	_	
241-2	41474-41477	Fig	_	
241-3	41477-41478	.	_	
241-4	41479-41480	2	_	
241-5	41481-41494	Resting-state	_	
241-6	41495-41500	alpha	_	
241-7	41501-41510	frequency	_	
241-8	41511-41515	band	_	
241-9	41516-41519	MEG	_	
241-10	41520-41530	functional	_	
241-11	41531-41543	connectivity	_	
241-12	41543-41544	.	_	

#Text=Functional connectivity for resting-state MEG alpha band.
242-1	41545-41555	Functional	_	
242-2	41556-41568	connectivity	_	
242-3	41569-41572	for	_	
242-4	41573-41586	resting-state	_	
242-5	41587-41590	MEG	_	
242-6	41591-41596	alpha	_	
242-7	41597-41601	band	_	
242-8	41601-41602	.	_	

#Text=Connectivity for controls (left column), first-episode patients (middle column), and the significant difference between groups (right column) are shown.
243-1	41603-41615	Connectivity	_	
243-2	41616-41619	for	_	
243-3	41620-41628	controls	_	
243-4	41629-41630	(	_	
243-5	41630-41634	left	_	
243-6	41635-41641	column	_	
243-7	41641-41642	)	_	
243-8	41642-41643	,	_	
243-9	41644-41657	first-episode	_	
243-10	41658-41666	patients	_	
243-11	41667-41668	(	_	
243-12	41668-41674	middle	_	
243-13	41675-41681	column	_	
243-14	41681-41682	)	_	
243-15	41682-41683	,	_	
243-16	41684-41687	and	_	
243-17	41688-41691	the	_	
243-18	41692-41703	significant	_	
243-19	41704-41714	difference	_	
243-20	41715-41722	between	_	
243-21	41723-41729	groups	_	
243-22	41730-41731	(	_	
243-23	41731-41736	right	_	
243-24	41737-41743	column	_	
243-25	41743-41744	)	_	
243-26	41745-41748	are	_	
243-27	41749-41754	shown	_	
243-28	41754-41755	.	_	

#Text=FDR-corrected significant differences (pFDR < 0.05) are indicated with • and uncorrected significant differences (puncorrected < 0.05) are indicated with *.
244-1	41756-41769	FDR-corrected	_	
244-2	41770-41781	significant	_	
244-3	41782-41793	differences	_	
244-4	41794-41795	(	_	
244-5	41795-41799	pFDR	_	
244-6	41799-41800	 	_	
244-7	41800-41801	<	_	
244-8	41801-41802	 	_	
244-9	41802-41806	0.05	_	
244-10	41806-41807	)	_	
244-11	41808-41811	are	_	
244-12	41812-41821	indicated	_	
244-13	41822-41826	with	_	
244-14	41827-41828	•	_	
244-15	41829-41832	and	_	
244-16	41833-41844	uncorrected	_	
244-17	41845-41856	significant	_	
244-18	41857-41868	differences	_	
244-19	41869-41870	(	_	
244-20	41870-41882	puncorrected	_	
244-21	41882-41883	 	_	
244-22	41883-41884	<	_	
244-23	41884-41885	 	_	
244-24	41885-41889	0.05	_	
244-25	41889-41890	)	_	
244-26	41891-41894	are	_	
244-27	41895-41904	indicated	_	
244-28	41905-41909	with	_	
244-29	41910-41911	*	_	
244-30	41911-41912	.	_	

#Text=Supplementary Fig. 3
#Text=Resting-state beta frequency band MEG functional connectivity.
245-1	41913-41926	Supplementary	_	
245-2	41927-41930	Fig	_	
245-3	41930-41931	.	_	
245-4	41932-41933	3	_	
245-5	41934-41947	Resting-state	_	
245-6	41948-41952	beta	_	
245-7	41953-41962	frequency	_	
245-8	41963-41967	band	_	
245-9	41968-41971	MEG	_	
245-10	41972-41982	functional	_	
245-11	41983-41995	connectivity	_	
245-12	41995-41996	.	_	

#Text=Functional connectivity for resting-state MEG beta band.
246-1	41997-42007	Functional	_	
246-2	42008-42020	connectivity	_	
246-3	42021-42024	for	_	
246-4	42025-42038	resting-state	_	
246-5	42039-42042	MEG	_	
246-6	42043-42047	beta	_	
246-7	42048-42052	band	_	
246-8	42052-42053	.	_	

#Text=Connectivity for controls (left column), first-episode patients (middle column), and the significant difference between groups (right column) are shown.
247-1	42054-42066	Connectivity	_	
247-2	42067-42070	for	_	
247-3	42071-42079	controls	_	
247-4	42080-42081	(	_	
247-5	42081-42085	left	_	
247-6	42086-42092	column	_	
247-7	42092-42093	)	_	
247-8	42093-42094	,	_	
247-9	42095-42108	first-episode	_	
247-10	42109-42117	patients	_	
247-11	42118-42119	(	_	
247-12	42119-42125	middle	_	
247-13	42126-42132	column	_	
247-14	42132-42133	)	_	
247-15	42133-42134	,	_	
247-16	42135-42138	and	_	
247-17	42139-42142	the	_	
247-18	42143-42154	significant	_	
247-19	42155-42165	difference	_	
247-20	42166-42173	between	_	
247-21	42174-42180	groups	_	
247-22	42181-42182	(	_	
247-23	42182-42187	right	_	
247-24	42188-42194	column	_	
247-25	42194-42195	)	_	
247-26	42196-42199	are	_	
247-27	42200-42205	shown	_	
247-28	42205-42206	.	_	

#Text=FDR-corrected significant differences (pFDR < 0.05) are indicated with • and uncorrected significant differences (puncorrected < 0.05) are indicated with *.
248-1	42207-42220	FDR-corrected	_	
248-2	42221-42232	significant	_	
248-3	42233-42244	differences	_	
248-4	42245-42246	(	_	
248-5	42246-42250	pFDR	_	
248-6	42250-42251	 	_	
248-7	42251-42252	<	_	
248-8	42252-42253	 	_	
248-9	42253-42257	0.05	_	
248-10	42257-42258	)	_	
248-11	42259-42262	are	_	
248-12	42263-42272	indicated	_	
248-13	42273-42277	with	_	
248-14	42278-42279	•	_	
248-15	42280-42283	and	_	
248-16	42284-42295	uncorrected	_	
248-17	42296-42307	significant	_	
248-18	42308-42319	differences	_	
248-19	42320-42321	(	_	
248-20	42321-42333	puncorrected	_	
248-21	42333-42334	 	_	
248-22	42334-42335	<	_	
248-23	42335-42336	 	_	
248-24	42336-42340	0.05	_	
248-25	42340-42341	)	_	
248-26	42342-42345	are	_	
248-27	42346-42355	indicated	_	
248-28	42356-42360	with	_	
248-29	42361-42362	*	_	
248-30	42362-42363	.	_	

#Text=Supplementary Fig. 4
#Text=Resting-state gamma frequency band MEG functional connectivity.
249-1	42364-42377	Supplementary	_	
249-2	42378-42381	Fig	_	
249-3	42381-42382	.	_	
249-4	42383-42384	4	_	
249-5	42385-42398	Resting-state	_	
249-6	42399-42404	gamma	_	
249-7	42405-42414	frequency	_	
249-8	42415-42419	band	_	
249-9	42420-42423	MEG	_	
249-10	42424-42434	functional	_	
249-11	42435-42447	connectivity	_	
249-12	42447-42448	.	_	

#Text=Functional connectivity for resting-state MEG gamma band.
250-1	42449-42459	Functional	_	
250-2	42460-42472	connectivity	_	
250-3	42473-42476	for	_	
250-4	42477-42490	resting-state	_	
250-5	42491-42494	MEG	_	
250-6	42495-42500	gamma	_	
250-7	42501-42505	band	_	
250-8	42505-42506	.	_	

#Text=Connectivity for controls (left column), first-episode patients (middle column), and the significant difference between groups (right column) are shown.
251-1	42507-42519	Connectivity	_	
251-2	42520-42523	for	_	
251-3	42524-42532	controls	_	
251-4	42533-42534	(	_	
251-5	42534-42538	left	_	
251-6	42539-42545	column	_	
251-7	42545-42546	)	_	
251-8	42546-42547	,	_	
251-9	42548-42561	first-episode	_	
251-10	42562-42570	patients	_	
251-11	42571-42572	(	_	
251-12	42572-42578	middle	_	
251-13	42579-42585	column	_	
251-14	42585-42586	)	_	
251-15	42586-42587	,	_	
251-16	42588-42591	and	_	
251-17	42592-42595	the	_	
251-18	42596-42607	significant	_	
251-19	42608-42618	difference	_	
251-20	42619-42626	between	_	
251-21	42627-42633	groups	_	
251-22	42634-42635	(	_	
251-23	42635-42640	right	_	
251-24	42641-42647	column	_	
251-25	42647-42648	)	_	
251-26	42649-42652	are	_	
251-27	42653-42658	shown	_	
251-28	42658-42659	.	_	

#Text=FDR-corrected significant differences (pFDR < 0.05) are indicated with • and uncorrected significant differences (puncorrected < 0.05) are indicated with *.
252-1	42660-42673	FDR-corrected	_	
252-2	42674-42685	significant	_	
252-3	42686-42697	differences	_	
252-4	42698-42699	(	_	
252-5	42699-42703	pFDR	_	
252-6	42703-42704	 	_	
252-7	42704-42705	<	_	
252-8	42705-42706	 	_	
252-9	42706-42710	0.05	_	
252-10	42710-42711	)	_	
252-11	42712-42715	are	_	
252-12	42716-42725	indicated	_	
252-13	42726-42730	with	_	
252-14	42731-42732	•	_	
252-15	42733-42736	and	_	
252-16	42737-42748	uncorrected	_	
252-17	42749-42760	significant	_	
252-18	42761-42772	differences	_	
252-19	42773-42774	(	_	
252-20	42774-42786	puncorrected	_	
252-21	42786-42787	 	_	
252-22	42787-42788	<	_	
252-23	42788-42789	 	_	
252-24	42789-42793	0.05	_	
252-25	42793-42794	)	_	
252-26	42795-42798	are	_	
252-27	42799-42808	indicated	_	
252-28	42809-42813	with	_	
252-29	42814-42815	*	_	
252-30	42815-42816	.	_	

#Text=Supplementary Fig. 5
#Text=Sensorimotor networks spatial correlations.
253-1	42817-42830	Supplementary	_	
253-2	42831-42834	Fig	_	
253-3	42834-42835	.	_	
253-4	42836-42837	5	_	
253-5	42838-42850	Sensorimotor	_	
253-6	42851-42859	networks	_	
253-7	42860-42867	spatial	_	
253-8	42868-42880	correlations	_	
253-9	42880-42881	.	_	

#Text=Spatial correlation (r) between resting-state fMRI and MEG components in the sensorimotor network.
254-1	42882-42889	Spatial	_	
254-2	42890-42901	correlation	_	
254-3	42902-42903	(	_	
254-4	42903-42904	r	_	
254-5	42904-42905	)	_	
254-6	42906-42913	between	_	
254-7	42914-42927	resting-state	_	
254-8	42928-42932	fMRI	_	
254-9	42933-42936	and	_	
254-10	42937-42940	MEG	_	
254-11	42941-42951	components	_	
254-12	42952-42954	in	_	
254-13	42955-42958	the	_	
254-14	42959-42971	sensorimotor	_	
254-15	42972-42979	network	_	
254-16	42979-42980	.	_	

#Text=Only correlations of r > 0.5 are illustrated.
255-1	42981-42985	Only	_	
255-2	42986-42998	correlations	_	
255-3	42999-43001	of	_	
255-4	43002-43003	r	_	
255-5	43003-43004	 	_	
255-6	43004-43005	>	_	
255-7	43005-43006	 	_	
255-8	43006-43009	0.5	_	
255-9	43010-43013	are	_	
255-10	43014-43025	illustrated	_	
255-11	43025-43026	.	_	

#Text=Supplementary Fig. 6
#Text=Visual networks spatial correlations.
256-1	43027-43040	Supplementary	_	
256-2	43041-43044	Fig	_	
256-3	43044-43045	.	_	
256-4	43046-43047	6	_	
256-5	43048-43054	Visual	_	
256-6	43055-43063	networks	_	
256-7	43064-43071	spatial	_	
256-8	43072-43084	correlations	_	
256-9	43084-43085	.	_	

#Text=Spatial correlation (r) between resting-state fMRI and MEG components in the sensorimotor network.
257-1	43086-43093	Spatial	_	
257-2	43094-43105	correlation	_	
257-3	43106-43107	(	_	
257-4	43107-43108	r	_	
257-5	43108-43109	)	_	
257-6	43110-43117	between	_	
257-7	43118-43131	resting-state	_	
257-8	43132-43136	fMRI	_	
257-9	43137-43140	and	_	
257-10	43141-43144	MEG	_	
257-11	43145-43155	components	_	
257-12	43156-43158	in	_	
257-13	43159-43162	the	_	
257-14	43163-43175	sensorimotor	_	
257-15	43176-43183	network	_	
257-16	43183-43184	.	_	

#Text=Only correlations of r > 0.5 are illustrated.
258-1	43185-43189	Only	_	
258-2	43190-43202	correlations	_	
258-3	43203-43205	of	_	
258-4	43206-43207	r	_	
258-5	43207-43208	 	_	
258-6	43208-43209	>	_	
258-7	43209-43210	 	_	
258-8	43210-43213	0.5	_	
258-9	43214-43217	are	_	
258-10	43218-43229	illustrated	_	
258-11	43229-43230	.	_	

#Text=Supplementary Fig. 7
#Text=Default-mode networks spatial correlations.
259-1	43231-43244	Supplementary	_	
259-2	43245-43248	Fig	_	
259-3	43248-43249	.	_	
259-4	43250-43251	7	_	
259-5	43252-43264	Default-mode	_	
259-6	43265-43273	networks	_	
259-7	43274-43281	spatial	_	
259-8	43282-43294	correlations	_	
259-9	43294-43295	.	_	

#Text=Spatial correlation (r) between resting-state fMRI and MEG components in the default-mode network.
260-1	43296-43303	Spatial	_	
260-2	43304-43315	correlation	_	
260-3	43316-43317	(	_	
260-4	43317-43318	r	_	
260-5	43318-43319	)	_	
260-6	43320-43327	between	_	
260-7	43328-43341	resting-state	_	
260-8	43342-43346	fMRI	_	
260-9	43347-43350	and	_	
260-10	43351-43354	MEG	_	
260-11	43355-43365	components	_	
260-12	43366-43368	in	_	
260-13	43369-43372	the	_	
260-14	43373-43385	default-mode	_	
260-15	43386-43393	network	_	
260-16	43393-43394	.	_	

#Text=Only correlations of r > 0.5 are illustrated.
261-1	43395-43399	Only	_	
261-2	43400-43412	correlations	_	
261-3	43413-43415	of	_	
261-4	43416-43417	r	_	
261-5	43417-43418	 	_	
261-6	43418-43419	>	_	
261-7	43419-43420	 	_	
261-8	43420-43423	0.5	_	
261-9	43424-43427	are	_	
261-10	43428-43439	illustrated	_	
261-11	43439-43440	.	_	

#Text=Supplementary Fig. 8
#Text=The following are the supplementary data related to this article.
262-1	43441-43454	Supplementary	_	
262-2	43455-43458	Fig	_	
262-3	43458-43459	.	_	
262-4	43460-43461	8	_	
262-5	43462-43465	The	_	
262-6	43466-43475	following	_	
262-7	43476-43479	are	_	
262-8	43480-43483	the	_	
262-9	43484-43497	supplementary	_	
262-10	43498-43502	data	_	
262-11	43503-43510	related	_	
262-12	43511-43513	to	_	
262-13	43514-43518	this	_	
262-14	43519-43526	article	_	
262-15	43526-43527	.	_	

#Text=Declaration of Competing Interest
#Text=Kristin Lottman, Timothy Gawne, Nina Kraguljac, Jeffrey Killen, Meredith Reid, and Adrienne Lahti declare no potential conflicts of interest.
263-1	43528-43539	Declaration	_	
263-2	43540-43542	of	_	
263-3	43543-43552	Competing	_	
263-4	43553-43561	Interest	_	
263-5	43562-43569	Kristin	_	
263-6	43570-43577	Lottman	_	
263-7	43577-43578	,	_	
263-8	43579-43586	Timothy	_	
263-9	43587-43592	Gawne	_	
263-10	43592-43593	,	_	
263-11	43594-43598	Nina	_	
263-12	43599-43608	Kraguljac	_	
263-13	43608-43609	,	_	
263-14	43610-43617	Jeffrey	_	
263-15	43618-43624	Killen	_	
263-16	43624-43625	,	_	
263-17	43626-43634	Meredith	_	
263-18	43635-43639	Reid	_	
263-19	43639-43640	,	_	
263-20	43641-43644	and	_	
263-21	43645-43653	Adrienne	_	
263-22	43654-43659	Lahti	_	
263-23	43660-43667	declare	_	
263-24	43668-43670	no	_	
263-25	43671-43680	potential	_	
263-26	43681-43690	conflicts	_	
263-27	43691-43693	of	_	
263-28	43694-43702	interest	_	
263-29	43702-43703	.	_	

#Text=References
#Text=Measuring alterations in oscillatory brain networks in schizophrenia with resting-state MEG: State-of-the-art and methodological challenges
#Text=The hallucinating brain: a review of structural and functional neuroimaging studies of hallucinations
#Text=A baseline for the multivariate comparison of resting-state networks
#Text=Tracking whole-brain connectivity dynamics in the resting state
#Text=
#Text=
#Text=Altered resting state complexity in schizophrenia
#Text=An information-maximization approach to blind separation and blind deconvolution
#Text=Brain structure, function, and neurochemistry in schizophrenia and bipolar disorder-a systematic review of the magnetic resonance neuroimaging literature
#Text=Functional connectivity in the motor cortex of resting human brain using echo-planar MRI
#Text=Measuring functional connectivity using MEG: methodology and comparison with fcMRI
#Text=Investigating the electrophysiological basis of resting state networks using magnetoencephalography
#Text=A method for making group inferences from functional MRI data using independent component analysis
#Text=Blind beamforming for non Gaussian signals
#Text=Decisional capacity for informed consent in schizophrenia research
#Text=Multimodal classification of schizophrenia patients with MEG and fMRI data using static and dynamic connectivity measures
#Text=Mapping functionally related regions of brain with functional connectivity MR imaging
#Text=Modulation of hippocampal theta and hippocampal-prefrontal cortex function by a schizophrenia risk gene
#Text=Dynamic functional connectivity analysis reveals transient states of dysconnectivity in schizophrenia
#Text=Temporal dynamics of spontaneous MEG activity in brain networks
#Text=Comparison of multi-subject ICA methods for analysis of fMRI data
#Text=Schizophrenia, neuroimaging and connectomics
#Text=Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging
#Text=Schizophrenia: a disconnection syndrome
#Text=Aberrant "default mode" functional connectivity in schizophrenia
#Text=Anatomical distance affects functional connectivity in patients with schizophrenia and their siblings
#Text=Decreased resting-state interhemispheric coordination in first-episode, drug-naive paranoid schizophrenia
#Text=Using short-range and long-range functional connectivity to identify schizophrenia with a family-based case-control design
#Text=Ventral tegmental area/midbrain functional connectivity and response to antipsychotic medication in schizophrenia
#Text=The relationship between MEG and fMRI
#Text=Validating the independent components of neuroimaging time series via clustering and visualization
#Text=Magnetoencephalographic and functional MRI connectomics in schizophrenia via intra- and inter-network connectivity
#Text=A sensor-weighted overlapping-sphere head model and exhaustive head model comparison for MEG
#Text=What happens after the first episode?
264-1	43704-43714	References	_	
264-2	43715-43724	Measuring	_	
264-3	43725-43736	alterations	_	
264-4	43737-43739	in	_	
264-5	43740-43751	oscillatory	_	
264-6	43752-43757	brain	_	
264-7	43758-43766	networks	_	
264-8	43767-43769	in	_	
264-9	43770-43783	schizophrenia	_	
264-10	43784-43788	with	_	
264-11	43789-43802	resting-state	_	
264-12	43803-43806	MEG	_	
264-13	43806-43807	:	_	
264-14	43808-43824	State-of-the-art	_	
264-15	43825-43828	and	_	
264-16	43829-43843	methodological	_	
264-17	43844-43854	challenges	_	
264-18	43855-43858	The	_	
264-19	43859-43872	hallucinating	_	
264-20	43873-43878	brain	_	
264-21	43878-43879	:	_	
264-22	43880-43881	a	_	
264-23	43882-43888	review	_	
264-24	43889-43891	of	_	
264-25	43892-43902	structural	_	
264-26	43903-43906	and	_	
264-27	43907-43917	functional	_	
264-28	43918-43930	neuroimaging	_	
264-29	43931-43938	studies	_	
264-30	43939-43941	of	_	
264-31	43942-43956	hallucinations	_	
264-32	43957-43958	A	_	
264-33	43959-43967	baseline	_	
264-34	43968-43971	for	_	
264-35	43972-43975	the	_	
264-36	43976-43988	multivariate	_	
264-37	43989-43999	comparison	_	
264-38	44000-44002	of	_	
264-39	44003-44016	resting-state	_	
264-40	44017-44025	networks	_	
264-41	44026-44034	Tracking	_	
264-42	44035-44046	whole-brain	_	
264-43	44047-44059	connectivity	_	
264-44	44060-44068	dynamics	_	
264-45	44069-44071	in	_	
264-46	44072-44075	the	_	
264-47	44076-44083	resting	_	
264-48	44084-44089	state	_	
264-49	44092-44099	Altered	_	
264-50	44100-44107	resting	_	
264-51	44108-44113	state	_	
264-52	44114-44124	complexity	_	
264-53	44125-44127	in	_	
264-54	44128-44141	schizophrenia	_	
264-55	44142-44144	An	_	
264-56	44145-44169	information-maximization	_	
264-57	44170-44178	approach	_	
264-58	44179-44181	to	_	
264-59	44182-44187	blind	_	
264-60	44188-44198	separation	_	
264-61	44199-44202	and	_	
264-62	44203-44208	blind	_	
264-63	44209-44222	deconvolution	_	
264-64	44223-44228	Brain	_	
264-65	44229-44238	structure	_	
264-66	44238-44239	,	_	
264-67	44240-44248	function	_	
264-68	44248-44249	,	_	
264-69	44250-44253	and	_	
264-70	44254-44268	neurochemistry	_	
264-71	44269-44271	in	_	
264-72	44272-44285	schizophrenia	_	
264-73	44286-44289	and	_	
264-74	44290-44297	bipolar	_	
264-75	44298-44308	disorder-a	_	
264-76	44309-44319	systematic	_	
264-77	44320-44326	review	_	
264-78	44327-44329	of	_	
264-79	44330-44333	the	_	
264-80	44334-44342	magnetic	_	
264-81	44343-44352	resonance	_	
264-82	44353-44365	neuroimaging	_	
264-83	44366-44376	literature	_	
264-84	44377-44387	Functional	_	
264-85	44388-44400	connectivity	_	
264-86	44401-44403	in	_	
264-87	44404-44407	the	_	
264-88	44408-44413	motor	_	
264-89	44414-44420	cortex	_	
264-90	44421-44423	of	_	
264-91	44424-44431	resting	_	
264-92	44432-44437	human	_	
264-93	44438-44443	brain	_	
264-94	44444-44449	using	_	
264-95	44450-44461	echo-planar	_	
264-96	44462-44465	MRI	_	
264-97	44466-44475	Measuring	_	
264-98	44476-44486	functional	_	
264-99	44487-44499	connectivity	_	
264-100	44500-44505	using	_	
264-101	44506-44509	MEG	_	
264-102	44509-44510	:	_	
264-103	44511-44522	methodology	_	
264-104	44523-44526	and	_	
264-105	44527-44537	comparison	_	
264-106	44538-44542	with	_	
264-107	44543-44548	fcMRI	_	
264-108	44549-44562	Investigating	_	
264-109	44563-44566	the	_	
264-110	44567-44587	electrophysiological	_	
264-111	44588-44593	basis	_	
264-112	44594-44596	of	_	
264-113	44597-44604	resting	_	
264-114	44605-44610	state	_	
264-115	44611-44619	networks	_	
264-116	44620-44625	using	_	
264-117	44626-44648	magnetoencephalography	_	
264-118	44649-44650	A	_	
264-119	44651-44657	method	_	
264-120	44658-44661	for	_	
264-121	44662-44668	making	_	
264-122	44669-44674	group	_	
264-123	44675-44685	inferences	_	
264-124	44686-44690	from	_	
264-125	44691-44701	functional	_	
264-126	44702-44705	MRI	_	
264-127	44706-44710	data	_	
264-128	44711-44716	using	_	
264-129	44717-44728	independent	_	
264-130	44729-44738	component	_	
264-131	44739-44747	analysis	_	
264-132	44748-44753	Blind	_	
264-133	44754-44765	beamforming	_	
264-134	44766-44769	for	_	
264-135	44770-44773	non	_	
264-136	44774-44782	Gaussian	_	
264-137	44783-44790	signals	_	
264-138	44791-44801	Decisional	_	
264-139	44802-44810	capacity	_	
264-140	44811-44814	for	_	
264-141	44815-44823	informed	_	
264-142	44824-44831	consent	_	
264-143	44832-44834	in	_	
264-144	44835-44848	schizophrenia	_	
264-145	44849-44857	research	_	
264-146	44858-44868	Multimodal	_	
264-147	44869-44883	classification	_	
264-148	44884-44886	of	_	
264-149	44887-44900	schizophrenia	_	
264-150	44901-44909	patients	_	
264-151	44910-44914	with	_	
264-152	44915-44918	MEG	_	
264-153	44919-44922	and	_	
264-154	44923-44927	fMRI	_	
264-155	44928-44932	data	_	
264-156	44933-44938	using	_	
264-157	44939-44945	static	_	
264-158	44946-44949	and	_	
264-159	44950-44957	dynamic	_	
264-160	44958-44970	connectivity	_	
264-161	44971-44979	measures	_	
264-162	44980-44987	Mapping	_	
264-163	44988-45000	functionally	_	
264-164	45001-45008	related	_	
264-165	45009-45016	regions	_	
264-166	45017-45019	of	_	
264-167	45020-45025	brain	_	
264-168	45026-45030	with	_	
264-169	45031-45041	functional	_	
264-170	45042-45054	connectivity	_	
264-171	45055-45057	MR	_	
264-172	45058-45065	imaging	_	
264-173	45066-45076	Modulation	_	
264-174	45077-45079	of	_	
264-175	45080-45091	hippocampal	_	
264-176	45092-45097	theta	_	
264-177	45098-45101	and	_	
264-178	45102-45124	hippocampal-prefrontal	_	
264-179	45125-45131	cortex	_	
264-180	45132-45140	function	_	
264-181	45141-45143	by	_	
264-182	45144-45145	a	_	
264-183	45146-45159	schizophrenia	_	
264-184	45160-45164	risk	_	
264-185	45165-45169	gene	_	
264-186	45170-45177	Dynamic	_	
264-187	45178-45188	functional	_	
264-188	45189-45201	connectivity	_	
264-189	45202-45210	analysis	_	
264-190	45211-45218	reveals	_	
264-191	45219-45228	transient	_	
264-192	45229-45235	states	_	
264-193	45236-45238	of	_	
264-194	45239-45254	dysconnectivity	_	
264-195	45255-45257	in	_	
264-196	45258-45271	schizophrenia	_	
264-197	45272-45280	Temporal	_	
264-198	45281-45289	dynamics	_	
264-199	45290-45292	of	_	
264-200	45293-45304	spontaneous	_	
264-201	45305-45308	MEG	_	
264-202	45309-45317	activity	_	
264-203	45318-45320	in	_	
264-204	45321-45326	brain	_	
264-205	45327-45335	networks	_	
264-206	45336-45346	Comparison	_	
264-207	45347-45349	of	_	
264-208	45350-45363	multi-subject	_	
264-209	45364-45367	ICA	_	
264-210	45368-45375	methods	_	
264-211	45376-45379	for	_	
264-212	45380-45388	analysis	_	
264-213	45389-45391	of	_	
264-214	45392-45396	fMRI	_	
264-215	45397-45401	data	_	
264-216	45402-45415	Schizophrenia	_	
264-217	45415-45416	,	_	
264-218	45417-45429	neuroimaging	_	
264-219	45430-45433	and	_	
264-220	45434-45446	connectomics	_	
264-221	45447-45458	Spontaneous	_	
264-222	45459-45471	fluctuations	_	
264-223	45472-45474	in	_	
264-224	45475-45480	brain	_	
264-225	45481-45489	activity	_	
264-226	45490-45498	observed	_	
264-227	45499-45503	with	_	
264-228	45504-45514	functional	_	
264-229	45515-45523	magnetic	_	
264-230	45524-45533	resonance	_	
264-231	45534-45541	imaging	_	
264-232	45542-45555	Schizophrenia	_	
264-233	45555-45556	:	_	
264-234	45557-45558	a	_	
264-235	45559-45572	disconnection	_	
264-236	45573-45581	syndrome	_	
264-237	45582-45590	Aberrant	_	
264-238	45591-45592	"	_	
264-239	45592-45599	default	_	
264-240	45600-45604	mode	_	
264-241	45604-45605	"	_	
264-242	45606-45616	functional	_	
264-243	45617-45629	connectivity	_	
264-244	45630-45632	in	_	
264-245	45633-45646	schizophrenia	_	
264-246	45647-45657	Anatomical	_	
264-247	45658-45666	distance	_	
264-248	45667-45674	affects	_	
264-249	45675-45685	functional	_	
264-250	45686-45698	connectivity	_	
264-251	45699-45701	in	_	
264-252	45702-45710	patients	_	
264-253	45711-45715	with	_	
264-254	45716-45729	schizophrenia	_	
264-255	45730-45733	and	_	
264-256	45734-45739	their	_	
264-257	45740-45748	siblings	_	
264-258	45749-45758	Decreased	_	
264-259	45759-45772	resting-state	_	
264-260	45773-45789	interhemispheric	_	
264-261	45790-45802	coordination	_	
264-262	45803-45805	in	_	
264-263	45806-45819	first-episode	_	
264-264	45819-45820	,	_	
264-265	45821-45831	drug-naive	_	
264-266	45832-45840	paranoid	_	
264-267	45841-45854	schizophrenia	_	
264-268	45855-45860	Using	_	
264-269	45861-45872	short-range	_	
264-270	45873-45876	and	_	
264-271	45877-45887	long-range	_	
264-272	45888-45898	functional	_	
264-273	45899-45911	connectivity	_	
264-274	45912-45914	to	_	
264-275	45915-45923	identify	_	
264-276	45924-45937	schizophrenia	_	
264-277	45938-45942	with	_	
264-278	45943-45944	a	_	
264-279	45945-45957	family-based	_	
264-280	45958-45970	case-control	_	
264-281	45971-45977	design	_	
264-282	45978-45985	Ventral	_	
264-283	45986-45995	tegmental	_	
264-284	45996-46000	area	_	
264-285	46000-46001	/	_	
264-286	46001-46009	midbrain	_	
264-287	46010-46020	functional	_	
264-288	46021-46033	connectivity	_	
264-289	46034-46037	and	_	
264-290	46038-46046	response	_	
264-291	46047-46049	to	_	
264-292	46050-46063	antipsychotic	_	
264-293	46064-46074	medication	_	
264-294	46075-46077	in	_	
264-295	46078-46091	schizophrenia	_	
264-296	46092-46095	The	_	
264-297	46096-46108	relationship	_	
264-298	46109-46116	between	_	
264-299	46117-46120	MEG	_	
264-300	46121-46124	and	_	
264-301	46125-46129	fMRI	_	
264-302	46130-46140	Validating	_	
264-303	46141-46144	the	_	
264-304	46145-46156	independent	_	
264-305	46157-46167	components	_	
264-306	46168-46170	of	_	
264-307	46171-46183	neuroimaging	_	
264-308	46184-46188	time	_	
264-309	46189-46195	series	_	
264-310	46196-46199	via	_	
264-311	46200-46210	clustering	_	
264-312	46211-46214	and	_	
264-313	46215-46228	visualization	_	
264-314	46229-46252	Magnetoencephalographic	_	
264-315	46253-46256	and	_	
264-316	46257-46267	functional	_	
264-317	46268-46271	MRI	_	
264-318	46272-46284	connectomics	_	
264-319	46285-46287	in	_	
264-320	46288-46301	schizophrenia	_	
264-321	46302-46305	via	_	
264-322	46306-46311	intra	_	
264-323	46311-46312	-	_	
264-324	46313-46316	and	_	
264-325	46317-46330	inter-network	_	
264-326	46331-46343	connectivity	_	
264-327	46344-46345	A	_	
264-328	46346-46361	sensor-weighted	_	
264-329	46362-46380	overlapping-sphere	_	
264-330	46381-46385	head	_	
264-331	46386-46391	model	_	
264-332	46392-46395	and	_	
264-333	46396-46406	exhaustive	_	
264-334	46407-46411	head	_	
264-335	46412-46417	model	_	
264-336	46418-46428	comparison	_	
264-337	46429-46432	for	_	
264-338	46433-46436	MEG	_	
264-339	46437-46441	What	_	
264-340	46442-46449	happens	_	
264-341	46450-46455	after	_	
264-342	46456-46459	the	_	
264-343	46460-46465	first	_	
264-344	46466-46473	episode	_	
264-345	46473-46474	?	_	

#Text=A review of progressive brain changes in chronically ill patients with schizophrenia
#Text=Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication
#Text=Disintegration of sensorimotor brain networks in schizophrenia
#Text=Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology
#Text=Aberrant hippocampal connectivity in unmedicated patients with schizophrenia and effects of antipsychotic medication: a longitudinal resting state functional MRI study
#Text=Resting-state brain activity in schizophrenia and major depression: a quantitative meta-analysis
#Text=First-episode schizophrenia: I.
265-1	46475-46476	A	_	
265-2	46477-46483	review	_	
265-3	46484-46486	of	_	
265-4	46487-46498	progressive	_	
265-5	46499-46504	brain	_	
265-6	46505-46512	changes	_	
265-7	46513-46515	in	_	
265-8	46516-46527	chronically	_	
265-9	46528-46531	ill	_	
265-10	46532-46540	patients	_	
265-11	46541-46545	with	_	
265-12	46546-46559	schizophrenia	_	
265-13	46560-46565	Basal	_	
265-14	46566-46573	ganglia	_	
265-15	46574-46580	volume	_	
265-16	46581-46583	in	_	
265-17	46584-46595	unmedicated	_	
265-18	46596-46604	patients	_	
265-19	46605-46609	with	_	
265-20	46610-46623	schizophrenia	_	
265-21	46624-46626	is	_	
265-22	46627-46637	associated	_	
265-23	46638-46642	with	_	
265-24	46643-46652	treatment	_	
265-25	46653-46661	response	_	
265-26	46662-46664	to	_	
265-27	46665-46678	antipsychotic	_	
265-28	46679-46689	medication	_	
265-29	46690-46704	Disintegration	_	
265-30	46705-46707	of	_	
265-31	46708-46720	sensorimotor	_	
265-32	46721-46726	brain	_	
265-33	46727-46735	networks	_	
265-34	46736-46738	in	_	
265-35	46739-46752	schizophrenia	_	
265-36	46753-46766	Schizophrenia	_	
265-37	46766-46767	,	_	
265-38	46768-46769	"	_	
265-39	46769-46773	just	_	
265-40	46774-46777	the	_	
265-41	46778-46783	facts	_	
265-42	46783-46784	"	_	
265-43	46784-46785	:	_	
265-44	46786-46790	what	_	
265-45	46791-46793	we	_	
265-46	46794-46798	know	_	
265-47	46799-46801	in	_	
265-48	46802-46806	2008	_	
265-49	46807-46811	Part	_	
265-50	46812-46813	3	_	
265-51	46813-46814	:	_	
265-52	46815-46827	neurobiology	_	
265-53	46828-46836	Aberrant	_	
265-54	46837-46848	hippocampal	_	
265-55	46849-46861	connectivity	_	
265-56	46862-46864	in	_	
265-57	46865-46876	unmedicated	_	
265-58	46877-46885	patients	_	
265-59	46886-46890	with	_	
265-60	46891-46904	schizophrenia	_	
265-61	46905-46908	and	_	
265-62	46909-46916	effects	_	
265-63	46917-46919	of	_	
265-64	46920-46933	antipsychotic	_	
265-65	46934-46944	medication	_	
265-66	46944-46945	:	_	
265-67	46946-46947	a	_	
265-68	46948-46960	longitudinal	_	
265-69	46961-46968	resting	_	
265-70	46969-46974	state	_	
265-71	46975-46985	functional	_	
265-72	46986-46989	MRI	_	
265-73	46990-46995	study	_	
265-74	46996-47009	Resting-state	_	
265-75	47010-47015	brain	_	
265-76	47016-47024	activity	_	
265-77	47025-47027	in	_	
265-78	47028-47041	schizophrenia	_	
265-79	47042-47045	and	_	
265-80	47046-47051	major	_	
265-81	47052-47062	depression	_	
265-82	47062-47063	:	_	
265-83	47064-47065	a	_	
265-84	47066-47078	quantitative	_	
265-85	47079-47092	meta-analysis	_	
265-86	47093-47106	First-episode	_	
265-87	47107-47120	schizophrenia	_	
265-88	47120-47121	:	_	
265-89	47122-47123	I	_	
265-90	47123-47124	.	_	

#Text=Early course parameters
#Text=Homotopic connectivity in drug-naive, first-episode, early-onset schizophrenia
#Text=Risperidone effects on brain dynamic connectivity-a prospective resting-state fMRI study in schizophrenia
#Text=High vs low frequency neural oscillations in schizophrenia
#Text=Task and resting-state fMRI studies in first-episode schizophrenia: A systematic review
#Text=Do antipsychotic drugs affect brain structure?
266-1	47125-47130	Early	_	
266-2	47131-47137	course	_	
266-3	47138-47148	parameters	_	
266-4	47149-47158	Homotopic	_	
266-5	47159-47171	connectivity	_	
266-6	47172-47174	in	_	
266-7	47175-47185	drug-naive	_	
266-8	47185-47186	,	_	
266-9	47187-47200	first-episode	_	
266-10	47200-47201	,	_	
266-11	47202-47213	early-onset	_	
266-12	47214-47227	schizophrenia	_	
266-13	47228-47239	Risperidone	_	
266-14	47240-47247	effects	_	
266-15	47248-47250	on	_	
266-16	47251-47256	brain	_	
266-17	47257-47264	dynamic	_	
266-18	47265-47279	connectivity-a	_	
266-19	47280-47291	prospective	_	
266-20	47292-47305	resting-state	_	
266-21	47306-47310	fMRI	_	
266-22	47311-47316	study	_	
266-23	47317-47319	in	_	
266-24	47320-47333	schizophrenia	_	
266-25	47334-47338	High	_	
266-26	47339-47341	vs	_	
266-27	47342-47345	low	_	
266-28	47346-47355	frequency	_	
266-29	47356-47362	neural	_	
266-30	47363-47375	oscillations	_	
266-31	47376-47378	in	_	
266-32	47379-47392	schizophrenia	_	
266-33	47393-47397	Task	_	
266-34	47398-47401	and	_	
266-35	47402-47415	resting-state	_	
266-36	47416-47420	fMRI	_	
266-37	47421-47428	studies	_	
266-38	47429-47431	in	_	
266-39	47432-47445	first-episode	_	
266-40	47446-47459	schizophrenia	_	
266-41	47459-47460	:	_	
266-42	47461-47462	A	_	
266-43	47463-47473	systematic	_	
266-44	47474-47480	review	_	
266-45	47481-47483	Do	_	
266-46	47484-47497	antipsychotic	_	
266-47	47498-47503	drugs	_	
266-48	47504-47510	affect	_	
266-49	47511-47516	brain	_	
266-50	47517-47526	structure	_	
266-51	47526-47527	?	_	

#Text=A systematic and critical review of MRI findings
#Text=Diagnostic interview for genetic studies.
267-1	47528-47529	A	_	
267-2	47530-47540	systematic	_	
267-3	47541-47544	and	_	
267-4	47545-47553	critical	_	
267-5	47554-47560	review	_	
267-6	47561-47563	of	_	
267-7	47564-47567	MRI	_	
267-8	47568-47576	findings	_	
267-9	47577-47587	Diagnostic	_	
267-10	47588-47597	interview	_	
267-11	47598-47601	for	_	
267-12	47602-47609	genetic	_	
267-13	47610-47617	studies	_	
267-14	47617-47618	.	_	

#Text=Rationale, unique features, and training.
268-1	47619-47628	Rationale	_	
268-2	47628-47629	,	_	
268-3	47630-47636	unique	_	
268-4	47637-47645	features	_	
268-5	47645-47646	,	_	
268-6	47647-47650	and	_	
268-7	47651-47659	training	_	
268-8	47659-47660	.	_	

#Text=NIMH Genetics Initiative
#Text=The brief psychiatric rating scale
#Text=Dysconnectivity in schizophrenia: where are we now?
269-1	47661-47665	NIMH	_	
269-2	47666-47674	Genetics	_	
269-3	47675-47685	Initiative	_	
269-4	47686-47689	The	_	
269-5	47690-47695	brief	_	
269-6	47696-47707	psychiatric	_	
269-7	47708-47714	rating	_	
269-8	47715-47720	scale	_	
269-9	47721-47736	Dysconnectivity	_	
269-10	47737-47739	in	_	
269-11	47740-47753	schizophrenia	_	
269-12	47753-47754	:	_	
269-13	47755-47760	where	_	
269-14	47761-47764	are	_	
269-15	47765-47767	we	_	
269-16	47768-47771	now	_	
269-17	47771-47772	?	_	

#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
#Text=Magnetoencephalography
#Text=The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity
#Text=Resting EEG in psychosis and at-risk populations--a possible endophenotype?
270-1	47773-47781	Spurious	_	
270-2	47782-47785	but	_	
270-3	47786-47796	systematic	_	
270-4	47797-47809	correlations	_	
270-5	47810-47812	in	_	
270-6	47813-47823	functional	_	
270-7	47824-47836	connectivity	_	
270-8	47837-47840	MRI	_	
270-9	47841-47849	networks	_	
270-10	47850-47855	arise	_	
270-11	47856-47860	from	_	
270-12	47861-47868	subject	_	
270-13	47869-47875	motion	_	
270-14	47876-47898	Magnetoencephalography	_	
270-15	47899-47902	The	_	
270-16	47903-47913	Repeatable	_	
270-17	47914-47921	Battery	_	
270-18	47922-47925	for	_	
270-19	47926-47929	the	_	
270-20	47930-47940	Assessment	_	
270-21	47941-47943	of	_	
270-22	47944-47962	Neuropsychological	_	
270-23	47963-47969	Status	_	
270-24	47970-47971	(	_	
270-25	47971-47976	RBANS	_	
270-26	47976-47977	)	_	
270-27	47977-47978	:	_	
270-28	47979-47990	preliminary	_	
270-29	47991-47999	clinical	_	
270-30	48000-48008	validity	_	
270-31	48009-48016	Resting	_	
270-32	48017-48020	EEG	_	
270-33	48021-48023	in	_	
270-34	48024-48033	psychosis	_	
270-35	48034-48037	and	_	
270-36	48038-48045	at-risk	_	
270-37	48046-48057	populations	_	
270-38	48057-48058	-	_	
270-39	48058-48059	-	_	
270-40	48059-48060	a	_	
270-41	48061-48069	possible	_	
270-42	48070-48083	endophenotype	_	
270-43	48083-48084	?	_	

#Text=EM algorithms for PCA and SPCA
#Text=Spectral fingerprints of large-scale neuronal interactions
#Text=Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring
#Text=Brainstorm: a user-friendly application for MEG/EEG analysis
#Text=Abnormal neural oscillations and synchrony in schizophrenia
#Text=Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis
#Text=Different frequencies for different scales of cortical integration: from local gamma to long range alpha/theta synchronization
#Text=Electrophysiological low-frequency coherence and cross-frequency coupling contribute to BOLD connectivity
#Text=Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks
#Text=Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
#Text=The role of the insula in schizophrenia
#Text=Frequency-specific alternations in the amplitude of low-frequency fluctuations in schizophrenia
271-1	48085-48087	EM	_	
271-2	48088-48098	algorithms	_	
271-3	48099-48102	for	_	
271-4	48103-48106	PCA	_	
271-5	48107-48110	and	_	
271-6	48111-48115	SPCA	_	
271-7	48116-48124	Spectral	_	
271-8	48125-48137	fingerprints	_	
271-9	48138-48140	of	_	
271-10	48141-48152	large-scale	_	
271-11	48153-48161	neuronal	_	
271-12	48162-48174	interactions	_	
271-13	48175-48188	Dysconnection	_	
271-14	48189-48191	in	_	
271-15	48192-48205	schizophrenia	_	
271-16	48205-48206	:	_	
271-17	48207-48211	from	_	
271-18	48212-48220	abnormal	_	
271-19	48221-48229	synaptic	_	
271-20	48230-48240	plasticity	_	
271-21	48241-48243	to	_	
271-22	48244-48252	failures	_	
271-23	48253-48255	of	_	
271-24	48256-48271	self-monitoring	_	
271-25	48272-48282	Brainstorm	_	
271-26	48282-48283	:	_	
271-27	48284-48285	a	_	
271-28	48286-48299	user-friendly	_	
271-29	48300-48311	application	_	
271-30	48312-48315	for	_	
271-31	48316-48319	MEG	_	
271-32	48319-48320	/	_	
271-33	48320-48323	EEG	_	
271-34	48324-48332	analysis	_	
271-35	48333-48341	Abnormal	_	
271-36	48342-48348	neural	_	
271-37	48349-48361	oscillations	_	
271-38	48362-48365	and	_	
271-39	48366-48375	synchrony	_	
271-40	48376-48378	in	_	
271-41	48379-48392	schizophrenia	_	
271-42	48393-48400	Altered	_	
271-43	48401-48407	medial	_	
271-44	48408-48416	temporal	_	
271-45	48417-48427	activation	_	
271-46	48428-48435	related	_	
271-47	48436-48438	to	_	
271-48	48439-48444	local	_	
271-49	48445-48454	glutamate	_	
271-50	48455-48461	levels	_	
271-51	48462-48464	in	_	
271-52	48465-48473	subjects	_	
271-53	48474-48478	with	_	
271-54	48479-48488	prodromal	_	
271-55	48489-48494	signs	_	
271-56	48495-48497	of	_	
271-57	48498-48507	psychosis	_	
271-58	48508-48517	Different	_	
271-59	48518-48529	frequencies	_	
271-60	48530-48533	for	_	
271-61	48534-48543	different	_	
271-62	48544-48550	scales	_	
271-63	48551-48553	of	_	
271-64	48554-48562	cortical	_	
271-65	48563-48574	integration	_	
271-66	48574-48575	:	_	
271-67	48576-48580	from	_	
271-68	48581-48586	local	_	
271-69	48587-48592	gamma	_	
271-70	48593-48595	to	_	
271-71	48596-48600	long	_	
271-72	48601-48606	range	_	
271-73	48607-48612	alpha	_	
271-74	48612-48613	/	_	
271-75	48613-48618	theta	_	
271-76	48619-48634	synchronization	_	
271-77	48635-48655	Electrophysiological	_	
271-78	48656-48669	low-frequency	_	
271-79	48670-48679	coherence	_	
271-80	48680-48683	and	_	
271-81	48684-48699	cross-frequency	_	
271-82	48700-48708	coupling	_	
271-83	48709-48719	contribute	_	
271-84	48720-48722	to	_	
271-85	48723-48727	BOLD	_	
271-86	48728-48740	connectivity	_	
271-87	48741-48745	Conn	_	
271-88	48745-48746	:	_	
271-89	48747-48748	a	_	
271-90	48749-48759	functional	_	
271-91	48760-48772	connectivity	_	
271-92	48773-48780	toolbox	_	
271-93	48781-48784	for	_	
271-94	48785-48795	correlated	_	
271-95	48796-48799	and	_	
271-96	48800-48814	anticorrelated	_	
271-97	48815-48820	brain	_	
271-98	48821-48829	networks	_	
271-99	48830-48843	Hyperactivity	_	
271-100	48844-48847	and	_	
271-101	48848-48865	hyperconnectivity	_	
271-102	48866-48868	of	_	
271-103	48869-48872	the	_	
271-104	48873-48880	default	_	
271-105	48881-48888	network	_	
271-106	48889-48891	in	_	
271-107	48892-48905	schizophrenia	_	
271-108	48906-48909	and	_	
271-109	48910-48912	in	_	
271-110	48913-48925	first-degree	_	
271-111	48926-48935	relatives	_	
271-112	48936-48938	of	_	
271-113	48939-48946	persons	_	
271-114	48947-48951	with	_	
271-115	48952-48965	schizophrenia	_	
271-116	48966-48969	The	_	
271-117	48970-48974	role	_	
271-118	48975-48977	of	_	
271-119	48978-48981	the	_	
271-120	48982-48988	insula	_	
271-121	48989-48991	in	_	
271-122	48992-49005	schizophrenia	_	
271-123	49006-49024	Frequency-specific	_	
271-124	49025-49037	alternations	_	
271-125	49038-49040	in	_	
271-126	49041-49044	the	_	
271-127	49045-49054	amplitude	_	
271-128	49055-49057	of	_	
271-129	49058-49071	low-frequency	_	
271-130	49072-49084	fluctuations	_	
271-131	49085-49087	in	_	
271-132	49088-49101	schizophrenia	_	
